Mechanisms of Hormone Resistance in Breast Cancer by Agthoven, A.J. (Ton) van
MECHANISMS OF HORMONE RESISTANCE 
IN BREAST CANCER 
TON V AN AGTHOVEN 

MECHANISMS OF HORMONE RESISTANCE IN BREAST CANCER 
MECHANISMEN VAN HORMOONRESISTENTIE BIJ BORSTKANKER 
PROEFSCHRIFf 
TER VERKRIJGING V AN DE GRAAD VAN DOCTOR AAN DE 
ERASMUS UNIVERSITEIT ROTTERDAM OP GEZAG V AN DE 
RECTOR MAGNIFICUS PROF. DR P. W. C. AKKERMANS M. A. 
EN VOLGENS BESLUIT VAN HET COLLEGE VOOR PROMOTIES 
DE OPENBARE VERDEDIGING ZAL PLAATSVINDEN OP 
WOENSDAG 11 NOVEMBER 1998 OM 11.45 UUR 
DOOR 
ANTONIUS JOHANNES VAN AGTHOVEN 
GEBOREN TE ROTTERDAM 
PROMOTIECOMMISSIE 
PROMOTOR: 
OVERIGE LEDEN: 
CO-PROMOTOR: 
Prof. dr J. W. Oosterhuis 
Prof. dr J. A. Grootegoed 
Prof. dr D. Bootsma 
Dr J. A. Foekens 
Dr Ir L. C. J. Dorssers 
Oil proefschrift werd bewerkt binnen de Afdeling Moleculaire Biologie van de 
Daniel den Hoed Kliniek, Academisch Ziekenhuis Rotterdam. Het onderzoek werd 
mede mogelijk gemaakt door financWle steun van de Josephine Nefkens Stichting en 
de Nededandse Kankerbestdjding. De uitgave kwam tot stand met financi~le steun 
van de Nededandse Kankerbestrijding, de Erasmus Universiteit Rotterdam en ICN 
Biomedicals B.V. 
Gedrukt bij Offsetdrukkerij Ridderprint B.V., Ridderkerk 

Contents 
Abbreviations 
Chapter 1. Introduction 
1.1. Development of breast cancer 
1.2. Antiestrogen therapy 
1.3. Estrogen receptor alpha 
1.4. Hormone resistance in breast cancer 
Chapter 2. Mechanisms of antiestrogen resistance 
2.1. Pharmacology of tamoxifen and its resistance 
2.2. Alterations in ER expression, structure and function 
2.3. Overexpression of different genes 
Chapter 3. Concluding remarks 
Chapter 4. Experimental work and discussion 
References 
Chapter 5. Papers 
1. Ectopic expression of epidermal growth factor receptors induces 
hormone independence in ZR-75-1 human breast cancer cells. 
Ton van Agthoven, Thecla L. A. van Agthoven, Henk Portengen, 
Jolm A. Foekens, and Lambert C. J. Dorssers. Cancer Research 52, 
8 
9 
11 
12 
14 
15 
17 
19 
19 
21 
27 
31 
38 
49 
5082-5088, 1992. 51 
2. Induction of estrogen independence of ZR-75-1 human breast 
cancer cells by epigenetic alterations. Ton van Agthoven, Thecla 
L. A. van Agthoven, Anita Dekker, John A. Foekens, and 
Lambert C. J. Dorssers. Molecular Endocrinology 8, 1474-1483, 
1994. 59 
3. Differential expression of estrogen, progesterone, and epidermal 
growth {actor receptors in normal, benign, and malignant human 
breast tissues using dual staining immunohistochemistry. Ton 
van Agthoven, Mieke Timmermans, John A. Foekens, Lambert C. 
J. Dorssers, and Sonja C. Henzen-Logmans. American Journal o{ 
Pathology 144, 1238-1246, 1994. 69 
4. Expression of estrogen, progesterone, and epidermal growth 
factor receptors in primary and metastatic breast cancer. Ton van 
Agthoven, Mieke Timmermans, Lambert C. J. Dorssers, and 
Sonja C. Henzen-Logmans. International Journal of Cancer 63, 
790-793,1995. 79 
5. Induction of antiestrogen resistance in human breast cancer cells 
by random insertional mutagenesis using defective retroviruses: 
Identification of bear-I, a common integration site. Lambert C. J. 
Dorssers, Ton van Agthoven, Anita Dekker, Thecla L. A. van 
Agthoven, and Elisabeth M. Kok. Molecular Endocrinology 7, 
870-878,1993. 83 
6. Identification of BCAR3 by a random search for genes involved 
in antiestrogen resistance of human breast cancer cells. Ton van 
Agthoven, Thecla L. A. van Agthoven, Anita Dekker, Peter J. van 
del' Spek, Lilian Vreede and Lambert c.J. Dorssers. The EMBO 
Journal 17, 2799-2808, 1998. 93 
Sununary 103 
Samenvatting 106 
Dankwoord 109 
Curriculum vitae 110 
Bibliografie 111 
Ab brevia tions 
AZA 
BCAR 
CAS 
eDNA 
DNA 
EGF 
ER 
ERE 
ICI 
IGF 
kb 
kD 
LTR 
MAPK 
mRNA 
MDR 
PCR 
PR 
RNA 
SH2 
SSCP 
TGF 
5-azacytidine 
breast cancer antiestrogen resistance 
Crk-associated substrate 
complementary DNA 
deoxyribonucleic acid 
epidermal growth factor 
esh'ogen receptor 
estrogen response elements 
Imperial Chemical Industries 
insulin-like growth factor 
kilo base 
kilo dalton' 
long terminal repeat 
mitogen-activated protein kinase 
messenger RNA 
multidrug resistance 
polymerase chain reaction 
progesterone receptor 
ribonucleic acid 
Src homology 2 
single strand conformation polymorphism 
transforming growth factor 
8 
1 
1 
1 
1 
1 
1 
1 
1 
1 
CHAP1£R 1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 , 

Introduction 
Antiestrogenic drugs such as tamoxifen are important in the management of hormone-dependent breast cancer. Treatment with tamoxifen prolongs disease-free survival and reduces mortality. Tamoxifen has few harmful side 
effects, it has low cost, is easy to administer, and has potential benefits on lipid and 
bone metabolism. However, the treatment is palliative and, hormone resistance of the 
tumor cells is almost inevitable, resulting in disease recurrence. The mechanisms 
underlying the progression of breast cancer, either spontaneously or therapeutically 
induced, to a form unresponsive to endocrine treatment, are largely unknown. 
Insight in these mechanisms may result in the development of new h'eatment 
strategies. The work described in this thesis focuses on possible mechanisms and 
genes involved in hormone resistance in breast cancer. 
1.1 Development of breast cancer 
The biological function of the mammary gland is to produce and secrete milk. This 
unique feature of mammals is vital for the feeding of the newborn and thus for 
survival of the species. The normal glandular epithelium of the adult female breast 
consists of ducts and lobular secretory alveoli. The stroma of the breast consists of fat, 
CotUlective tissue, blood vessels and lymphatics. Two different cell types line both 
ducts and alveoli: the luminal epithelial cells and the myoepithelial cells, which have 
clearly distinguishable phenotypes. Luminal cells are characterized by the expression 
of keratins 7, 8, 18, and 19, whereas keratins 5 and 14, alpha smooth muscle actin, 
vimentin, collagen IV and laminin have been demonstrated in myoepithelial cells 1 .... 
Also the expression pattern of hormone receptors and epidermal growth factor (EGF) 
receptor is different. Luminal cells express classical estrogen receptor a. (ER) and 
progesterone receptor (PR, an estrogen-responsive gene product) and EGF receptor. 
Myoepithelial cells show strong expression of EGF receptor and are negative for ER 
andPRs. 
Over 95% of primary breast malignancies originate from the luminal epithelial 
cells of the glandular epithelium 6. Adenocarcinomas of the breast are classified in 
either ductal or lobular lesions, and can further be divided in non-invasive or 
invasive tumors 7. Invasive tumor cells can disseminate by infiltrating through tissue 
spaces, and can invade both lymphatics and blood vessels. Metastases primarily 
develop in lymph nodes, and later at distant sites as lungs, bones and liver. At 
presentation, approximately 40-50% of patients has lymph node metastases and 
<10% already has clinically manifested distant metastases. When there is no evidence 
of metastasis at presentation of the disease, therapy is usually restricted to local 
treatment of the tumor. Since a substantial percentage of women with apparently 
localized breast cancer will have occult (or micro) metastases by the time of diagnosis, 
success of local treatment will often be limited. Patients with no evidence of 
progressive disease may therefore benefit from adjuvant chemo- or endocrine 
therapy 8. Patients with metastatic disease will require some form of systemic 
treatment such as endocrine- or chemotherapy. 
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In the Western world today, breast cancel' is the most common cancer in women 
(appmximately one third of all types of cancer), affecting one out of ten women, The 
most clearly identified risk factors for breast cancer are female sex and age, with 
occurrence predominantly in postmenopausal women, However, more than 70% of 
the patients over the age of 50 have no apparent additional risk factors, This implies 
that the etiology of breast cancer is pmbably multifactorial, including inherited, 
hormonal and envimnmental factors 9-14, Hormones and gmwth factors play an 
important mle in the development and the physiology of the adult breast, 
Presumably estrogen, one of the major regulatory hormones for the normal breast, 
plays a crucialmle in pmmoting breast cancer 15-17, Several lines of evidence support 
this hypothesis, In the normal ductal and lobular epithelial cells, from which most 
breast tumors arise, ER is expressed in varying amounts, depending on the 
developmental stage 5,18, Approximately 70% of primary breast tumors contain ER, 
and these presumably depend on the pmliferative effect of estrogens 19,20, The risk of 
breast cancer is correlated with the number of menstrual cycles and thus with the 
time of activation of the ovaries, which are the primary producers of estrogens, and 
the time of menopause, the inactivation of the ovaries, Ovariectomy, when performed 
early in life, reduces the risk of breast cancel' to that of men, approximately 1 % of the 
risk in women 21, Finally, ovariectomy can inhibit growth of breast cancer, which can 
be explained by the elimination of estrogens, which are required to activate the ER 
and to stimulate proliferation of the tumor cells 18,22, These observations strongly 
suggest that the development of the majority of breast cancers is estmgen-dependent. 
1,2 Antiestrogen therapy 
A large proportion of breast tumors expresses ER and appears dependent on 
estrogens for proliferation, Consequently, the ER is an important target for 
pharmacotherapy, The rationale for many endocrine therapies for breast cancer is the 
inhibition of the proliferative effects of estrogens, The first compounds developed to 
interfere with the ER were highly toxic ", In 1969, tamoxifen developed as a possible 
drug for oral contraception by Imperial Chemical Industries (ICI) Pharmaceuticals 
(now Zeneca) was shown to be an effective inhibitor of breast cancer growth 
(reviewed by 24), Most ill vitro studies suggest that tamoxifen, like other antiestrogens, 
competes with estradiol for binding to the ligand-binding domain of the ER 25-27, The 
antiestrogen complexes with the ER, and the complex may still bind to the DNA. 
However, this complex will not result in modulation of expression of the ER-target 
genes 28, Antiestrogens may thus block hormone signaling and induce growth arrest 
of the tumor cells 25,29-32, Tamoxifen has been the first choice endocrine therapy in the 
adjuvant setting after surgery for breast cancer, and in patients with advanced breast 
cancer for >20 years now, Presently, it is evaluated as a preventive agent in women at 
high-risk for developing breast cancer =, 
Nonsteroidal antiestrogens such as tamoxifen display also some estrogenic 
characteristics 36, In some tissues and cell types, they can activate gene expression 37 
and are therefore classified as partial agonists, An important estrogenic activity of 
tamoxifen is the increase of osteoblastic activity resulting in the preservation of bone 
density in postmenopausal women :lB,", Tamoxifen also appears to have an effect on 
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lipid metabolism, resulting in lower serum cholesterol levels, which may decrease the 
incidence of myocardial infarction "',41, Increased risk of endometrial cancer due to 
tamoxifen treatment was reported, This association is insignificant compared to the 
beneficial effects of tamoxifen, and until now no causal association has been 
established (reviewed by 42), Tamoxifen has other cellular effects not mediated 
through the ER, among others enzyme inhibition (protein kinase C and calmodulin) 
and growth factor modulation 434h, Treatment with tamoxifen induces synthesis of 
transforming growth factor P (TGFP), a negative growth regulator of breast cancer 
cells 47-49, and decreases insulin-like growth factor I (IGFI) levels, a growth stimulator 
of breast (cancer) cells 50,51, New and more effective antiestrogens have been 
developed 52.54, Different antiesh'ogens may differ in their effects on various cell types 
and in their interactions with ER 55-57. Some of these compounds, including ICI 
164,384 and ICI 182,780, lack agonistic activity 53,584). These so-called pure 
antiestrogens are currently.evaluated in clinical trials for the treatment of patients 
with primary breast cancer and advanced breast cancer resistant to tamoxifen 61,62. 
Pure antiestrogens will not have the beneficial effects on bone and lipid metabolism 
of tamoxifen. New compounds have to be designed, combining the antagonistic 
effects on breast cancer cells and agonistic effects on bone and lipid metabolism. 
Tamoxifen has been used for more than 20 years. In the adjuvant setting after 
surgery for early breast cancer it reduces the recurrence rate by 25%, mortality by 
16%, and the incidence of conh'alateral breast cancer by 40% (reduction in annual 
odds) 8. Although these reductions are small, the impact is significant due to the high 
incidence of breast cancer. In patients with metastatic disease who originally had ER-
positive primary tumors, treatment with tamoxifen causes remissions in 
approximately 50% of the patients 63-66. Although treatment with antiestrogens can 
delay recurrences or induce remissions of the disease, metastases refractory to 
treatment will develop in almost all cases. Several factors may be responsible for 
tamoxifen resistance (reviewed by 17,26,67,75), including decreased levels of ER, 
mutation or splice variants of ER, agonistic effects of tamoxifen, altered drug 
metabolism, de /lova production of estrogens, overexpression of several genes, 
interactions with the environment and increase in antiestrogen bindIng sites. 
Nevertheless, for the majority of breast cancers the mechanisms responsible for 
development of resistance to hormonal therapy are still not known. Better 
understanding of tamoxifen resistance may lead to new treatment strategies or the 
development of new therapeutic agents. Knowing the mechanism of antiestrogen 
resistance is also important for patients non-responsive to second-line hormone 
therapy, Finally, understanding of tamoxifen action and associated resistance may be 
of particular importance for preventing breast cancer in women who are at high-risk 
of developing the disease 76. 
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1.3 Estrogen receptor alpha 
The major effects of estrogens and antiestrogens are mediated through the ER. 
Changes in structure and function of ER have been implicated in antiestrogen 
resistance, Therefore, a concise review will be given of the known structure and 
function of the ER. A schematic representation of the ER is presented in Figure 1. The 
ER belongs to the superfamily of nuclear hormone receptors. These receptors function 
as transcription factors when they are activated by their ligand. Other members of 
this family include receptors for other steroid hormones, vitamin D, thyroid hormone, 
ecdysone and retinoic acid 77"". 
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Figure 1. 
Schematic representation of the estrogen receptor. The top portion of the figure shows the genomic 
organisation. The eight exons are indicated by black boxes. Below the genomic DNA the configuration of 
the spliced mRNA is presented, The bottom part of the figure shows the functional domains of the 
estrogen receptor protein. 
Estrogens diffuse across the cell membrane and bind to the ER, to form 
homodimers that bind with high affinity to specific DNA enhancer elements termed 
estrogen response elements (ERE) and characterized by the consensus sequence 
GGATCnnnGATCC 84. Consequently, most estrogen-responsive genes are controlled 
by EREs located either upstream or downstream of the transcription initiation site. 
The structure and number of EREs, may vary noticeably between different genes. The 
estrogen-ER complex bound to the DNA interacts with other transcription factors and 
with components of the transcriptional complex to modulate gene transcription 85. 
The exact mechanism of estrogen-induced transcription activation is still largely 
unknown. Recent studies have led to the identification of various coactivator proteins 
that appear to modulate the functional activity of the ER (!6.88. 
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The ER gene has eight exons spanning more than 140 kb, and is located on human 
chromosome 6q 25.1 89. It encodes a nuclear protein of 593 amino acid residues with a 
molecular mass of 66 kilodalton (kDa). Comparison of the sequences of the ER 
complementary DNA (cDNA) with that of different members of the hormone 
superfamily revealed six regions with varying homology, labeled A to F starting from 
the N-terminus 90. The many reported functional activities to these domains are 
indicated in Figure 1. ER can activate transcription through two distinct activation 
regions. The NH2-terminal region AlB contains the ligand-independent activation 
function-1 (AF-1) domain. The AF-2 domain is located in the COOH-terminal E-
region, which can only activate transcription in the presence of ligand 77.79Jj'. The 
individual activities of the two activation domains depend on the target promoter 
and cell type 91. Region C, contains two zinc finger motifs which are responsible for 
the specific DNA binding activity of the protein based on the recognition of the ERE 
of target genes. Region 0 functions as a hinge between the hormone- and the DNA-
binding domains and contains the sequences required for nuclear localization of the 
receptor 90. Region E, the hormone-binding domain, is responsible for ligand binding, 
receptor dimerization and activation of transcription of estrogen-responsive genes. 
Region E also contains a site for binding of heat-shock proteins. It is suggested that in 
the absence of estrogen, the DNA-binding domain is masked by the hormone-
binding ,Iomain. Hormone binding results in relieving this masking effect. Region F 
has a modulatory effect on the transcriptional activity of the ER 92. 
Recently, an ERP subtype was described, which may explain some of the cell and 
promoter-specific effects %-95. The gene encodes a protein of 485 amino acid residues 
that shares respectively 96% and 58% identity with the DNA- and ligand binding 
domains of ERa. In contrast to the AlB domain, the hinge region and the F-domain 
are not conserved 93,96. Expression of ERP was observed in many tissues including 
thymus, spleen, ovary, testis, and in both ERa positive- and negative tumors 93.97. The 
formation of heterodimers of ERa and ERP was demonstrated in a mammalian two-
hybrid system and in transfection experiments 98,99. This suggests the existence of 
three pathways of estrogen signaling: via ERa 01' ERP homodimers, and via the 
formation of heterodimers in cells expressing both receptor subtypes. The 
identification of this second estrogen receptor will lead to a re-evaluation of estrogen 
signaling and physiology. 
1.4 Hormone resistance in breast cancer 
During development and progression of a tumor, the cells may undergo diverse 
changes 1<JO.102. Breast tumors are composed of malignant cells and non-malignant 
cells, including stromal, adipose, and vasculature cells, macrophages and lymphocyte 
infiltrations. During tumor progression complex cell-cell interactions take place 
involving malignant and non-malignant cells and the extracellular matrix, eventually 
resulting in the lethal ability of tumor cells to invade tissues and to metastasize. 
Hormone-resistant breast tumors can be classified in three groups. First, inh'insic 
resistant tumors; the ER-negative group of tumors. Most of the actions of estrogens 
leading to cell proliferation appear to be mediated by the ER. Consequently, 
progression to ER-negative disease would result in tumors unresponsive to 
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antiestrogen therapy, Second, intrinsic resistant ER-positive tumors, which are 
refractory to initial tamoxifen therapy. Third, tumors with acquired resistance; the 
remainder of the ER-positive tumors, which initially responds to antiestrogens, but 
becomes resistant under therapy. The mechanisms underlying the resistance of these 
latter two categories may be similar and only reflect a difference in the state of tumor 
progression at the moment of starting with therapy. Progression from a hormone-
dependent state to hormone insensitivity may be the result of a mutational event, 
followed by clonal selection 103,HM. Other observations have implied epigenetic 
mechanisms 105,106, which are heritable alterations in gene function that are mediated 
by factors other than changes in primmy DNA sequence, for example 5-
methylcytosine DNA methylation. Epigenetic changes as opposed to mutations may 
result in the same phenotypic change simultaneously in a large proportion of the 
tumor cells. 
Many possible mechanisms for antiestrogen resistance have been postulated and 
studied, including: alteration of metabolism or availability of tamoxifen, changes in 
ER and function, and overexpression of different genes. Data supporting multiple 
possible mechanisms and the model systems used in these studies are reviewed in the 
next chapter. 
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Mechanisms of antiestrogen resistance 
2.1 Pharmacology of tamoxifen and its resistance 
Alteration in the pharmacology of the drug was postulated as a possible mechanism for tamoxifen resistance by experimental and clinical observations 70. Tamoxifen is metabolized in the liver to several 
compounds with different biological properties. N-desmethyl tamoxifen is the major 
metabolite, which has a comparable biological activity as tamoxifen. Another major 
metabolite is 4-hydroxy-tamoxifen, which has a higher affinity for the ER and a 
stronger biological activity. An increased metabolism of tamoxifen to agonistic 
compounds could explain the existence of tumors with a tamoxifen-stimulated 
phenotype. However, tamoxifen analogues with fixed ring structures, resistant to 
metabolic conversion into estrogenic metabolites, were also able stimulate cell 
proliferation 72,,07.,09. Furthermore, tamoxifen metabolites acting as agonists are oniy 
found in low amounts in tumors so far 110,111. However, accumulation of tamoxifen in 
the tumor does not always lead to the same level as the circulating concentration 
112.11'. Tamoxifen may be bound to other binding proteins than the ER, designated 
antiestrogen binding sites 115,116. Metabolism of tamoxifen may be responsible for 
some of the resistant tumor phenotypes, but there is no clear evidence that it can 
explain the majority of the cases with observed clinical tamoxifen resistance. 
2.2 Alterations in ER expression, structure and function 
Most of the actions of estrogens and antiestrogens are exerted via the ER. 
However, expression of ER in the (primary) tumor does not guarantee successful 
antiestrogen therapy. Half of the patients with ER-positive tumors do not respond to 
the drug despite the presence of a functional ER. Furthermore, over 50% of the 
tumors with acquired tamoxifen resistance continue to express ER and often PR, an 
indicator of a functional ER. Therefore, resistance cannot be explained simply by loss 
of ER expression 117-119. ER-negative metastases may be the result of tumor 
heterogeneity and clonal selection of ER-negative tumor cells. ER may also be lost as 
a result of progression to a more malignant and metastatic tumor phenotype. 
Expression of ER is very heterogeneous in ER-positive primary tumors. Gross 
differences in ER expression levels and percentages of ER-positive cells are observed. 
Immunohistochemical analysis seldom shows biopsies containing 100% ER-positive 
tumor cells. Consequently this variation in expression may lead to the outgrowth of 
ER-negative tumor populations. Similar differences in expression levels were 
observed in ER-positive breast cancer ceHlines. When these cell lines are subcloned, 
all resulting cell clones are ER-positive, again with heterogeneous expression, 
suggesting regulatory mechanism for the ER level 5,120. 
Several groups of investigators have studied the ER gene at different cellular 
levels, i.e., at the genomic, the mRNA, and the protein level. Loss of heterozygosity at 
the ER locus has previously been reported 121 but does not correlate with ER status of 
the tumor 122. Neither can the majority of the ER-negative tumors be explained by loss 
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of chromosome 6q 123. Southern blot analysis of ER-negative breast tumors did not 
show major rearrangements in the ER locus, indicating that the loss of ER expression 
is not associated with large chromosomal rearrangements or deletions 124,125. These 
results were confirmed by a more detailed study, using polymerase chain reaction 
(PCR) analysis of the ER gene. Analysis of all eight exons of ER-negative breast 
tumors did not show abnormalities in the size of the PCR product compared to ER-
positive tumors 126. Other investigators performed a detailed and sensitive analysis of 
the eight exons by single-strand conformation polymorphism (SSCP) analysis. This 
technique can detect point mutations and very small deletions or rearrangements, 
which may have been missed by the former studies. In a series of 188 breast tumors, 
including 70 ER-negative tumors, only two missense mutations were identified in the 
same ER-negative tumor. In another study, SSCP analysis of the ER cDNA of 20 
tamoxifen-sensitive and 20 tamoxifen-resistant tumors, all ER-positive, revealed two 
mutations in the tamoxifen-resistant tumors, leading to a truncated ER with a 
defective hormone binding domain 127. These studies show that mutations in the ER 
gene do occur, but at low frequency. They cannot account for the majority of ER-
negative or tamoxifen-resistant breast tumors 128-130. 
The DNA methylation status of CpG residues is an important factor regulating 
eukaryotic gene expression and differentiation. Although exceptions have been 
reported, for most genes there is an inverse relationship between the degree of DNA 
methylation and the level of expression (reviewed by 131.133). Constitutively expressed 
housekeeping genes are generally present in a demethylated state. Genes with tissue-
specific expression patterns are usually hypomethylated in the cells expressing the 
gene and hypermethylated in the cells lacking expression. Aberrations in methylation 
patterns and levels have been described in tumors and do play a role in the 
development of neoplasia 1". Changes in the methylation pattern of the ER could 
result in altered gene expression, and this could influence the phenotype of the 
tumor. Methylation status was analyzed of both regulatory and coding sequences of 
the ER gene 125,135. It was shown that DNA methylation of the ER gene is different in 
estrogen target and non-target tissues. In primary breast tumors, upstream sequences 
of the ER tend to be hypomethylated in ER-positive tumors and more methylated in 
ER-negative tumors. No association was observed between ER status of a tumor and 
different levels of methylation in the coding sequences of the gene. Another study 136 
showed that in cell lines the Not! restriction enzyme site present in the 5' CpG island 
of the ER gene is methylated in ER-negative cell lines but not in ER-positive cell lines. 
Furthermore, a higher level of DNA methyltransferase was observed in ER-negative 
cell lines, suggesting an increased ability to methylate DNA, which may explain the 
loss of ER expression in cell lines. Recently, these ill vitro observations were 
confirmed in biopsies of primary breast tumors. A significant correlation between 
aberrant methylation of the ER and the PR genes and lack of gene expression was 
shown 137. This mechanism of gene silencing could account for loss of ER and PR gene 
expression in a significant proportion of breast tumors, resulting in antiestrogen 
resistance. If methylation changes are involved, demethylating agents pOSSibly can be 
used to reinduce ER expression. From the therapeutic point of view, this approach is 
only meaningful when the tumor cells starting to reexpress the ER also loose their 
estrogen-independent phenotype. 
In the last few years, much attention has been given to expression of variant ER 
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mRNAs. Several variant ER mRNAs have been detected in breast cancer cell lines, 
breast cancers, and in normal breast tissues 138-141. The presence of ER variants 
derived from alternatively spliced mRNAs functioning as dominant positive, 
estrogen-independent transcription factors may induce hormone independent tumor 
growth. Expression of variant ER appears to be a process that occurs in every cell that 
expresses the prima1y transcript. Until now, it is not clear whether these alternatively 
spliced RNAs result in variant proteins, and the clinical significance remains to be 
established 142.14.l. 
2.3 Overexpression of various genes 
Overexpression of growth factors, growth factor receptors, or other components 
of signaling cascades leading to proliferation, may provide selective growth 
advantage to cells progressing along the malignant pathway. A possible role for 
suspected genes in the development of resistance might be established by 
overexpressing the gene of interest in hormone-dependent breast cancer cells. To this 
end, a number of candidate genes have been studied in transfection experiments, 
including the genes encoding Ras, EGF receptor, HER2, FGF4, RAF1, IGFII, cyclin 01 
and MORl. 
Ras 
One of the first candidate genes for hormone resistance exa1nined by transfection 
experiments was v-HRas 144, the oncogene of the Harvey murine sarcoma virus and 
the homologue of human c-HRas. Isolation of members of the Ras oncogene family 
(HRas, KRas and NRas), as the transforming gene from genomic ONA of different 
human carcinomas, implicated an important role of this gene family in the 
development of neoplasia. In human neoplasms, Ras genes can be activated by single 
amino acid changes at codons 12, 13 or 61, or by 5- to 50- fold amplification of the 
wild type gene 145. Ras plays a major role as a molecular switch in many signal 
transduction pathways, which lead to cell proliferation and differentiation. Ras is a 
GTPase that cycles between an inactive GOP-bound and an active GTP-bound form. 
Many ligands that stimulate cell surface receptors including EGF receptor, HER2 and 
FGF receptor, h'ansduce their signals via Ras. Overexpression of Ras has been 
described in breast tumors. Also point mutations at amino acid codon 12 (glycine to 
valine) were detected in HRas. Mutations or overexpression may therefore playa role 
in tumorigenesis and progression of some breast tumors, although Ras mutations 
occur infrequently in breast cancer (less than 5%). 
A possible role for activated Ras genes in hormone independence was studied by 
transfection of v-HRas into MCF-7 cells, which resulted in an ER-positive, estrogen-
independent phenotype 144. The v-HRas gene product differs from the c-HRas 
protein, p21, at two amino acid residues: glycine is replaced by arginine at position 12 
and alanine is replaced by threonine at position 59. Overexpression or single 
mutation of c-HRas had no effect on hormone dependence 146. Over the last few years 
many components of the Ras signal cascade have been identified 147.148. It is possible 
that deregulation of the Ras signal transduction pathway via other mechanisms than 
mutation of Ras itself may playa role in the progression of breast cancer 149. 
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EGF receptor 
In comparing hormone-dependent and hormone-independent breast cancer cell 
lines and primary tumors, the absence of ER and expression of a high level of EGF 
receptor in the latter group is often noted, as reviewed by '",), The EGF receptor/ 
ErbB-1 gene is the cellular homologue of the v-ErbB oncogene, originally identified in 
avian erythroblastosis viruses 151,152, The EGF receptor is a 170 kDa transmembrane 
glycoprotein with tyrosine kinase activity encoded by a gene on human chromosome 
7p12 153, Overexpression of EGF receptor has been observed in several types of cancer 
and cancer-derived cell lines, such as squamous cell carcinomas of the lung, 
glioblastomas, gastric carcinomas, bladder carcinomas, phyllodes tumors, and ovary-
and breast carcinomas, Overexpression of the recombinant EGF receptor cDNA into 
NIH-3T3 mouse fibroblasts lacking endogenous EGF receptor expression resulted in 
ligand-dependent transformation ill vitro and in vivo 154.155, 
EGF receptor protein has been detected in normal breast, breast cancers and 
breast cancel' cell lines, Six different ligands that bind to the EGF receptor have been 
identified, These include EGF, transforming growth factor CJ. (fGFCJ.), amphiregulin, 
heparin-binding EGF, beta-cellulin and epiregulin 156, Binding of a ligand to the EGF 
receptor results in receptor dimerization and activation of tyrosine kinase activity, 
leading to receptor autophosphorylation on multiple tyrosine residues 157, Signaling 
proteins with Src homology 2 (SH2) domains bind to these tyrosine-phosphorylated 
residues, initiating multiple signaling cascades leading to stimulation of proliferation 
or differentiation 158, EGF receptor can form heterodimers with the other members of 
the ErbB family, In combination with the different ligands, this may result in signal 
diversification, explaining the various functions of the ErbB family 159-161, In 
approximately half of the human breast cancers, EGF receptor expression is detected 
(range 14-91 %, dependent on the assay used) 150, Expression of EGF receptor is 
inversely related to expression of ER in breast cancer cell lines and in primary breast 
tumors both on the mRNA and the protein level 5,150,162, The presence of EGF receptor 
indicates a poor prognosis in primary breast cancer and correlates with failure of 
response to endocrine therapy in recurrent breast cancer 163.164, 
Two reports have been published involving ectopic expression of EGF receptor in 
human ZR-7S-1 breast cancer cells, The first study failed to demonstrate a relation 
between EGF receptor expression and hormone dependence 165, However, our study 
showed that expression of EGF receptor could bypass hormone dependence 166, 
Estrogen-dependent ZR-75-1 cells were infected with a retrovirus carrying the EGF 
receptor cDNA, The parental ZR-75-1 cells are fully estrogen-dependent for 
proliferation, and growth is inhibited in the presence of antiestrogens, The 
transduced cells, designated ZR/HERc, were ER-positive and EGF receptor-positive 
and acquired a proliferative response to EGF, Treatment with anti estrogens in the 
presence of EGF resulted in bypassing of estrogen-dependent growth, Furthermore, 
in contrast to the parental cells, prolonged antiestrogen treatment of ZR/HERc cells 
resulted in progression to estrogen independence and down-regulation of ER. 
Interference of ER and EGF receptor signal transduction pathways in ZR/HERc cells 
was observed when simultaneously activated 166, Influences of ER on expression of 
EGF receptor were demonstrated by antisense ER experiments in MCF-7 cells, 
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Decrease in the level of ER resulted in up-regulation of EGF receptor mRNA 167. 
These results may explain the observed inverse relationship of ER and EGF receptor 
in primary breast tumors and provide a potential link between loss of estrogen 
sensitivity and the acquisition of autonomous growth. 
HER2 
Another member of the ErbB family is HER2 (also called ErbB-2, neu or p18S). 
This proto-oncogene encodes a 185 kDa transmembrane tyrosine kinase receptor with 
close similarity to the EGF receptor 168. Amplification of the HER2 proto-oncogene, 
localized on human chromosome 17q21-22, leading to overexpression of the receptor 
protein is reported in approximately 20% of primary breast cancers. Overexpression 
can also occur from a single-copy gene (reviewed by 16,,). HER2 can enhance and 
stabilize dimerization of other ErbB members, but a ligand has not been clearly 
identified. Overexpression of HER2 is thought to lead to dimerization of the receptor, 
resulting in its autophosphorylation and activation of the protein tyrosine kinase 
domain. Overexpression of HER2 is sufficient to transform mouse NIH 3T3 cells 170. 
Overexpression of HER2 is inversely related to expression of ER and PR in breast 
cancer and is associated with high tumor grade. Furthermore, HER2 overexpression 
or gene amplification in breast tumors is associated with poor response to tamoxifen 
treatment in both ER-positive and ER-negative tumors 171.175. 
To determine a possible causal role of HER2 in estrogen independence, MCF-7 
cells were transfected with a HER2 cDNA construct. Cell clones showing over-
expression of the recombinant gene, in comparison with expression levels observed in 
the parental cells, were no longer sensitive to tamoxifen. However, tumor take in 
nude mice of these transfectants was still estrogen-dependent, but tamoxifen could 
not inhibit further outgrowth of the tumors 176,177. 
PGP4 
Fibroblast growth factors (FGFs) are a family of proteins that are important in 
development and angiogenesis. FGFs are transforming in NIH-3T3 cells and have 
been implicated in tumorigenesis and metastasis of breast tumors 178,179. Transfection 
of MCF-7 cells with FGF4 resulted in cell lines that are able of forming progressively 
growing, metastatic tumors in ovariectomized and tamoxifen-treated nude mice 
180,181. MCF-7/FGF4 cells are stimulated by tamoxifen and inhibited by estrogens. 
Whether this reflects some of the clinical observations remains to be established. 
Interestingly, FGF4 transfected cell lines could support growth and metastasis of the 
parental cell line, when both cell lines were coinjected in nude mice into the same site. 
This supports a role for paracrine factors in mixed populations of tumor cells of 
different states of malignant progression 182. FGP expression may be important in the 
progression of breast tumors from estrogen dependence to estrogen independence, 
and in the development of a metastatic phenotype. 
RAP! 
One of the major pathways activated by the EGF receptor ligands is the mitogen-
activated protein kinase (MAPK) phosphorylation cascade 158. The activated receptor 
interacts with an activated Ras, resulting in subsequent activation of the RAFI proto-
oncogene. RAFI is a serine threonine kinase that can directly phosphorylate nuclear 
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factors like p53, and indirectly transcription factors such as Myc, Elk and Rsh. MCF-7 
cells were transfected with a RAFI expression construct containing an amino-
truncated protein with constitutive kinase activity. Constitutive RAFI activity in 
MCF-7 cells is incompatible with growth in the presence of estrogen. However, under 
estrogen depleted conditions, RAF1 activity can stimulate growth 183. 
IGFII 
Insulin and insulin-like growth factors type I and II can stimulate growth of a 
number of breast cancer cell lines. These effects are mediated via the IGFI receptor 
which synergizes with estrogen in stimulating the growth of breast cancer cells ill 
vitro. IGFI and IGFII are expressed by fibroblasts in benign and malignant breast 
tissue 184. IGFII was overexpressed in estrogen-responsive MCF-7 cells to determine 
whether this would result in an autocrine growth mechanism. Increased expression, 
following transfection, of IGFII resulted in loss of estrogen dependence for 
proliferation and enhanced anchorage independent growth 1(}5,185. 
Cyclin D1 
Cell cycle progression is controlled at a series of checkpoints to ensure orderly 
progress of cell division. The mechanism for these control points involves sequential 
transcriptional activation of cyclin genes, and consequent transient accumulation of 
different cyclins with cyclin-dependent kinases 186,187. Deregulated expression of 
components of this strictly regulated system may lead to loss of normal growth 
control. Overexpression of cyclin D1 with or without amplification of the 
chromosomal locus 11q13 has been described for many tumors including breast 
cancer 188-192. Treatment with antiestrogens of breast cancer cells ill vitro results in 
rapid down-regulation of cyclin D1 mRNA expression, and G1 cell cycle arrest ". 
Therefore, overexpression of cyclin D1 could result in antiestrogen resistance. This 
h,rpothesis is supported by transfection experiments of cyclin D1 in breast cancer cells 
1 • T -470 cells were chosen because they are ER-positive and there is no evidence for 
cyclin D1 overexpression or amplification. Overexpression of cyclin D1 was sufficient 
for growth factor-independent acceleration of cells into S-phase. Similar experiments 
were performed in MCF-7 cells with an inducible cyclin D1 expression construct 1 ... 
Overexpression of cyclin D1 resulted in a continued proliferation potential under 
low-serum conditions, in contrast to control cells, which ceased to grow. This 
phenomenon is caused by a reduced cell cycle exit from G, to Go phase in the cells 
with overexpression of cyclin D1'93. Similar experiments performed with MCF-7 cells 
showed that growth of cyclin D1-overexpressing cells is still efficiently inhibited by 
antiestrogens 195. Recently, it was suggested that cyclin D1 binds to the ER and 
activates its transcriptional activity independent of estrogen 196,197. The role for 
overexpression of cyclin D1 in clinical breast cancer is contradictory with the 
experiments in T -470 cells. High levels of the protein are detected in well 
differentiated, ER-positive tumors, which respond well to tamoxifen treatment for 
metastatic disease 198,199. 
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MOR1/ p-glycoprotein 
Multidrug resistance (MOR) is a major problem in the chemotherapeutic 
treatment of cancer 200. Almost all breast cancers treated with cytotoxic chemotherapy 
develop multidrug resistance. Often this resistance is associated with high expression 
of the MORl gene, an energy-dependent efflux pump that reduces intracellular drug 
levels. If tamoxifen was a substrate of MORl this pump could be involved in 
antiestrogen resistance. MCF-7 cells transduced with the MORl gene exhibit a 
multi drug resistant phenotype. Nevertheless, overexpression of MORl did not result 
in cross-resistance to antiestrogens or loss of ER expression 201. Although this study 
showed that transfection of MORl did not result in tamoxifen resistance in MCF-7 
cells, some evidence exists for involvement of MORl in antiestrogen resistance. In the 
first study, a correlation was observed between p-glycoprotein level in tumors post 
treatment and response to tamoxifen 202. In the second study, MORl mRNA 
expression in the primary tumor was found to correlate with resistance to hormone 
therapy 203. 
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CHAPTER 3 

Concluding remarks 
I n Chapter 2, a variety of possible mechanisms causing antiestrogen resistance have been reviewed. For most of the described genes and mechanisms direct evidence for involvement in acquired tamoxifen resistance in clinical breast 
cancer is still required. Expression of EGF receptor and amplification of HER2 in 
primary tumors will predict a failure to respond to tamoxifen therapy 173,2"'. The 
transfection experiments reviewed above have revealed important facts leading to a 
better understanding of tumor progression. The major drawback of this approach, 
however, is its limitation to known and candidate genes. Unknown genes with yet 
unknown functions are not addressed. Review of these studies strongly suggests that 
many different mechanisms may account for antiestrogen resistance. The molecular 
mechanisms responsible for clinical tamoxifen resistance in the majority of ER-
negative and ER-positive breasts cancers still have to be elucidated. Further search for 
different gene products conferring antiestrogen resistance is needed. 
Random search for genes involved in hormone independence may be 
accomplished by transfection of total cDNA libraries into hormone-dependent breast 
cancer cells. High quality libraries containing full-length cDNAs are required for this 
approach. Transfer of cDNAs causing tamoxifen resistance would result in estrogen-
independent cell clones. Subsequently, the putative resistance gene may be identified 
and isolated using the expression vector sequences of the integrated eDNA. 
Thus far, one study was published applying this strategy 205. Mixtures of several 
cDNA libraries were transfected into tamoxifen sensitive MCF-7 cells. Tamoxifen 
selection of the transfected MCF-7 cells resulted in isolation of several resistant 
clones. One of these clones was further characterized, and had retained ER expression 
which is the phenotype of typical clinical tamoxifen resistance. Although this cell 
clone was isolated after cDNA transfection, involvement of the integrated cDNA has 
still to be established, and a spontaneous event, leading to antiestrogen resistance, has 
to be excluded, In Chapter 4 we discuss the use of retroviral insertional mutagenesis, 
to identify genes involved in antiestrogen resistance. 
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CHAP1ER 4 

Experimental work and discussion 
The aim of the experimental work described in this thesis was to gain insight into the mechanisms involved in antiestrogen resistance in human breast cancer, and to develop tools for the identification of involved genes. To 
accomplish this, a random search for involved genes was initiated. An approach was 
chosen in which estrogen-dependent breast cancer cells were altered by retroviral 
insertion mutagenesis. Retroviruses integrate into the DNA of the host cell and 
introduce random mutations, which may result in altered gene expression. Selection 
of the infected cells in the presence of antiestrogens (4-hydroxy-tamoxifen) should 
allow cells, which have acquired a favorable mutation to proliferate. The integrated 
retrovirus serves as a tag, which facilitates the isolation of the involved gene near or 
at the integration site. To assess the feasibility of this approach different experiments 
were performed, described in Chapter 5. 
Breast cancer cell lines for the study of honnone resistance 
It is widely accepted that human breast cancers are initially dependent upon 
estrogens for development and progression 69,206. During tumor progression 
eventually resulting in dissemination of the disease, estrogen-dependence is lost, and 
finally ER-negative tumor cell clones may emerge. The cellular and molecular 
mechanisms underlying these changes are poorly understood. Primary cultures of 
breast cancer specimens would provide ideal model systems for studying the 
progression of breast cancer, However, solid tumors are difficult to grow ill vitro, and 
large-scale experiments are therefore at present not feasible 2m, Hence, cell lines 
derived from breast tumors are widely used instead. With some limitations they 
proVide valuable models in the study of hormone resistance. Most breast cancer cell 
lines are ER-negative and are used for the study of hormone resistant disease. MCF-7, 
ZR-75-1, and T-47D are ER-positive cell lines, used in the study of the progression of 
hormone dependent breast cancer 105,200,209. Both MCF-7 and ZR-75-1 cells express 
functional ER and are estrogen dependent for growth both ill vitro and ill vivo. The T-
47D cell line is less suitable for our studies because of its genetic instability 210,211, 
which could result in a high rate of spontaneous development of resistant cell clones. 
The MCF-7 cell line is the most Widely used model and many variant cell lines have 
been established 17,200,209. Our initial experiments indicated that in comparison with 
MCF-7 cells, ZR-75-1 cells exhibited a more stable estrogen-dependent phenotype 
during prolonged large-scale culture experiments. For this reason ZR-75-1 cells were 
chosen for most of the experiments described in this thesis. 
The ZR-75-1 human breast cancer cell line was first described by Engel et al. 212. It 
was established from a patient treated for infiltrating ductal carcinoma by 
mastectomy and subsequent chemo- and antiestrogen therapy. Cells from a 
malignant ascites effusion were brought successfully into culture. This cell line is 
estrogen-dependent for growth, although the patient did not respond to treatment 
with tamoxifen. The ZR-75-1 cell line has been used for the study of hormone 
dependence in human breast cancer in many laboratories. 
ZR-75-1 cells maintained in our laboratory are fully estrogen-dependent for 
proliferation ill vitro and ill vivo 166. Depletion of estrogens or addition of an excess of 
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antiestrogens to the culture medium results in long-term growth inhibition of the 
cells. The rate of spontaneous progression of ZR-75-1 cells to hormone independence 
in the presence of 111M 4-hydroxy-tamoxifen (a more active metabolite of tamoxifen) 
was estimated to be less than 10" within a period of 5 weeks of selection 213. This 
stable estrogen-dependent phenotype is a valuable characteristic of the ZR-75-1 cells 
for the study of mechanisms involved in the progression to hormone independence. 
Ectopic expression of EGF receptor in ZR-75-1 cells. 
In Chapter 5.1, we show that transduction of the EGF receptor to estrogen-
dependent breast cancer cells is sufficient to bypass hormone dependence. This 
implicates that activation of a single gene is sufficient to induce hormone-resistance. 
This notion is important, because it is a prerequisite for successful retroviral 
insertional mutagenesis. Coordinate alteration of more than one gene in a single cell 
is technically not feasible in a restricted number of cells. 
Epigenetic mechanisms in antiestrogen resistance. 
In Chapter 5.2, we describe the effects of epigenetic changes in gene expression as 
a possible mechanism of development of hormone independence. Estrogen-
dependent ZR-75-1 cells were treated with 5-azacytidine to cause DNA 
demethylation. This may result in activation of genes controlled by CpG containing 
promoters. High numbers of cell clones developed upon treatment with 5-azacytidine 
in the absence of estradiol or in the presence of antiestrogens. Expression of ER, PR 
and pS2 (two estrogen-responsive genes) was down-regulated and expression of EGF 
receptor and HER2 was up-regulated in these ZR/ AZA cells. Proliferation of 
ZR/ AZA cells could be inhibited with an EGF receptor-blocking antibody, 
suggesting an autocrine growth mechanism. Our data show that hormone resistance 
may be caused by epigenetic mechanisms, affecting a large proportion of the cells 
simultaneously. 
Expression of ER, PR, and EGF receptor in breast tumors. 
Chapters 5.3 and 5.4: It has been shown that EGF receptor is expressed in tumors 
unresponsive to endocrine therapy. As described in Chapter 5.1, interference of ER 
and EGF receptor signal transduction pathways was observed when both receptors 
were activated simultaneously. Furthermore, ER and EGF receptor double positive 
cells rapidly progressed to a hormone-resistant phenotype. EGF receptor expression 
is inversely related to expression of ER in primary breast tumors. However, 
approximately 50% of ER-positive tumors express EGF receptor. It was not clear 
whether these two different receptors were simultaneously expressed in individual 
cells. In Chapters 5.3 and 5.4 we describe the expression patterns of ER, PR, and EGF 
receptor at the single cell level in a series of primary breast tumors and non-
malignant breast tissue biopsies. The observations were extended to a comparison of 
expression patterns in primary tumors and their metastases. It was shown that 
coexpression of ER and EGF receptor, and of PR and EGF receptor in tumor cells is a 
rare phenomenon, but does occur in non-malignant epithelial breast cells. Expression 
of ER and PR was determined at the single cell level in both primary tumors and their 
corresponding lymph node metastases, or in synchronously or metachronously 
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occurring bilateral breast cancer. Surprisingly, little differences were observed 
between steroid receptor expression of the primary tumor and the corresponding 
metastasis, or in bilateral breast cancers 5,214. This indicates that loss of ER is not a 
prerequisite for tumor spread to the lymph nodes, and may represent a late event in 
tumor progression and development of hormone-resistance. 
Retroviral insertional mutagenesis. 
In Chapter 5.5, our approach to unravel the mechanisms of antiestrogen resistance 
by retroviral insertional mutagenesis and the first common integration site linked 
with antiestrogen resistance are described. A random search for involved genes by 
reh'oviral insertional mutagenesis was performed. Retroviruses may act as naturally 
occurring mutagens, becaus~ integration of proviruses into the DNA of a host cell is 
part of their life cycle 215. Insertion of the provirus results in rearrangement of the 
chromosomal DNA of the host cell, which may lead to alteration of gene expression. 
Genes in the vicinity of or at the integration site may be activated, inactivated or 
truncated by the retrovirus. Consequently, reh'oviruses may mimic (epi-)genetic 
changes leading to tumor progression. Development of convenient retroviral vectors 
216 and safe packaging cell lines 217 have made retroviral tagging an attractive tool for 
in vitro mutagenesis. Retroviruses show little selectivity for specific DNA sequences, 
which is a prerequisite for random mutagenesis 218. Another favorable property of the 
retroviruses for gene targeting is the reported selection for transcriptionally active 
regions in the genome 219. Furthermore, infection is a highly efficient process, 
compared with frequencies obtainable by stable transfection of plasmids. In mouse 
models, many proto-oncogenes have been identified as key genes involved in 
tumorigenesis by insertional mutagenesis (reviewed by 22'). Three major mechanisms 
for up-regulation of gene expression have been identified; promoter insertion, 
readthrough activation and enhancer insertion (reviewed by 220.221). Inactivation of 
gene expression by retroviruses is a less likely mechanism due to the presence of the 
second allele, or even additional clu'omosomes in the situation of polyploidy, which is 
often observed in established cell lines. Comparison of the genomic DNA of a 
number of related tumors or cell lines may show the existence of common integration 
sites. This term refers to a particular locus that is occupied by proviruses in different 
independent tumors or cell lines. The presence of a retroviral genome integrated in a 
specific locus of several independently arisen tumors or cell lines strongly suggests 
that a specific gene function was altered by the viral integration, which resulted in the 
development of the tumor or the outgrowth of a cell clone. Our efforts to infect as 
many as possible cells in a particular experiment has the disadvantage that a single 
cell clone may have been infected by a number of retroviruses not all contributing to 
the altered phenotype. Identification of a common integration site facilitates the 
identification of the responsible locus involved in a specific process. The retrovirus 
with its unique DNA sequence in the host cell serves as a tag to isolate the locus and 
the involved gene. 
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Identification of genes involved in tamoxifen resistance 
ZR-7S-1 cells , 
Infection with retroviruses , 
Selection with tamoxifen , 
Resistant cell clones , 
Integration site specific probe , 
Southern blot analysis , 
Common integration site 
.....c> 
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BCAR2 
BCAR3 
• Characterize locus ,
Transfer of locus 
<I- Somatic cell hybrids 
Isolation of candidate gene 
/~, 
Tumor analysis , 
Western blots 
Immunohistochemistry 
Clinical correlation? 
T ransfection Function 
Signal cascade 
Tamoxifen resistant? Treatment? 
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BCARllocus 
Retroviral insertional mutagenesis and selection in the presence of tamoxifen 
resulted in eighty tamoxifen resistant cell clones. Search for common integration sites 
resulted in the identification of BCARl (Chapter 5.5). Further evidence for the 
involvement of this locus in tamoxifen resistance was obtained by somatic cell hybrid 
experiments. Cell hybrids of parental ZR-75-l cells and one of the BCARl clones 
showed that the resistant phenotype co-segregated with the BCARllocus. Molecular 
cloning of the gene adjacent to the integrations and subsequent expression analysis 
showed that it was up-regulated in the BCARl clones compared to the ZR-75-l cells. 
Sequence comparison analysis demonstrated that BCARl is the human homologue of 
the rat p130 Crk-associated substrate (CAS) gene (A. Brinkman et al.; manuscript in 
preparation). p130CAS has the structural characteristics of an adapter gene 222-224. It 
was localized on human chromosome 16q22-23, by fluorescent in situ hybridization 
(T. van Agthoven, unpublished results). Distinct signal transduction pathways have 
been identified that led to tyrosine phosphorylation of p130CAS suggesting that it may 
playa role in integrin- 225.226 and mitogen-mediated signal transduction 227. The exact 
role of BCARl in development of hormone resistance has to be determined. 
BCAR2locus 
Further experiments involving somatic cell fusion identified a second resistance 
locus BCAR2 affected in two cell lines of the panel 228. Recently a possible candidate 
gene in this locus was isolated using cDNA selection, screening of eDNA libraries, 
and RACE strategies. Northern analysis with these eDNA probes identified 
transcripts of 5 and 8 kb in BCAR2 cell lines and in other human tissues. Transfection 
experiments to demonstrate the role of this candidate gene are progress O. 
Veldscholte, unpublished results). 
BCAR3 locus 
In Chapter 5.6 we report on the cloning and partial characterization of the BCAR3 
gene, involved in tamoxifen resistance 229. The BCAR3 locus was identified as a 
common integration site in six independently derived cell clones with a proviral 
integration in a 5 kb region, strongly suggesting that this locus carries the gene 
involved in tamoxifen resistance. Furthermore, cell fusion experiments showed that 
transfer of this locus confers tamoxifen resistance to the tamoxifen-sensitive recipient 
cells. Screening of Northern blots with the common integration site-specific DNA 
probe identifies a transcript in estrogen-independent MDA-MB-231 breast cancer 
cells and in different normal human tissues. This 3.4 kb mRNA is up-regulated in the 
antiestrogen-resistant cell lines in comparison with the expression level observed in 
the parental ZR-75-1 cells. The cDNA was isolated from a testis libraty. Transfection 
of a BCAR3 cDNA construct induces antiestrogen resistance in ZR-75-1 and MCF-7 
cells. Sequence comparisons of the BCAR3 cDNA clone show that this transcript 
represents a novel gene containing an SH2 domain, suggesting a role in signal 
transduction. Another domain shows some homology with a part of the yeast CDC48 
gene which has a role in cell division and apoptosis. 
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Cumulative data from in vitro studies and analyses of tumor biopsies strongly 
suggest that many different mechanisms may account for antiestrogen resistance. The 
molecular mechanisms that are operative in clinical tamoxifen resistance still have to 
be explained for the majority of ER-negative and ER-positive breast cancers. 
Presently, three new genes that playa role in tamoxifen resistance in vitro have been 
identified in our laboratory. We have shown that retroviral insertional mutagenesis is 
a useful approach to identify (novel) genes involved in antiestrogen resistance. The 
identification of the BCAR1/p130CAS and BCAR2 and BCAR3 genes may provide 
important new insights in the biology of breast cancer. Further search for different 
gene products conferring antiestrogen resistance is needed. They may be identified 
from our panel of cell lines. It is essential to establish the role of these gene products 
in clinical breast cancer. Furthermore, it will be of great importance to establish which 
signaling cascades, leading to proliferation, are active in hormone-resistant breast 
cancer cells. Therapeutic strategies may ultimately be developed intervening with 
these escape routes of the tumor cells. 
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Ectopic Expression of Epidermal Growth Factor Receptors Induces Hormone 
Independence in ZR-7S-1 Human Breast Cancer Cells' 
Ton \'an Agtlioven,l Thecla L. A. mn Aglhown, Henk Portengen, John A. Foekens, and Lambert C. J, Dorssers 
Dtpal/m,,,t ,,[Molrcular Bi%g)' {T. v. A., T. LA . ••• ~_. L C. J. D.f and DhifiOl! of EnJo.;rin~ Oncology {II. P., I. A, r.J. Tltt 0,. f>ilnit/ dtlf Hwd Canc(r C(nI(r, 
P. O. Box $101, )00,1 AE Rotterdam. {he Ntlhrr!a~Js 
ABSTRACT 
Epldumal gro~lh (~tlor (EGF) re,eplol Is InHrsd)' rdated to ex· 
pruslon of \'~trogtll receptor (ER) and progesterone H(eptor In primal)" 
brnsl lumors and is II Mgathe predictor (or respon'!e to endocrtM 
thuap)" To Inlesligale II. possible C1lusal role of EGF receptor uprn· 
!Ion In breast cancer progression to hormone IndependenN. \'Ie hut 
(:luted an experimental cell s)'stem. Epldumal gWl'llh factor receptor 
complem~ntary DNA I>iS Introduced III estrogen-deptlldent ZR·7S-1 
bru.st can(U Nils, and the resulting ZRjHERc cells exhibited a mito-
genic response to epldnmal grolllh faClor, thus b}puslng utrogen 
dependence. This EGF·induced prollferation could nOI be Inhlbllffi by 
antleslrogens. In additilJn, we noted changes In cell morpho!og)' and 
kentln expression of EGF·sllmulat~d ZR/HERc (ells, suggesthe of an 
altered dIfferentiation stale. Furthermore, IntlJleranee of functllJnal En 
and EGF receptor signal transductIon pathll/l}'s in ZR/HERc ails lias 
obsened during simultaneous aetllallon, IIhlch posslbl)' explains the 
Inluse relationship of ER and EGF receptor e~prusion In primary 
tumors. In contrast to the parenlal cells, ZR/HERc cells rapldl)' pro· 
gressed 10 II slltble ER·negatlle phenot)pe IIhen cultured in the pres· 
ence of the antlestrogen b)·drox)"·tamoxlfen. These results suggest II 
possible role tor EGF receptor [n progressIon of breast cancer to hor· 
mone IndependeMe. 
INTRODUCTION 
The development of the normal mammary gland is regulated 
by steroid hormones and polypeptide growth faclors. Insights 
into the mechanisms b)' which these factors induce cell prolif· 
eration and diITerentiation and how these factors are imolved in 
breast tumor proliferation ha~'e remained limited (1-3). Antag-
onists of steroid hormones are clinically important in the man-
agement of breast cancer, especially the antiestrogen, tamoxifen 
(4, 5). Antiestrogens compete with estrogen for binding to the 
ER) and can antagonize the action of estrogens on gene expres· 
sion via different mechanisms (6-8). About one-Ihird of pa-
lients with advanced breast cancer show an objeclh'e response 
to endocrine treatment. In case of response, progression from a 
hormone-sensitive to a hormone-insensitive state occurs almost 
inevitably during prolonged therapy. The mechanisms underly· 
ing this progression are complex and, as yet, unclear (9-13). 
Numerous studies have established that, in human primary 
breast cancer, expression of EGF receptor is inversely corre-
lated with ER expression (14). In addition, expression of EGF 
receptor and ER in breast cancer cell lines is also im'ersely 
related (15). Generally, patients with ER·negath·e primary tu· 
mots ha\'e a worse prognosis than those with ER'positiH! tu· 
Re~r.ed 5/~{n; an'epted 7/'Jin. 
He COlts of publkJtion of this .1..Itk1e IIUt defrJjed in pm h th~ pJjmtnt of 
PJgt~h'fgf!. This ~l1kle mUlt thudore ~ htreb)' ml1~~d aJ\<flium~nr in 3C\:ord· 
3nCt "ith 18 U.S.c. S-K"tiOD l1H ~o!et)" to indicate this fad. 
1 ThiJ "(>lk "'" suppOrted h the Josephine I\ef\en. Stkhting Jnd the Out;:h 
Canw S<Xiel)' (OOHK n-tll). 
1 To "hom w\uel!s (or reprints should be .ddres.s<:d. 
'The abbre>iations uS(d ar(; ER, estrogen r(<<ptor; [Gr, epidmnal g'o"tll 
f~tor; ,O:-O;A. ~omplementu)· O:"'A; DCS. OOliM <aIr ~~rum: SF~[. !(rum·free 
mffiium; MTT, J.(~.S-dimeth}hhilZot.2·~1)-2,S-diphen)lt<trlZotjum bromide; 
BSA. ooliM S(rum albumin; PR, progeS(UOM (~ptor; PBS. p~olphjte-bulTe'ed 
salin,; DCC, dHtriUl-roated (h:!.fi:o.l; rcs. fetal calf S(rum. 
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mors (16). Whether patients with EGF receplor-positil"e tu· 
mors have an unfa\'orable prognosis is at present a matter of 
debate (for a re\'iew, see Ref. 17). Ne\'ertheless, it has ~en 
shown that tumors expressing EGF receptors fail to respond to 
hormonal therapy (18, 19). The relation between EGF receptor 
expression and a possible causal role in the de\'elopment of 
hormone-independent tumors is unknown. A feasible approach 
to address this question is to ill\'estigate in vitro Ihe biological 
consequences of ectopic expression of EGF receptors in hor-
mone·dependent cells. 
For the present stud)', we created a new cell system to study 
ill vitro the role of EGF receptor gene expression in progression 
of human breast tumor cells to hormone independence. Since 
growth of the ZR·75-1 human breast cancer cell line is fully 
estrogen dependent, this cell line pro\'ided an atlracth'e in vitro 
model. We transduced the human EGF receptor cDNA in es-
trogen-dependent ZR· 75-1 celts and studied the effects of EGF 
receptor expression on hormone- and EGF-mediated cell pro· 
liferation, differentiation, and progression to hormone indepen· 
dence. 
MATERIALS AND METHODS 
Cells. ZR-7S-1 and ZRJHERc cells are mainlained in RPMI·16-10 
medium (Gibco BRL, Life Technologies Ltd, Paisley, United King· 
dom) supplemented with 10% heat·ina(lhated IlCS (H) Clone Labora· 
tories Inc, logan, UT) and In', 17i:!·eslradiol. The kar)"otypic charac-
teristicsoflhe ZR-75-1 human breast can(er cell line maintained in our 
laboratof}' and the deril'ed ZRJHERc celJs are similar to the original 
published data for ZR-75-1 (20). Cytogenetic analyses were carried out 
using R·banding. PA311 cells (2t) were maintained in Ham's F·Il! 
Dulbecco's modified Eagle's medium. 1: I (Sigma, St. louis, MO), with 
10% BCS. Cell cultures lleee fOutinely checked for M"'COp!<UfII4 con· 
lamination with a DNA·staining rea.:tion using the bisbenlimid3.lole 
fluorochrome, Hoechst 33258. 
Hormones. 17~·Estradiol (Merck, Darmstadt, German}'), 4-0H-
tamo\ifen, and ICII6-i,384 (lCI, Me.:desfleld, Uniled Kingdom) sto.:k 
solutions were made in absolute ethanol and stored at "'Co EGF, from 
mouse submaxillary glands, .... ;l.S obtained from Ilwhringer Mannheim 
Gmbh, Mannheim, Germany. 
Retrodral Gene Transfn. Clonal ampholropic NTK·HERc lieus· 
producing cell tines lIere established b}' infection of PAJI7 cells lIith 
cell·free (O,-lS I'm flltrated) supernatant of NTK/HERc \irus·produdng 
(22) psi·2 cells for 17 h in the presence of 81'" Pol)brene (Sigma). 
Clones lIere selected in medium lIith I mg/ml ofG41S (Gibco BRL). 
Using the same procedure, we infe.:ted the ZR·7S-1 .:ells lIith the 
amphotropic NTKlHERc receptof \'irus, and cell clones (ZRlHERc) 
.... ere isolated using G-I18 selection and expanded in estradiokontain· 
ing medium. 
Cell PloliferatilJn E"{perimenls. Cells from subconfluent cultures 
wefe han'wed by treatment .... ith tf}'Psin·EDTA (tf}"psin, 0.05%: 
EDTA, 0.5 m'r). Single cells were plated into 2S-cm1 plastic culture 
flasks (Costar Europe Ltd., Cambridge, MA) in medium with 10% 
BeS, lIithout e>lradiol. Mler 2-1 h, 10 allow for cell attachment, the 
culture medium lias replaced lIith e'perimental medium. RPM[-16~0 
medium lIilhout phenol red, supplemented with 10% heat-inacthated 
FCS and stripped b}' DCC. lias used. The mathematical technique of 
leibolilz il al. (23) lias used to obtain tbe generation time ofea(h cell 
clone. E~pHimenls to e\alu~te the dTects of the addililu in Snl were 
performed using the MIT assar (24). Cells .... ere distributed in 96· .... ell 
plales in RP~1I·1640 plus 10~il DeS \0 a11o .... for cell allachmenl. Aftu 
24 h, Ihe culture merlium .... as replaced .... i!h achemkally defined SFM, 
consisting of Ham's F·12lDulbecco's modified Eagle's medium (1:1) 
lacking phenol red and supplemented .... ith 0.2% BSA (purified; Be· 
hring .... erke AG, Marburg, German)"}, 2 m', glulamine, 10-3 ~! trans· 
ferrin, 10 "g/ml porcine insulin (Organon, Oss, the Netherlands), and 
50 ng/ml sodium selenite. MIT reduction .... as ass3}'ed after 6 da}s of 
culture b}' measuring the absorbance at 510 nm .... ith an automatic 
microplate reader (Tilemc. Flow Laboratories Ltd., Inine, Scotland). 
Quantlt.atioD of Hormone and EGf Receptors. Cells were cultured in 
225·cm2 flasks in medium containing 10% BeS and I n'l estradiol. 
Appro~imalel)' 5-1 x 10' cells were preincubaled for 11 h in SFM, 
prior to hanesting wilh 0.5 m\l EDTA. This preincubation was per-
formed, since Ihe presence of growth faclors in serom andlor fndoge-
noud)' product'd b)' the Nils interfered .... ith the estimation of receptor 
numbers. Ilinding of ml·EGF to ZRtHERc cells .... as masled up to 
80% .... hen proXuhure in SFM \las omimd. Cell pellets were stored at 
-80'C until UM'. Cell pellets were puh'erized and homogeniz.ed with a 
mkrodismembrator at -196T, as described else\lhere (2S}. The ho-
mogenale \IllS centrifuged for 20 min at 100,000 x g at 4'C, and Ihe 
supematant fraction (c)losolk extract) was used for ER and PR deter· 
minations, using commncial1)' a\ailable enlyme immunoassa>' kits 
(ER·EIA, PgR·EIAj Abbol\ Laboratories, Chicago, IL). The membrane 
fraction for EGF receptor determination .... as resuspended by homoge· 
nization of the 100,000 x g pellet in 2.5 101 PBS solution containing 
Badtradn (Sma.. Heidelberg, German)') (70 "glml), with three 5-s 
bursts of an Omni-1000 tissue homogenizer (Omni International, 
Waterbury, Cl), and subsequentl)· clariOed by centrifugation for 10 min 
at 1000 x g. ~lu1tiple·poinl Scatchard analyses of Il~I_EGF binding 10 
membrane preparations "'fre performed as dHcribed pre\10usl)' \lilh 
minor modifications (26, 27). Briefl)', 100·,,1 membrane preparations 
\lere incubated in a final \olume of 140 "I for 18 h at 20'C lIith 
increasing concentrations (0.15-3.5 n\,) of IHI·EGF (spedfic acti\'it~·, 
500 Cilmmol, mouse EGF, receptor grade, Sigma; radiolabeled with 
ProlSg 125, Baker Fine Chemicals, Philipsburg. NJ) in the absenN and 
presence of a 200-fold excess of nonradioacliw EGF. Separation of 
bound and free EGF \las performed by h)'dro.\}'lapatile adsorption. 
Hydro:\)'lapalite.bound radioacthit)' .... as counted. 
Immunonuorescence. Cells were haneSled with 0.5 m', EDTA, 
washed \lith PBS plus 0.5% BSA, and C)locentrifuged on slides. The 
slides were fl\ed for 5 min in methanol and I min in acelone at -20T. 
SlidH \Hre hpt frozen unlil use. Indirect immunonuorescence staining 
lias performed al ambient temperature. Slides \lere rinsed in PBS plus 
0.5% DSA prior 10 specific antibody binding. Incubation of primary 
antibodies \las performed in a wet chamber for 60 min al ambient 
temperature. After \lashing. the slides \lere inCUbated for 30 min \lith 
J 5 "I goat anti·mouse immunoglobulin-fluorescein isolhioqanate (Da-
copam, Glostrup. Denmark). After a Ona/ washing with PBS contain· 
ing 0.5% BSA for 15 min, the slides were mounlfd in gl)'cero/lPBS 
(4:1) \lith an antibleach ag~nt, 1,4.Diaubk)'cJo·octane (Sigma). The 
antibodies u~d In this stud)' .... ere ReK 105 to keratIn 1, ~I 20 to 
keralin 8, ReK 106 to keratin 18. LP2K to keratin 19, and RY 202 to 
\imentin and H.\IFG-2. Anti·desmin .... as a kind gift from Sanbio BY, 
Vden, The :-"etherlands. 
RESULTS 
Expression of the EGF Receptor cDNA In ZR·7S-1 Celis, 
The human EGF receptor cDNA (28) was effidently intro-
duced into ZR·7S-! cells with the retroviral \'ector NTK·HERc 
(22), which carries the human EGF receptor eDNA under con· 
trol of the herpes simplex thymidine kinase promotor_ The 
combination \lith the neomycin resistance gene expressed from 
the 5' LTR provides a selectable marker. After the ZR-75-1 
ails were infected with the retroviral \'fctor NTKlHERc, six 
G4 J g·resistant clones were selected with one integrated cop)' of 
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the EGF receptor cDNA and a different integration pallern, 
indicating their independent origin (determined by Southern 
anal~'sis using a Neo probe, data not shown). ZRlHERc clones 
\\ere studied for their EGF receptor expression by SC3tchard 
analysis using \HI·EGF. ZR/HERc clones contained high·af· 
fin it)' ml-EGF binding sites (Kd = 0.9-1.5 n\l) with different 
EGF receptor !c\'els (range, 43-251 fmol/mg membrane pro-
lein) (Table I and Fig. I). in contrast, the parental cell line 
ZR·75-1 contained no detectable EGF receptors, as deter-
mined in 8 independently performed Scatchard analyses. EGF 
receptor mRNA was found only in ZRlHERc clones and not in 
the ZR-75-1 parental cells (Northern analysis not shown). All 
generated dones retained ER and PR receptor expression, sim-
ilar to the parental ZR-75-1 cells (Table I). 
Proliferation·inducing Effects or EGF on ZR-75-1 and ZR/ 
HERe Cells. To test the functionality of the ectopicall~' ex-
pressed EGF receptors, ZRlHERc cells were examined for a 
proliferative response to EGF, The number of general ions dur-
ing a 12·day culture period of six independently derived EGF 
receptor-expressing dones is presented in Fig. 2. VirtualJ)' all 
examined dones responded to EGF with cell proliferation, and 
all clones exhibited a dear increase in cell size and change of 
cell morphology (see Fig. 7 and below). EGF induced a signif-
icant increase in ZRlHERcceli populalion-doubling time com-
pared to stimulation with estradiol. The parental cell line ZR· 
75-1, expressing no delectable EGF·binding sites, did not show 
any response to EGF in >10 independent experiments. Subse-
quently a shorHerm culture assay was performed to determine 
the effect of EGF and estradiol on MIT reduclion in SFM. 
Although estradiol is a poor inducer of ZR-75-1 cell prolifer-
ation in our serum·free system as determined by cell counting 
(not sho\\n), MIT reduclion in both ZR-7S-1 cells and ZRJ 
HERe cell dones was significantly increased after 6 days or 
culture in the presence of estradiol (Fig. 3). EGF stimulation of 
ZR-75-1 cells in this serum·free assay did not affect MTT 
reduction. In contrast, ZRlHERc dones exhibited a dear en· 
largement of the cell size, a change in morphology, and a strong 
increase in MIT reduction (Fig. 3), indicating that EGF in· 
duced an elevation of the mitochondrial acth'ity in these cells 
independently of proliferalion. 
EGF Can Bypass Inhibition of OH·Tamoxlfen, ZR·7S-1 
cells maintained in our laboratory are strictly estrogen depen-
dent for proliferation (Fig. 4, see also Figs. 2 and 3). Estrogen-
induced stimulation ("Quid be completely inhibited by the simul-
taneous addition of the antieslrogen OH·tamoxifen (I !.1M), 
Similarly to ZR-75-1 cells, the estrogen-induced stimulation of 
ZRlHERc cells was ("Qmpletely suppressed by the antieslrogen 
OH-tamoxifen. In contrast, the EGF-induced 9·fold growlh 
stimulation of the ZRlHERc cell culture could not be inhibited 
by OH-tamoxifen (Fig. 4). These results demonstrate thai the 
Table I bplw/on (Of horm(Ont rtaplOIJ and EGF ItUflClJ en ZR·7S-J ond 
ZRIII£R(uIlJ 
C~l1i ... ae tro ... n in medium containing IO~. BCS and tstudio! II n,.). Ctl1i 
(5-7 x 10') ... ere han filed ... ilh O.~ m,. EOTA. an~r oHrnight incubalion in 
Sf~l. for receptor delerminallons, Value! are in fmo!/mg pro,dn. 
CtH tine EGF receptor E. PR 
ZR·75 I J4 >SOO 
ZRIHERc IA 181 J4 >500 
ZRflIERc tD 
" 
62 >500 
ZR/HERc IE 
" 
JJ >500 
ZRnlERc IF 2" 
" 
>SOO 
ZRIHERc IG 81 91 >SOO 
ZR/HERc 111 
" 
53 >500 
• :-"0 !p~ifi~ llJj·EGf binding. 
estrogen-dependent proliferation palhwa)' can be bypassed by 
exogenous EGF in cells carrying eClOpically expressed EGF 
receptors. 
Estrogen Responsheness after Pre-cuHure \lith EGF. To es-
tablish whether preculture of ZRlHERc (or ZR-7S-I)cells with 
EGF would affect subsequent estrogen-dependent proliferation, 
cells were cultured for 12 days in the absence and presence of 
EGF (Fig. SA) and subsequently replated in estradiol-contain-
ing medium. Fig. 58 shows that preculture of ZRlHERc cells 
with EGF reduced secondary colon), formation to 15% when 
compared to preculture in the absence of EGF. The ability to 
form colonies by the parental ZR-75-1 cells was not affected by 
preculture with EGF. The differences ohserwd were not a result 
of variation in plating efficiencies. To investigate whether 
down-regulation of ER in EGF-treated ZRIHERc cells had 
occurred and thus could explain the loss of estrogen response, 
the number of steroid receptors was determined on the same 
batch of cells (Fig. SA), Following additional culture for 2 days 
in estradiol-containing medium, to allow also measurement of 
Bound/Free 
0.4,----------, 
+ 
0.2 
o 
+ 
500 
Bound EGF IpM! 
1000 
fig. I. &atchaJd anal}si! of EGF binding. lllJ·EGF_binding slOdits lIere 
~rform~d a$ dll.(:ribed In ~Ma1erials and Method5.~ Specific binding of t~r~e 
"Pf.senl3Iiw dones (HERc·IA. -ID, and ·IF) i5 ploued. 
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Fig. 2. Proliferation·inducing tfftC15 of EGF. ZR·75-1 and ZRiHERc ctlb (2 
x 10!) lI~re plated In RPMIIBCS mtdium in 2~-<ml culture n&.!u. Afler 24 h. 
th~ medium II&.! feplac~d .. itb RPMIIDCC·FCS, "ilhoul EGf (0), "ilh rGF 
{OJ. or "ilh estradiol (U). Cell, ..ere baJHlled 00 day 12 and counted, and Ihe 
oumber of generatioos "a.s calculated. 
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Fig. J. Effect of EGF and eslradiol in SFM on MIT reductlon by ZR·i3-1 
celis (ZR) snd ZRfHERc cell clones. Celts "ere plated in RPMIIBCS medium 11 
a deMil} of 2500cells/..en.oo da} 0; af1er 24 h, I~t medium ";i.$changed 10 SFM 
(0), SFM CDntaining estradiol (I n'l. a), or EGF (10 ng/ml, 0). Cell s1imulation 
.. a5delermined on da} 6 u5ing the ~ITT als!} and is shown a.\ Ihe abso.bance 510 
om reading. All UIUH au t~e mUM of 8 ..e1l5 (:tSD). 
PR expression, extracls prepared from Ihese ZRfHERc cells 
contained high amounts of bolh ER and PR (Table 2). The 
presence of PR indicates thaI the lack of colon)' formation 
induction of EGF-Ireated ZRlHERc cells b)' eslradiol was not 
caused by a defeclh·e ER machinery, since PR expression is 
regulated by ER (29). 
EGF-medlated Growth Control, To address the Question of 
whether EGF-mediated e\CnlS are dominant O\"er those of es-
tradiol or n·ce I"ersa, the eITt'cls of EGF and estradiol "hen 
supplied individually or simultaneously were inwstigated, The 
number of ZRlHERc cells in the estradiol-stimulated (l0 or 
100 p.'I) cultures was signifkanlly reduced by Ihe additional 
presence of 10 ng/ml EGF (Fig, 6), in spile of lhe growth 
stimulatory effects of EGF in the absence of estradiol. Inhibi-
tory effects of EGF alone (up to 100 ng/ml) were nol obsm·ed 
(not shown). Furthermore, the morphology of these ZRlHERc 
cells was similar to Ihe cell cultures supplemented \\ith EGF 
alone. Increase of cell population·doubling lime of ZRfHERc 
cells was also obsen-ed in long-term cultures (20 days) stimu· 
lated with EGF and I n~l estradiol (data not shown), Cultures 
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Fig. 4. [ITeCi QfOH'lamo\ir~n on EGF- 01 Wradiol·ffitdimd prollfml1ion of 
ZR·75-1 and ZRlH£R~(tlls. Celb (1.5 x IO~) "ert plated in RPMJIBCS me-
dium. Afltr 24 h, the following fwors "He added: EGf (10 nglm!, oJ, EGF + 
OH·ramo\ifUl (I ~", OJ, estradiol (l D". III), or estradiol + OH·tamo\ifen (III), 
Tbe means.t SD oftriplkate incub~lion!. han!Sled and counted 00 dl} 10, au 
plomd. 
A B 
ZRntERo 2R-76-' ZRnlER¢ 2R·16-\ 
Fig. 5. RepJaling emden') afln precuhure "ilb EGF. ZR·75-1 and ZR! 
HERe cells (I x 107) 'Mle plalfd on day 0 in medium rl~s 4.5% DeC·fCS. 
... ilhoul (OJ or "ilh EGF (10 nglml, 0) (in duplka\e). The cells "err hanmed 00 
da) 12 and cQunle.! (Al, Subsequeml)', singk-<eU suspension! containing I x 10"' 
cells 'Hie sHded in 2S-<rn1 n1.lks "ill! medium (Qnlaining estradiol (I fl"). MIH 
12 da~~ of c~!t~rt. the number of {~n colonies ",u detnmined (8). 
supplemented with EGF and 100 n~IICI 164,384, which com-
pletely eliminates the stimulatory effect of 10 p~1 estradiol, 
showed slightly enhanced proliferation of the cells (Fig. 6; two 
additional independent experiments nOI shov,-n). This rna}' be 
explained b)' neutralization of remnant traces of estradiol in the 
DCC serum b)' the pure antagonist. Our results strongly suggest 
that simultaneous induction of ER-medialed gene activation 
and EGF receptor signal transduction in ZR/HERc cells is nol 
tolerated. 
Structural Alterations of ZR/HERc Cells Cullured '>lith 
EGF. ZRlHERc cells could be maintained in culture for >14 
weeks with EGF in the absence of estradiol, \Iithout apparent 
loss ofl'iability «5%), as determined by the trypan blue exclu-
sion method and reduction of MIT in individual cells. Stimu-
lation of ZRIHERc cells with [GF resulted in altered cell mor-
phology. The Cell volume increased significantly, and some cells 
contained manrl'acuoles (Fig. 7, A and B). In addition, the cells 
appeared more Ilallened, and a stronger adherence to the plas-
tic culture flask was noted compared to ZRlHERc or ZR-75-1 
cells cultured in the presence of estradiol. To determine 
whether EGF-induced maturation rna}' explain these morpho-
logical alterations and the faiture of secondary colony forma-
tion in estrogen-contal'ning medium (Fig. 5), expression ohar-
ious cyloskeletal proteins and the milk fat globule antigen 
(HMFG-2) membrane glycoprotein was studied using mono-
clonal antibodies. Intermediate filaments haw been established 
as markers of cell differentiation and are well preseo'ed during 
malignant transformation (30). ZR·75-1 cells expressed ker-
atins 8, 18, and 19, typical for the luminal epithelial cell. in both 
estradiol- and EGF·supplemented cultures, EGF induced an 
increase of keratin 8. 18, and 19 structures in ZRlHERc cells 
after 10-12 days of culture, compared to control cultures with 
estradiol. E\'Cn more noticeable was the change in liIament 
structure for keratins 8 and 18, which changed from a loose 
network of slender fibers to a very dense structure when stim-
ulated with EGF (Fig, 7, C and D). No such changes were 
obsen'(d in ZR-7S-1 cells. To exclude that this phenomenon 
was solely due to reduction of proliferation, ZRlHERc and 
ZR-75-1 cells incubated for 12 days in media without EGF or 
estradiol were analyzed, These cells did not show a change in 
cytoskeletal structure and displayed a moderate decrease in ker-
atin expression lewis. All studied cells were negatil'e for keratin 
7, desmin, and I'imentin, Cell membrane HMFG·2 expression 
was strongly increased following Ir{'alment of ZRlHERc cells 
\\ith EGF, Since HMFG-2 is a marker for mature cells (31), 
Ihis result suggests that ZRlHERc cells progress to a more 
mature state following treatment with EGF, 
Progression to Hormone Independence. We next determined 
whether ectopic expression of EGF receptors would effect 
the rate of progression to a completely hormone-independent 
phenotype, ZRlHERc cells and control ZR-75-1 cells wert 
cultured in medium containing 10% BCS and excess OH-
tamoxifen (l jJ\I), The gro .... 1h ofZR-7S-1 cells was completely 
Tablt 2 SMUt 't(ipro, txpfijsfo~ by ZR·75-J und ZRIHER( ails 
('(11~ (I x 10') "ue ",,!lured in m~dium "hh tO~ DCC·fCS ,onlaining no 
addili,fS or EGF (10 nJl/ml) a.\ indical~d. Mltr 12 da)s, a !mAll portion "'&5 Ujtd 
for the rfplaling !ludy tFig, ~B), and lhe remaining (dh "ere inc~ba1td in 
eS1tadiol·!upp!emfnled medium for 2 da~s. Afler 11 funhu 4 h inClibalion in SfM. 
the (elll ... ere hanemd "ith 0,5 m'l £DTA and uled for rl\;eplOr dmrmination$. 
Value! are in fmo!!mg proain . 
(,~H Ent Addition £GF re~eplOr ER PR 
ZR·75-1 NO 
" 
>SOO 
ZR·75-1 EeF 
" 
>500 
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Fig. 6. Effecl or EGF on CI!radiol·S1imutaled proliferation of ZRIHERc (el!~ 
('el!s(2 x 100j"ue plated in 25-cml nash in mediumfOn1aining 10% D('C·FCS 
!upplemtnted "ith EGF (10 ng/ml), ~\!radiol (£2, to or tCIJ P',j, and ICi 
IM,J84 (100 Mil as indkaud. ('ells "ere bancmd and CQunltd on dl) 12. 
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fig. 7. [Gr·ind~ced ch,ngts in morpholog) and hr.tin npression of ZRIHERc ,db. PhAse-contrast photomicrographicf ZRIJIERc ,tlls rultured "ilh I 1l.'1 
17/i'-emadiol (A) and ZRllIERc cells cllhure<l for 12 d3)"S in lhe presence of 10 ni/ml EGF (8). Jmmunofluore.\i;;:fi1 dettelion oHerat;n 8 npre!sion in ZRlIlERc 
cells cuhured "ilh I fl'! 17/i'-nlrJdiol (O and in the presence of 10 ng/m! EGF ID) for 12 daIS. 
arrested under Ih('se conditions, but ZRIHERc cells stnrted to 
proliferate after 3-4 weeks, showing many foci. Individual 
clones haw been isolated, demonstrating stable grO\\lh in the 
presence of EGF. Receptor analysis showed that e,pression of 
ER was strongly reduced to 3-13 fmol/mg protein, and PR was 
no longer detectable. Apparently, ZR/HERe cells progressed to 
a hormone-independent, EGF-d('pendent phenotype (ER-I±, 
PR-, and EGF receptor positive) under selection of the anti-
estrogen. 
DISCUSSION 
Although many endocrine tumors respond 10 hormonallher-
apy, progression of the tumor to a hormone-independent phe-
notype is ine\'itable. ER and PR status of primary human breast 
tumors provide important markers for response to endocrine 
therapy. EGF receptor expression has been suggested as a prog-
nostic factor for ('arly progression during primary endocrine 
therap)' (18,19). Whether the EGF receptor plays a causal role 
in the biology and the clinical course of breast cancer is not 
knO\\n. Howewr, the presence oflransforming growth factor CI 
and EGF in breast tumor tissue has been established (32) and, 
thus, could slimulale cell proliferation \'ia Ihe EGF receptor. In 
an attempt to obtain insight into the biological basis of anties-
!rogen resistance and to siudy Ihis possible aulocrine loop, the 
consequence of eClopic expression of the EGF receptor in a 
model human breast cancer cell line was inrcstigated. This 
study demonstrates successful transduction of functional hu-
man EGF receptors in ZR-75-1 cells which are completely 
estrogen dependent and de,'oid of EGF receptors. Retroviral 
introduction of the EGF receptor cDNA under control of a 
heterologous promotor resulted in expression of high-amniI}' 
binding sites for EGF. Cell clones (ZR/HERc) have been ob-
tained with different quantities of ml-EGF-binding sites 
(range, 43-251 fmollmg membrane protein). ZRlHERc cells 
acquired a responsh'eness to EGF, independently of the hor-
monal pathway in proliferation (serum romaining) and MIT 
:lSSa~s (serum free). These results indicate that ZR-7S-1 cells 
possc~s all necessa!)' intracell ular properties for transduction of 
signals prOl ided by EGF. No correlation was seen wlw('('n the 
EGF-induc('d proliferation of indh'idual clones and the levcls of 
EGF receptor e:<.pression. E\'en clones containing loll' leH~ls of 
EGF receptors respond('d to EGF \\ith cell prolifaation (Table 
I nnd Fig. 2) and striking morphological alterations within I 
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week of culture, Estrogen·dependent growth of ZR-75-1 and 
ZRlHERc cells could be completely inhibited by OH·tamoxifen 
or ICI 164,384, in contrast to the responsiveness to EGF of 
ZR/HERc cells. Therefore, ZR/HERc cells exhibit a hormone-
and EGF'responsive phenotype. ZRlHERc cells retained the 
capacity to form tumo~ in nude mice and to grow in soft agar 
in the presence of estradiol, Neither tumor formation nOr col-
ony formation was observed in Ihe absence of estradiol with 
EGF supplementation. Prolonged in .'irro culture in the pres-
ence of EGF resulted in a significantly increased cell popula-
tion·doubling time of the ZRlHERc cells, but unlimited prolif-
eration potential was retained. The altered cell morphology, the 
changed keralin expression, and the increased HMFG·2 ex-
pression suggest Some maturation of the cells, which may ex-
plain the increased cell·doubling time, Preculture of ZRlHERc 
cells with [GF resulted in loss of estrogen·dependent prolirer-
ation, despite the presence of a functional hormonal pathway, 
Funhermore, we obsen'ed a negath'e interaction of EGF_ and 
estradiol· mediated gro'1\1h, when supplied simultaneously. Our 
results differ from the data of Val veri us er al. (33), who failed to 
induce a honnone-independent phenotype by transfection (Jf 
the EGF receptor cDNA in ZR-75-1 cells. The reason for this 
discrepanc)' is as yet unknown but might be explained by clonal 
differences in the ZR-75-1 cell line, The ZR-75-1 cells used in 
our studies are fully dependent on estradiol for growth and do 
not express detectable EGF receptors, Valverius et ai, (33) used 
an estrogen'responsive subdone, which also expressed EGF 
receptors. 
Little information is a\'ailable concerning coexpression and 
function of ER and EGF receptors on individual cells in pri· 
mary breast cancer using immunohistochemical techniques. Toi 
etal. (34) noted that in ERlEGF receptor·positive tumors, EGF 
receptor-stained cells were distributed in\'ersely of ER·positive 
cells. It is not known whether functional EGF receptor and ER 
signal pathwa)'S are compatible in an indi\'iduaicell, Both EGF 
and estrogen are important regulators of normal breast epithe-
lial cell de\'elopment but may no! function simultaneously, The 
im'f(se correlation between ERIPR expression and EGF r':cep-
tor expression in primary breast tumors agrees very well v.ith 
the negative interaction of ER and EGF receptor stimulation on 
proliferation of ZR/HERc cells, Histochemical analysis of nor· 
maJ breast tissue as well as malignant tissue may establish 
whether coexpression of estrogen recept(Jrs and EGF receptors 
occurs in single cells and at what stage of epithelial cell differ-
.:ntiation. In this way. the hypothesis that these regulatory com· 
ponents function in separate stages of lissue development and 
Ihus give rise to different classes of breast tumors rna)' be ex-
plored, 
aUf experiments in Ihe ZRfHERc model show Ihal pro· 
longed culture in the presence of excess OH-tamoxifen results 
in antihormone-resistant subclones lacking expression of ER 
and PR, Similar conditions failed to induce proliferating sub-
clones of the parental ZR· 75-1 cells. These results suggest that 
as a consequence (Jf antiestrogen therapy ER expr.:ssion of 
initially hormone·responsh'e cells can be dO'1\n modulated, reo 
sulting in cells .... ith an EGF receplor·posith·eIER-negative phe-
notype, Whether this observation reflects the clinical situation 
remains a matter of study, Further im'estigations in model sys· 
terns and .... ith immunohistochemical techniques to study indio 
\idual cells in biopsy specimens (Jbtained before and after ther· 
apy are needed to establish whether·EGF receptor plays a role 
in progression to hormone independence during antiestrogen 
therapy of breast cancer. 
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In conclusion, the results presented in this paper show that 
ectopic expression of the EGF receptor, in the presenCe of its 
ligand, can b}'pass estrogen·dependent proliferation .... ith con· 
comitant change in differentiation ofZR-75-1 cells. Our results 
suggest that an incompatibility between active ER and EGF 
receptor signal transduction pathways exists, which may result 
in dO'1\n·modulation ofER expression during antiestrogen ther-
apy and, thus, could contribute to the failure of endocrine treat-
ment. ZR-75-1 and the derh'ed ZRlHERc cells provide an 
attracti\-e model to study progression from hormone-dependent 
to hormone·independent growth and the interplay between ER 
and EGF receptor signal pathways. 
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Antagonists of steroid hormones are clinically im-
portant in the management of breast cancer. How-
ever, the duration of response Is limited due to the 
development of hormone·independent tumors in vir-
tually all cases. In an attempt to oblain insight into 
the mechanisms underlying antiestrogen resistance, 
the consequences of epigeneUc changes in gene 
expression were studied In vitro. Estrogen-depend-
ent ZR·75·1 human breast cancer cells were treated 
with 5-azacytldine, an inhibitor of DNA methylation, 
and cultured in the absence of estradiol or in the 
presence of antlestrogens. Estrogen'independent 
cell colonies developed wllhln 3 weeks at high fre-
quency In 5-azacytidine-treated cultures (0.7 x 
10-3), In contrast to control cultures (510-3). The 
derived cells (ZR/AZA) were resistant to 4·hydroxy-
tamoxifen and lei 164,384, Independent of the se-
lection protocol, but had lost the ability to grow 
anchorage· Independent. Whereas expression of es· 
trogen receptor, progesterone receptor, and pS2 
were down-regulated, expression of epidermal 
growth factor (EGF) receptor and HER2/neu were 
increased In ZR/AZA cells. In contrast to the stable 
altered expression paHerns of estrogen receptor 
and EGF receptor, transient keratin 7 expression 
was observed. Transforming growth factor'a mRNA 
was identified in ZR-75-1 cells and ZR/AZA cells 
and EGF·like peptides were secreted in the culture 
medium. Proliferation of ZR/AZA cells could be par-
tially inhibited with an EGF receptor-blocking anti· 
body. Presence of both growth factor receptors and 
possible ligands suggests the development of an 
autocrine growth mechanism. Our data show that 
epigenetic alterations of gene expression result in 
rapid progression of breast cancer cells to hormone 
Independence. (Molecular Endocrinology 8: 1474-
1483, 1994) 
INTRODUCTION 
Breast growth and development is regulated by a com· 
plicated set of interactions among hormones and poly· 
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peptide growth factors with their specific cellular recep-
tors (1, 2). These regulators may be produced by the 
cell itself, by surrounding cells, or by cells at distant 
sites (3). Estrogen receptor (ER) and the progesterone 
receptor (PR). like other members of the steroid hor-
mone receptor family. are ligand-inducible transcription 
factors (4. 5) which. among other functions. play an 
important role in the biology of the normal mammary 
gland (3). The ER and its ligand have been implicated 
in the development and progression of breast cancer 
(6-8). However, the presence of both ER and PA in 
primary breast tumors identifies patients with a lower 
risk of relapse and prolonged survival (6, 9). Further-
more, ER is a target for endocrine therapy of clinical 
breast cancer. The therapeutic strategies using antag· 
onists of hormones are based on the dependence of 
breast cancer cells on estrogens for proliferation. These 
antagonists exert their inhibitory eHects on cell prolif-
eration via the hormone receptor system (10). Currently 
the nonsteroida! antiestrogen tamoxifen is established 
as the first choice of endocrine therapy of advanced 
breast cancer, in particutar when the primary tumor is 
steroid hormone receptor·positive (11, 12). Approxi-
mately 50% of these patients with ER·posilive primary 
tumors will have an objective response. However, the 
treatment is palliative and the majority of patients will 
experience a relapse (7, 13-16). 
The mechanism of progression to hormone inde-
pendence and toss of response to hormonal therapy is 
yet poorly understood. Changes in therapy response 
may be related to alterations in the ER function and 
signal cascade, alterations in the paracrine interactions, 
and changes in the drug pharmacology (see for review 
Refs. 3,15, and 17-19). ER variants have been impli· 
cated in response failure (20-26) but do not appear to 
account for most tamoxifen·resistant breast tumors 
(27). Altered regulation of gene expression in breast 
cancer cells has been implicated in the development of 
estrogen-independent disease and toss of response to 
hormonal therapy (28, 29). Stable changes in gene 
expression can derive from both genetic and epigenetic 
mechanisms and may result in altered cel! phenotypes. 
The cytosine analog 5-azacytidine (5-azaC) is a potent 
inhibitor of methylation of newly synthesized DNA and 
an inducer of cett differentiation. In many studies it has 
been shown that treatment with 5-azaC can result in 
activation of silent genes and in altered phenotypes of 
target cetts (30-33). Whether methylation of DNA plays 
a causal role in repression of genes in vivo is not futty 
understood (34). Genes with tissue-specific expression 
often undergo de novo methylation in cultures of estab-
lished cett lines. This may explain the loss of celt type-
specific functions and repression of nonessential prop-
erties in culture (35). It has been shown that specific 
functions can be activated in cultured cancer cett lines 
by treatment with 5-azaC. Furthermore, subjection to 
sp9cific selection protocols resulted in the identification 
of mechanisms and genes involved in specific proc-
esses of these cetts (36-38). 
The aim of this study was to establish the conse-
quences of epigenetic changes on estrogen depend-
ence of human breast cancer cetts. The ZR-75-1 human 
breast cancer cell line is a welt characterized in vitro 
model with which to study the progression of estrogen-
dependent cells to estrogen independence (38, 39). 
These cells are entirely estrogen-dependent, and 
growth is completely inhibited with antiestrogens (39). 
We have treated ZR-75-1 cells with 5-azaC and deter-
mined the effects on estrogen dependence and gene 
expression of various ER-regulated genes in vitro. 
RESULTS 
Induction of Epigenetic Alterations 
Human breast carcinoma lR-75-1 cells maintained in 
our laboratory are strictly estrogen-dependent for pro-
liferation (39). Culture in the absence of estradiol or the 
addition of the antiestrogens 4-hydroxy-tamoxifen or 
IC1164,384 to estrogen-contaIning cultures resulted in 
a complete growth arrest (37,39). lR·75-1 cells were 
treated with different concentrations of 5-azaC (range 
0.1-10 liM) for 3 days to induce epigenetic alterations. 
Subsequently the cells were exposed to antiestrogens 
or cultured in estrogen-depleted medium. Within 3 
weeks of selection, proliferating cell clones were ap-
parent in a background of nonproliferating celts. The 
number of 5-azaC-induced, estrogen-independent 
clones was dose dependent over a narrow effective 5-
azaC concentration range. In Fig. 1 the results of 4-
hydroxy-tamoxifen selection are shown. Maximal num-
bers of antiestrogen-resistant colonies were observed 
in cultures containing 5 pM 5-azaC during 3 days. This 
resulted in approximately 730 clones per 106 plated 
cetts using 1 JIM 4-hydroxy-tamoXifen selection. This 
pool of colonies was mass-cultured and designated lA/ 
AlA·TAM celts. Furthermore, single cell-derived sub-
clones were generated using conditioned medium of 
murine CAIP cells (38) and hereafter referred to as lA/ 
AlA 1, 2, and 3_ Experiments performed in the pres-
ence of 100 nM tC1164,384 resulted in approximately 
the same number of colonies (desIgnated lR/AlA-ICI 
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Fig. 1. Induction of Antiestrogen Resistance by Treatment 
with 5-Azacytidine 
Frequency of colonies after treatment of ZA-75-1 cells with 
increaSing doses of 5-azaC and culture in the presence of 1 
pM 4-hydroxy-tamoxifen. Colony numbers were determined 
on day 17 after start of selection, 
cells). In estrogen-deprived medium, the number of 
estrogen-independent colonies (deSignated lR/AZA-
DCC cetls) was approximately 60% lower, compared to 
4-hydroxy-tamoxifen or ICI164,384 seleclion. Control 
cultures of lR-75-1 cells not exposed 10 5-azaC, but 
subjected to the same selection procedures, did not 
result tn estrogen-independent growth. This is in agree-
ment with our previously reported frequency (:::;10-5) of 
spontaneous development of estrogen independence 
of these ZR-75-1 cetts (38). 
Down-Regulation of ER, PR, and pS2 ExpressIon 
We performed ribonuclease (ANase) protection analysis 
assays and Northern analysis to examine whether 
down-regulation of ER and ER-regulated genes in ZA/ 
AlA cells had occurred and could explain anliestrogen 
resistance. RNase protection analyses using an anti-
sense ER complementary DNA (cDNA) probe showed 
that lR/AlA cens contained reduced ER mRNA levels 
in comparison with the wild type ZR-75-1 cells. In the 
single cen clone lR/AlA 3, EA mANA was barely 
detectable (Fig. 2). RNase protection assays (Fig. 3) 
with an antisense PR cDNA probe showed that the 
estrogen-induced PR mRNA expression was strongly 
reduced in ZR/AlA celts (range -2-20% of the level 
observed in ZR-75-1 celts). 
The expression of the pS2 gene is like the PA gene 
under strict control of ER in breast cancer celts and 
may reflect functional ER signal transduction (40-43), 
pS2 mRNA levels were determined by Northern blotting 
wilh subsequent hybridization to a pS2 probe. lR-7S-
1 cells, which proliferate only in the presence of estra-
diol, showed very high expression of pS2 mRNA (Fig, 
4). lR/AZA·TAM, ·ICI, and ·DCC pools and lR/AlA· 
TAM subclones were cultured in the presence and 
(]) r- C\t (I) « 
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Fig. 2. RNase Protection Assay 10 Detect ER and EGF Recep-
lor Expression in ZA-7S-1 Cells and the Derived lA/AZA Cells 
Twenty micrograms of lotal ANA of ZR·75·1 (ZA), lR/AZA· 
Ie! (ICI) •• TAM (Tam), -DCC (DCC). ZR/AZA subclones (AZA ,. 
AZA3), and control lANA were used. Positions of the protected 
fragments of EA, EGF receptor, and '),actin mANA are indio 
cated. Undigested probes for EA, EGF receptor, and i-actin 
are shown In the left lane (probe). Only Ihe relevant parts of 
the auloradiographs are shown. 
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Fig. 3. RNase Protection Assay 10 Delect PA and TGFo mRNA 
Total ANAs 01 ceUs cultured lor 5 days without estradiol (-), 
with 1 (1M estradiol (+), with 4·hydroxy-tamoxifen {tl. or in the 
absence 01 estradiol and subsequently stimulated for 5 h (#) 
(see also Fig. 2). 
absence of estradiol. In the absence of estradiol, the 
ZA/AZA cells did not express pS2 mANA. In the pres· 
ence of estradiol, ZA/AZA·DCC cells showed efficient 
induction of pS2 mANA, comparable with expression 
levels detected in the parental lR·75·1 cens. In lR/ 
AZA·TAM celts, estrogen·induced pS2 expression was 
lower (-40% of the level observed in lR·75-1 cells), 
whereas in lR/AlA·ICI cells pS2 induction was almost 
completely lost (5%) compared to lR·75·1 celts (Fig. 
4). lA/AlA subclone 1 showed high pS2 expression 
when stimulated with estradiol, comparable to ZR-75-
t ceUs. Subclone 2 contained very low inducible pS2 
61 
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Fig. 4. Northem Blot Analysis of pS2 mANA from ZA·75-1 
Cells and ZA/AZA Cells 
Pooled clones of ZA/AlA-DCC, ·TAM, and ·ICI. were cul-
tured in the presence (+) or absence (.) of 1 nM estradiol. Total 
ANA (20 I'g) was blotted and hybridized with a pS2 probe. 
The same blot was hybridized with a glyceraldehyde-3-phos· 
phate dehydrogenase probe as an internal control. 
Table 1. Expression of Estrogen, Progesterone. and EGF 
~eceptors on lA-75-1 and lA/AlA Cells 
ER PR 
Cel[ Une EGFA 
-E~/+E~ -E~/+E2 
ZA-75-f -/115 /625 ND 
lA/AlA·DCC -/15 -/56 49 
lA/AlA·Tam 3/8 0/1 72 
lA/AlA-ICi 3/5 0/0 62 
lR/AlA·1 -/9 -/19 ND 
lA/AlA·2 -/2 -/2 20 
lA/AlA·3 -/5 -/1 28 
ZAJAlA-4 '/5 1/3 27 
For receptor determinations, lR·75-f cells were cullured con-
linuously in the presence of f nM estradiol. ZR/AlAC(!lls were 
cullured in the presence of Hp-estradiol (E2) fer 4 days, to 
allow measurement of EA-induced PA expression (+E2). In 
addition, ER and PA of lR/AlA·Tam, rCI, and clone 4 were 
detennined In the absence of 17p-eslradio! (-E2). Values are 
in femtomoles/mg protein. NO, No specific [ml)·EGF binding 
dele<:led. 
mRNA levels (4%) and in clone 3 no pS2 mANA was 
detected (Northern bIoI not shown). 
Subsequently, the amount of steroid receptors of 
ZA/AZA and ZA-75-1 cells was determined. Cytosolic 
extracts prepared from ZA-75-1 cells contained high 
fevels of ER (115 fmol/mg cytoso!ic protein) and PR 
(625 fmol).ln contrast, cytosolic extracts prepared from 
ZR/AlA pools as well as single cell clones contained 
reduced or hardly detectable EA protein levels (2-15 
fmol). This was also apparent for eSlrogen·Jnduced PR 
prole!n levels (0-56 fmol) (Table 1). 
EGF Receptor Expression Is Induced In 
ZR/AZA Cells 
The parental lA·75·1 cells, used in our experiments, 
expressed ER and PA but contained no detectable EGF 
receplors (39). We have shown that treatment of ZR· 
75·1 cells with 5·azae and subsequent selection with 
antiestrogens resulted in down·regulation of EA expres· 
sion. To examine whether the observed down·regula· 
tion of ER was possibly accompanied by an up-regula· 
tion of EGF receptor expression, RNase protection 
assays were performed on RNA preparations of lA/ 
AlA·TAM, -lei, and -DeC celis and single cell clones, 
using an antisense EGF receptor cDNA probe. These 
analyses showed up-regulation of EGF receptor mANA 
levels in all tested lA/AlA cells as compared with lR-
75-1 cells, except for clone 1, in which we failed to 
detect EGF receptor mANA (Fig. 2). Scatchard analysis 
using [125IJEGF was performed on membrane prepara-
tions of lA/AlA cells to determine EGF receptor 
expression at the protein level. lR/AlA cell pools and 
subclones contained readily detectable, but variable, 
numbers of EGF binding sites (Table 1). Figure 5 shows 
an example of Scatchard plots of lA/AlA cell pools 
selected in either 4-hydroxy-lamoxifen or ICI 164,384 
medium. 
Loss of HER2/neu Regulation by Estrogens in ZR/ 
AZA Cells 
The HER2/neu protooncogene is down-regulated by 
estrogen-activated EA in ER-positive breast cancer cell 
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Fig. 5. Scatchard Analysis of EGF Binding 
100 
ZRjAZA cells were cultured to confluence in 225 cm? flasks 
in RPMI1640 medium supplemented with 10%, BCS. SpecifiC 
binding of lA/AZA·ICI (+) and ZA/AlA·TAM (6) is plotted. 
The amount of {125I]EGF binding sites was 62 and 72 fmol/mg 
membrane protein with dissociation constant (Ko) 01 0.7 and 
0.6 OM, respectively. Parental ZA-75·1 cells contained no 
dete<:table EGF receptors. 
62 
lines (44-46). lR/AlA cells contained no, or low, levels 
of EA in comparison with parenta! lR·75·1 cells. We 
determined HER2/neuexpression tevels in lR-75-1 and 
lA/AlA cells with different residual levels of EA, cul-
tured in the presence and absence of estradiol. Figure 
6 shows that HER2/neu is clearly down-regulated in 
estradiol-stimulated lR-75-1 cells, as compared with 
control celis arrested with 4-hydroxy-tamoxifen. tn con-
trast, no differences were observed in lA/AlA cells 
cultured in the presence or absence of estradiol. All 
tested lA/AlA ce!llines contained high levels of HEA2/ 
neu mANA. 
Transient Activation of Keratin 7 
lA/AlA cells presented with marked morphological 
differences in comparison with the parental estrogen-
stimulated lA-75-1 cells or the nonproliferating control 
lA·75-1 cultures in the presence of antiestrogens. 
These morphological differences presumably reflect al-
terations in differentiation slale regulated by the expres-
sion of genes determining ceU structure, extracellular 
matrix attachment, and cell-celi communication. In a 
previous study we showed structural changes and in-
creased keratin expression in lA-75-1 cells transfected 
with the EGF receptor eDNA (39). Changes in expres-
sion of keratins may indicate an alteration In maturation 
stale of cells (47). To address the question whether 
lA/AlA cells acquired altered differentiation character-
istics, keratin and vimentin expression was studied, 
using various monoclonal antibodies. Parental lA-75-1 
cells expressed keratin 8, 18, and 19, and no vimentin 
expression was observed. !n addition to keratin 8, 18, 
and 19, we detected large amounts of keratin 7 in ZR/ 
AlA-TAM, ·ICI, and ·DeC cells, These experiments 
were repeated with available single cell lA/AlA clones. 
Only sporadic ceUs expressed keratin 7 in these single 
cell clones. Furthermore, when ZA/AlA cell pools were 
cultivated over a prolonged time (3 months), keratin 7 
expression was detected only in a subset (6-11%) of 
ceUs. lA/AlA cells were negative for vimentin expres-
sion. 
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Fig, 6. ANase Prote<:tiOfl Assay to Detect HEA2jneu mANA 
ZR-75-1 celts were cultured in the presence 01 1 pM 4· 
hydroxy-tamoxifen (I) or 1 nM estradiol (+) and lA/AZA cells 
cultured In the presence (+) or absence (-) 01 estradiol. 
Growth Characteristics of ZR/AZA Cells 
lR/AlA cells were completely antiestrogen-resistant 
and estradiol-independent for proliferation. Furthermore 
lR/AlA cells exhlbited resistance to 4-hydroxy-tamox-
ifen and lei 164,384, independently of the selection 
strategy (data not shown). The growth characteristics 
of the lA/AlA cells, compared 10 the parental estro-
gen-stimulated lR-7S-1 celfs, were also changed. In 
contrasllo lR-75-1 celfs, proliferation of lA/AlA cells 
was extremely cell density-dependent. Initial attempts 
to subclone lR/AlA pools, in order to obtain homo-
geneous single cell clones, failed probably due to this 
strong dependency on cell densUy. In contrast from the 
parental lR-75-1 cells, lR/AlA cens could be moder-
ately stimulated by the addition of EGF to the culture 
medium in a dose-dependent manner (Fig. 7A). To 
evaluate the contribution of endogenous EGF-like pro-
teins on basal proliferation of lR/AlA cells, we used 
the murine hemopoietic cell line 320, which is not 
responsive to EGF, and the EGF-responsive 32D/HEAc 
cells carrying the human EGF receptor eDNA. In con-
trast to the parental 320 cells, the 32D/HERc cells 
were stimulated by conditioned media of lA-75-1 cells 
and lA/AlA cells, Indicating the presence of EGF-like 
activity in the conditioned medium of these cells (Fig. 
7B). ANase protection assays showed that both the 
lR-75-1 cells and the lA/AlA cells expressed trans-
forming growth factor-a (TGFa) (Fig. 3). In lR-7S-1 
cens the TGFa mANA level was increased approxi-
mately 3-fold by estradiol, whereas lR/AlA cells 
showed no gross differences between estradiol-stimu-
lated or nonstimulated cultures. Expression of both 
functional EGF receptors and TGFa suggests an auto-
crine growth mechanism via the EGF receptor signaling 
pathway. To further assess this autocrine loop, we 
studied the effects of an EGF receptor-blocking anti-
body on the growth of lR/AlA cells and lR-75-1 
control cells. Addition of O.11l9/ml of the EGF receptor-
blocking monoclonal antibody to the cultures resulted 
in 23-30% inhibition of 3-(4,5-dimethylthiazo!-2-yl)-2,5-
diphenyltetrazolium bromIde (MIT) reduction by lR/ 
AZA cells (Fig. 7C). Further inhibition was observed 
when 0.5 or 1 P9/ml antibody was added to the culture 
medium, which resulted in up to 53% growth reduction. 
The estrogen-stimulated proliferation of the lR-75-1 
cells was not reduced with 0.1 or 0.5 Ilg/ml antibody. 
Only the addition of 1 Ilg/ml antibody to lR-75-1 cul-
tures resulted in a minor (5%) growth inhibition. 
We determIned whether down-regulation of EA in 
lR/AZA cells had altered the anchorage-independent 
growth properties of these cells. ZA-75-1 cells showed 
effiCient anchorage-independent growth in the presence 
of estradiol (1885 colonies per 104 plated cells) while 
no growth was observed In the absence of estradiol. In 
contrast to the parenta! ce!1s, no proliferation of lR/ 
AlA pools and the subclones was observed in soft 
agar either in the presence or absence of estradiol. 
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A, Effect of EGF on MTT reduction by lA/AZA celfs. Celfs 
(5 x 103) were plated In medium with 15% BCS. After adher-
ence of the cells the medium was changed for FCS-OCC 
contalning medium. Cell stimulation In response to EGF was 
measured on day 6. Data are the means of eight wells (±SD). 
B, EGF-hke pepUdes in conditioned media of lA/AlA cells. 
320 (D) and EGF-responsive 32D/HEAc cells (IJl) were cultured 
ovemlght with or without 10 ng/m! of EGF or with addition of 
15% conditioned medium of lA/AlA-TAM pool cells, lA/ 
AZA-Ie! pool cells, or lA-75-1 cells. DNA synthesis was 
determined by measuring the uptake of [3Hlthymidine eH-TdA) 
as described (68). Data are tile means of triplicate incubations 
(±SD). C, Effect of anti-EGF receptor-blocking antibody on 
MTI reduction by lR-75-1 cells (lA) and lA/AlA leI, -Tam, 
and -DeC celfs. lA/AlA cells were plated at a density of 1011 
well in APMf/BCS medium containing no (0), 0.1 ",g/mll,D), 
0.5 jJg/ml (D), or 1 ",g/ml (11) antibody. The culture medium of 
lA-75-1 cells was supplemented with 10 pM estradiol to 
stimulate cell proliferation. MIT reduction without addition of 
anti-EGF receptor antibody is depicted as 100%. All values 
are the mean of eight wells (so< 5%). 
DISCUSSION 
Antiestrogens are used extensively for the treatment of 
breast cancer (16). Although up to 50% of human breast 
tumors respond to endocrine therapy, progression of 
the tumor to a hormone-independent phenotype is in· 
evitable. Insight into the mechanisms underlying aolies-
\rogen resistance is a prerequisite for improvement of 
therapy. Cell line models have been used to identify 
genetic elements contributing to progression from hor· 
mone-dependent growth to hormone independence. 
Loss of hormone dependence was observed after long-
term steroid depletion or prolonged selection with var-
ious types of anliestrogens and adriamycin (reviewed 
by Refs. 29 and 48) and appears associated with altered 
gene expression but not with major gene amplification 
(49). Ectopic expression of v-Ha-ras (50), fibroblast 
growth factor 4 (51), Her2/neu (52), and EGF receptor 
(39) In breast tumor cell Jines resulted in altered hor-
mone responsiveness and implicates these genes in 
progression. Transfeclion of random eDNA libraries (53) 
and insertional mutagenesis using retroviruses (38) 
could also transform the hormonal phenotype and may 
lead to the identification of different genes. 
In this study we report the eHects of epigenetic 
changes in gene expression as a possible mechanism 
of development of antiestrogen resistance. lR-75-1 
cells treated with the hypomelhylating agent 5-azaC 
rapidly developed ceU colonies in the absence of estra-
diol as weU as in the presence of antieslrogens. Cell 
dones were obtained when selected with both the 
partial antagonist 4·hydroxy·tamoxifen and with the 
pure antiestrogen ICI 164,384. Furthermore, 5·azaC-
treated cultures depleted of estrogens progressed to 
estrogen independence and antiestrogen resistance. 
lR/AlA pools and sutx:lones were cultured for several 
months and showed stable estrogen-independent phe-
notypes. 
Proliferation of lA/AlA cells could not be stimulated 
by estradiol. Furthermore, various EA'mediated re-
sponses were strongly reduced as a consequence of 
the down-regulation of EA. Transcription of PR is 
strictly controlled by ER in breast tissue (40) and is 
strongly diminished in the lR/AlA cells at the-mANA 
and the protein level. Only low levels of PR were 
detected in the lA/AlA cells and correlated with the 
residual ER protein levels. The expression of pS2 in 
malignant breast epithelial cells is also under strict 
control of activated EA (41). However, in contrast to 
PR, pS2 expression was still well induced by moderate 
or low ER levels. The expression of TGFa has also 
been shown to be modulated by EA (54). Our results 
demonstrated moderately increased levels of TGFa 
mANA in estradiol·stimulated lR-75-1 cells, but no 
significant changes were observed in various lR/AlA 
pools and subc/ones when stimulated with estradiol. 
This Indicates that TGFa is constitutively expressed in 
lR/AlA cells independently of ER. Expression of 
HER2/neu is inhibited by estrogens in estrogen-respon-
sive breast cancer cells, at both the mANA and the 
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protein level (44-46, 55). lA/AlA cells contained high 
levels of HEA2/neu mANA, which expression was no 
longer down-regulated by residual EA as occurred in 
the parental ceUs. lA-75-1 cells treated with 4-hydroxy-
tamoxifen showed high expression levels 01 HEA2/neu, 
which is down-regulated by the addition of estrogen, in 
agreement with published data (44-46, 55). ZA/AlA 
cells selected for estrogen-independent growth exhibit 
decreased ER levels and consequenlly have lost the 
major part of the EA-mediated transcription regulation 
of /fans-activated genes. Our data suggest that the 
induction of PA expression requires a higher threshold 
level of EA than needed for pS2 induction and thus pS2 
may provide a more sensilive monitor for reSidual ER 
function. Analogous to the regulalion of PR, expression 
of HER2/neu and TGFa, estrogen-induced morphOlogy, 
and anchorage-independent growth also appear to re-
quire high levels of EA expression. 
lA/AlA cells were extremely dependent on cell den-
sity for proliferation, which could be bypassed, at least 
partia1fy, through the addition of EGF or conditioned 
medium of mouse fibroblasts. Furthermore, conditioned 
media obtained from lA/AZA cells as well as lA-75-1 
cultures contained EGF·like peptides. Moreover, signif-
icant amounts of TGFa mANA were detected in lA-
75·1 cells and lA/AlA cells. TGFa is a potent mitogen 
for a variety of epithelial cells and has high affinity for 
the EGF receptor. Our results show that hypomethyta-
tion of lA-75·1 cells resulted in up-regulation of EGF 
receptor gene expression. In contrast to the parental 
cells, lR/AlA cells acquired a responsiveness to EGF, 
indicating the presence of a functional EGF receptor 
signa! cascade. Simultaneous expression of TGFa and 
EGF receptor in lA/AlA cells is suggestive of an 
escape from estrogen regulation via an autocrine 
growth mechanism. This suggestion is supported by 
the obselVation that an EGF receptor-blocking antibody 
does interfere with thIs autocrine loop (Fig. 7C). 
We demonstrated down·regulation of EA expression 
when lA-75-1 cells were trealed with 5-azaC and 
selected for estrogen independence. Except for quan-
titative differences, this phenomenon was independent 
of the selection regimen and occurred in mass-cultured 
pools of colonies as well as in single cell clones. Appar-
ently, the reduction or loss of ER expression and func-
tion is a prerequisite for estrogen·independent prolifer-
ation of lA/AlA cells. In contrast to the parental celt 
line, lA/AlAcells expressed EGF receptor mRNAand/ 
or EGF binding sites. It is well established that EGF 
receptor expression is inversely related with EA expres-
sion in primary breast cancer tissues and in breast 
cancer cell Hnes (for a review, see Aef. 56). Furthermore, 
EGF receptor is expressed in tumors unresponsive to 
endocrine therapy (57, 58). lA/AlA cells, generated 
for this study, also exhibited this inverse relation be-
tween EA and EGF receptor expression. In a previous 
paper we described the transduction of the EGF recep-
tor eDNA in lA-75·1 cells and showed that simultane-
ous stimulation of EA and EGF receptors resulted in 
interference of these signal pathways. Furthermore, 
antiestrogen treatment resulted in rapid progression to 
estrogen Independence and down-regulation of ER (39). 
Recently, we determined the expression patterns of ER 
and EGF receptors at the single celf level in a series of 
ER-posilive primary breast tumors with dual·stalning 
immunohistochemical techniques (59). Expression of 
ER and EGF receptors was detected In most biopsy 
specimens either In the tumor cells or in nonmalignant 
cells present in the tumor. However, coexpression of 
ER and EGF receptors in the same tumor celts was a 
rare event, in agreement with another study (60). In 
normal ducts adjacent to the tumor cells, we frequenlly 
observed coexpression of ER and EGF receptors in 
individualluminai epithelial cells. This phenomenon was 
also observed in normal breast tissue Indicating a role 
In normal development (59). The inverse relationship of 
ER and EGF receptor gene expression observed In the 
development and progression of breast cancer may be 
explained by interference of simultaneous activation of 
these signal pathways prohibiting rapid proliferation. 
The effect of 5-azaC on the differentiation state of 
ZA-75·1 cells was assessed by studying the interme-
diate filament expression pattern (47). Inverse relation 
between keratin and vimentin expression has been 
documented In a subset of EA-negative breast cancer 
cell lines (61). Association between vimentin expression 
and EA-Independent breast cancer was also observed 
(62). A positive correlation between EGF receptor and 
vimen!in expression in ER-negative breast tumors has 
been reported (63), In the present study, we show that 
ZR-75·1 and ZR/AlA celts expressed keratin 8, 18, 
and 19 and no vimentin expression was observed, 
illustrating that the estrogen·independent phenotype is 
not accompanied by a switch from keratin to vimenlin 
expression. Treatment of lR-75-1 cells with 5-azaC 
resulted in activation of keratin 7 expression. Keratin 7 
Is commonly expressed in luminal epithelial cells of the 
breast, but rarely at high levels in cultured breast cancer 
cell lines (64, 65). Interestingly, small amounts of keratin 
7 were detected In ER-negaUve breast cancer cell lines 
and not in ER-positive celt lines with a sensitive assay 
(47). However, in lA/AZA cells expression of keratin 7 
was transient, which may be explained by de novo DNA 
methylation during prolonged culture, resulting In Inac-
tivation of the keratin 7 gene. Presumably, high expres-
sion levels of keratin 7 expression is not essential for 
continuous proliferation In vitro. 
Our study shows that epigenetic alterations in gene 
expression can change the honnonal dependence of 
breast cancer cells. We demonstrated that altered in-
volvement of growth factor and receptor may contribute 
to the transition from antiestrogen-responsive to anties-
trogen-unresponslve breast tumor cell proliferation in 
vitro. Treatment with 5-azaC resulted In a greater than 
4 log increase in estrogen-independent colony forma-
tion, compared to control cultures. This Is extremely 
high in comparison with the frequency of classical mu-
tations, which are changes in DNA sequence (point 
mutation, deletion, insertion, rearrangement), Heritable 
changes based on modulation of epigenetic changes in 
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gene expression may therefore explain the acquisition 
of estrogen independence and short benefit of anties-
trogen therapy. 
MATERIALS AND METHODS 
Cells and Cullure Conditions 
ZR-75-1 human breast cancer cells were cultured In APMI 
1640 medium supplemented with 10% heal-inactivated bovine 
calf serum (BCS) and 1 nM 17p-estradiol as described (39). 
The derived ZA/AlA ce1ls were maintained in RPMI 1640 
containing 15% BCS. The cytogenetic characteristics of the 
ZA·75-1 cell line maintained in our laboratory and the variant 
estrogen-independent ZAfAZA cells are similar to the pub-
lished data for ZA-75-1 cells (66). 
Induction 01 Estrogen Independence 
ZA-75-1 cells (107)were exposed to 5-azaC (Sigma, SI. louis, 
MO) for 3 days (range 0.1-10 ~M) in the presence of 1 nM 
estradiol to stimulate cell proliferation. Subsequently, the me-
dium was changed and 5·azaC was omitted. After an addi-
tiona! 2 days of culture without 5·azaC, the cells were har-
vested, counted, and reseeded at 3 x 106 cells per 75 cm1 
flask. Selection for estrogen-independent cell growth was 
performed either in the presence of 1 ~M 4·hydroxy-tamoxifen 
or 100 OM ICI 164,384, a generous gift of ICI (Macclesfield, 
UK) or In phenol red-free APMI 1640 medium supplemented 
with 4.5% fetal calf serum, stripped by dextran-coated char-
coal (FCS·DCC). ZR·75-1 cells, not treated with 5-azaC, 
served as control cultures. Estrogen-independent colonies 
were pooled and mass-cultured in selection medium for further 
analysis, Previous experiments showed marked growth ad· 
vantage and Improved attachment of hormone-independent 
ZA·75-1· derived cen clones In the presence of conditioned 
medium of murine CAIP fibroblastic cells (38l. In a subsequent 
experiment, cells resistant to 4-hydroxy·tamoxifen were sub-
cloned in medium supplemented with 1 ~M 4-hydroxy·tamox-
ilen plus 10 ~g/ml porcIne insulin (Org'anon, Oss, The Nether-
lands) and 10% conditioned medium of CRIP cells. After two 
passages, clones were expanded in medium with 15% BCS. 
In lotal, eight subclones were isolated and three were ran· 
domly chosen for further analysis. 
Assays of Cell Growth 
The 3-(4,5-dimethylthlazol·2·yl)-2,5-diphenyltetrazolium bro-
mide (MTT)-assay was used to evaluate the effects of additives 
to the culture medium on cell proliferation (39, 67). 
32D1HEAe cells were used to detect EGF-like activities in 
conditioned media of ZA/AZA cells in a bioassay. 32D/HEAe 
cells originated from 320 (interteukin·3-dependent myelold 
leukemia cells) after introduction of the human EGF cDNA 
utilizing a retroyjral vector In a similar manner as previously 
described (39, 68). In contrast to the parental 320 celis, 3201 
HERe cells expressed EGF binding siles and exhibited a 
transient proliferative response to EGF. DNA synthesIs-assay 
eH-TdR uptake) was used to detennine proliferative response 
of 320 and 32D/HERe cells and was performed as described 
previously (68). 
EGF receptor blocking studies were performed with EGF 
receptor (Ab-1) blocking monoclonal antibody from Oncogene 
Science, Inc. (Manhasset, NY). 
Anchorage-independent growth was determined in the pres-
enceor absence of 1 nM estradkll, by plating 10· cells in APMI 
medium containing 20% BCS and 0.3% agar on top of, a 
solidified 0.6% agar layer In 35-mm Petri dishes. After 11 days 
of culture the ability of the cells to form colonies was deter-
mined. 
RNA Isolation and Northern Blot Analysis 
RNA was isolated by lysis of the cells with guanidine thiocya-
nate salt and cesium chloride centrifugation as previously 
described (69,70). Northern blot analysis was performed with 
1.2% agarose-formaldehyde gels with 20 J.lg total RNA as 
described elsewhere (70). RNA was transferred to nitrocellu-
lose membranes (Schleicher & SchuH, Dassel, Germany). 
Probes were random primer labeled using o._3~p (Amersham, 
Buckinghamshire, UK). The probe used was a 528 base pair 
(bp) cDNA human pS2 probe (41). Hybridization was per-
formed overnight in 9%, dextran sulfate-50% formamide. Final 
washing was performed In 0.3 x sodium citrate-O.l% sodium 
dodecyl sulfate at 65 C. The efficiency of recovery and the 
integrity of the RNA were checked by hybridization with glyc-
eraldehyde-3·phosphate dehydrogenase probe. Filters were 
exposed to Kodak X·Omat AR films at -70 C using intensifying 
screens. 
RNase Proteclfon Analysis 
RNase protection was carried out according to standard pro-
cedures (70), using 20 J.lg tota! ANA. The following probes 
were used: EA, a 252 bp cDNA fragment [nucleotide positions 
1248-1500 according to Green et al. (71)); EGF receptor, a 
340 bp EGF receptor cDNA fragment (nucleotide 2951-3291 
according to UHrich et al. (72)); TGFa, a 600 bp NCOI TGFn 
cDNA fragment (73); PR, a 123 bp cDNA fragment (nucleotide 
positions 3171-3294 according to Kastner et al. (74)1; HER2/ 
neu, a 376 bp BamHl/EcoAI cDNA fragment (nucleotide posi-
tions 1075·1451 according to Coossens et al.(75)). In all 
experiments a probe for i-actin (76) was used to measure 
ANA recovery. 
Quantitative Assessment 01 ER, PA, and EGF Receptors 
Immunc.reactive cytOSOlic ER and PA were measured using 
commercially available enzyme immunoassay (EIA) kits, (Ab-
bott laboratories, ChIcago, IL) as instructed by the manufac-
turer. ZR/AZA cells were cultured in medium supplemented 
with 1 OM estradiol lor 4 days, to allow measurement of EA· 
induced PA expression. Cell pellets and cytosolic extracts 
were prepared as described (39), after a 4·h preculture in the 
absence of estradiol. EGF receptor expression was deter-
mIned by Scatchard analyses of 1251 EGF bInding and using 
hydroxylapatite to separate bound and free ligand as previ-
ously described (39, 77). 
Immunolluorescence 
Immunological detection of keratins was performed on cyto-
centrifuged cells and/Of on a monolayer of cells growing in 
leighton lubes (Costar Europe ltd., Cambridge, MAl, as 
described (39). The monoclonal antibodies used in this study 
were RCK 105 to keratin 7, M 20 to keratin 8, RCK 106 to 
keratin 18, and lP2K to keratin 19. 
Acknowledgments 
The excellent assistance of Marly Stuurman-Smeets, Erica 
Binnendijk-Noordegraal, and Henk Portengen with receptor 
determinations and Scatchard analyses is greaUy appreciated. 
We thank Drs. P. Chambon and M. C. Aio (Strasbourg, France) 
for ER, PR, and pS2 probes and Dr. A. Ullrich (Martinsried, 
Germany) for EGF receptor probe. 32D/HERc cells were a 
kind gift of Dr. I. P. Touw (Rotterdam, The Netherlands). 
Furthermore we thank Dr. F. Ramaekers (Maastricht, The 
Netherlands) for the antikeratin monoclonal antibodies and ICI 
66 
Farma (Aidderkerk, The Netherlands) lor the gilt of the anti-
estrogens. 
Received May 2,1994. Revision received July 11, 1994. 
Accepted July 28,1994. 
Address requests for reprints to: Ton van Agthoven, De-
partment of Molecular Biology, Dr. Daniel den Hoed Cancer 
Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Neth· 
erlands. 
This work was supported by the Dutch Cancer Society 
(Grant DDHK 92·111). 
REFERENCES 
1. O:;borne MP 1987 Breast development and anatomy. In: 
Harris JA, Hellman S, Henderson IC, Kinne W (eds) Breast 
Diseases. lippincott Company, PhiladelphIa, pp 1-14 
2. Mauvals·Jarvis P, Sitruk·Ware A, Kullenn F 1988 The 
role of hormones in the pathogenesis of benign breast 
disease. In: Grundfest·Broniatowskl S, Esselstyn CB (oos) 
Controversies In Breast Disease. Marcel Dekker, Inc., 
New York, pp 43-61 
3. Clarke A, Dickson RB, Lippman ME 1992 Hormonal as-
pects of breast cancer. Growth factors, drugs and stromal 
interactions. Crit Rev OnCOl HematoI12:1-23 
4. Evans RM 1988 The steroid and thyroid hormone receptor 
superfamily. Science 240:889-895 
5. Beato A 1989 Gene regulation by steroid hormones. Cell 
56:335-344 
6. Jensen EV 1981 Hormone dependency of breast cancer. 
Cancer 47:2319-2326 
7. Horwitz KB 1993 Mechanisms of hormone resistance in 
breast cancer. Breast Cancer Res Treat 26:119-130 
8. King AJB 1993 Estrogen and progestin effects in human 
breast carcinogenesis. Breast Cancer Res Treat 27:3-15 
9. McGuire Wl, Clark OM, Dressler LG, Owens MA 1986 
Role of steroid hormone receptors as prognostic factors 
In primary breast cancer. NaU Cancer lnst Monogr 1 :19-
23 
10. Parker MG 1993 Action 01 'pure" antiestrogens in inhibit-
ing estrogen receptor action. Breast Cancer Aes Treat 
26:131-137 
11. Fisher B, Aedmond C, Brown A, Wickerman Dl, Wolmark 
N, Altegra J, Escher G, Uppman M, Savlov E, Willclif J, 
Fisher ER 1983 Influence of tumor estrogen and proges· 
terone receptor levels on the response to tamoxifen and 
chemotherapy in primary breast cancer. J Clin Oncol 
1:227-241 
12. McGuire Wl1987 Prognostic factors for recurrence and 
survival in human breast cancer. Breast Cancer Res Treat 
10:5-9 
13. Pritchard KI, Sutherland DJA 1989 The use of endocrine 
therapy. Hematol Oncol Clin North Am 3:765-805 
14. Santen RJ, Manni A, Harvey H, Aedmond C 1990 Endo-
crine treatment of breast cancer in women. Endocr Rev 
11:221-265 
15. Jordan VC, Murphy CS 1990 Endocrine pharmacology of 
antiestrogens as antitumor agents. Endocr Aev 11:578-
610 
16. Early Breast Cancer Trial Collaboration Group 1992 Sys-
temic treatment of early breast cancer by hormonal, cy· 
totoxic, or immune therapy. 133 Randomised trials involv· 
ing 31,000 recurrences and 24,000 deaths among 75,000 
women. lancet 339:1-15;71-85 
17. Katzenellenbogen BS 1991 Antiestrogen resistance: 
mechanisms by which breast cancer cells undermine the 
effectiveness 01 endocrine therapy. J Nail Cancer Inst 
83:1434-1435 
18. King AJB 1992 Progression from steroid sensitive 10 
insensitive state In breast tumour. Cancer Surv 14:131-
146 
19. Johnston SAD, Dowselt M. Smith IE 1992 Towards a 
molocular basis for tamoxifen resistance in breast cancer. 
Ann OncoI3:503-511 
20. McGuire Wl, Chamness GC, Fuqua SAW 1991 Estrogen 
re<:eptor variants In ctinical breast cancer. Mol Endocrino! 
5:1571-1577 
21. Scott GK, Kushner P, VigneJl, Benz CC 1991 Truncated 
forms of DNA-binding estrogen re<:eplors in human breast 
cancer. J Clin Invest 88:700-706 
22. Murphy lC, Ootzlaw H, Hamerton J. Schwarz J 1993 
Investigation of the origin 01 variant, truncated estrogen 
receptor-like mANAs identified in some human breast 
cancer biopsy samples. Breast Cancer Aes Treat26:149-
161 
23. Fuqua SAW, Allred DC, Eltedge AM, Krieg Sl, Benedix 
MG, Nawaz Z, O'MaJfey BW, Greene Gl, McGuire WL 
1993 The EA·positive/PgR-negative breast cancer phe-
notype is not associated with mutations within the DNA 
binding domain. Breast Cancer Res Treat 26:191-202 
24. Jiang SY, Parker CJ, Jordan VC 1993 A model to descnbe 
how a point mutation of the estrogen receptor alters the 
structure-function relationship of antiestrogens. Breast 
Cancer Res Treat 26:139-147 
25. Mikslcek RJ, Lei Y, Wang Y 1993 Exon skipping gives 
rise to alternatively spliced forms of the estrogen receptor 
in breast tumor cells. Breast Cancer Res Treat 26:163-
174 
26. Koehorst SGA, Jacobs HM, Thijssen JHH, Blankenstein 
MA 1993 Wild type and aUernallvely spliced estrogen 
receptor messenger RNA in human meningioma tissue 
and MCF7 breast cancer cells. J Steroid Biochem Mol 
BioI 45:227-233 
27. Kamik PS, Kulkarni S, Liu XP, Budd GT, Bukowski AM 
1994 Estrogen receptor mutations In tamoxifen-reslstant 
breast cancer. Cancer Res 54:349-353 
28. Dorssers LGJ, Van Agthoven T, Sieuwerts AM 1991 
Genetic mochanlsms involved in progression to hormone 
independence of human breast cancer. In: Berns PMJJ, 
Romljn JC, Schroeder FH (eds) Me<:hanisms of Progres-
sion to Hormone-Independent Growth of Breast and Pros-
tatic Cancer. Parthenon Publishing Group Ltd, Camforth, 
UK, pp 169-182 
29. Clarke R, Thompson EW, leonessa F, Lippman J, Mc-
Garvey M, Frandsen Tl, Bruenner N 1993 Hormone 
reSistance, invasiveness, and metastatic potential in 
breast cancer. Breast Cancer Res Treat 24:227-239 
30. Taylor SM, Jones PA 1979 Multiple new phenotypes 
induced in 10T1/2 and 3T3 cells treated with 5·azacyti-
dine. Cell 17:771-779 
31. Awedimento EV, Obici S, Sanchez M, Gallo A, MusU A, 
Gottesman ME 1989 Reactivation of thyroglobulin gene 
expression in transformed thyroid cells by 5·azacytidine. 
CeI158:1135-1142 
32. Hansen RS, Gartler SM 1990 5-Azacytidine-induced reac-
tivation of the human x chromosome- linked PGKI gene 
Is associated with a large region of cytosine demethylation 
in the 5' CPG island. Pro<: Nail Acad Sci USA 87:4174-
4178 
33. Lee SW, Tomasello C, Swisshelm K, Keyomarsi K, Sager 
R 1992 Down-regulation 01 a member of the S100 gene 
family in mammary carcinoma cells and reexpression by 
azadeoxycytidine treatmen\. Proc Nat! Acad Sci USA 
89:2504-2508 
34. Bird A 1992 The essentials of DNA methylation. Cell 70: 
5-8 
35. Antequera F. Boyes J, Bird A 1990 High levels of de novo 
methylation and altered chromatin structure at CpG is-
lands in celilinas. Cell 62:503-514 
36. HabetsGGM, Vander Kammen R, Scholtes WHM, Collard 
JG 1990 Induction of Invasive and metastatic potential in 
mouse T-Iymphoma cells (BW5147) by treatment with 5-
azaCylidine. Clin Exp Metastasis 9:379-390 
67 
37. Van Agthoven T, Van Agthoven TLA, Foekens JA, Dors-
sers LCJ 1993 Regulation of gene expression involved in 
the progression of human breast cancer to honnone 
independence. Ann NY Acad Sci 684:250-252 
38. Dorssers LCJ. Van Agthoven T, Dekker A, Van Agthoven 
TLA, Kok EM 1993 Induclion of antiestrogen resistance 
in human breast cancer cells by random insertional mu-
tagenesis using defective retroviruses: identification of 
bear-I, a common integration site. Mol Endocrinol7:870-
878 
39. Van Agthoven T, Van Agthoven TLA, Portengen H, Foe-
kens JA, Dorssers LCJ 1992 Ectopic expression of epi· 
dermal growth factor receptors induces hormone inde-
pendence in ZR-75-1 human breast cancer cells. Cancer 
Res 52:5082-5088 
40. Horwitz KB, McGuire WL 1978 Estrogen control of pro-
gesterone receptor in human breast cancer. Correlation 
with nudear processing of estrogen receptor. J Bioi Chern 
253:2223-2228 
41. Maslakowski P, Breathnach R, Bloch J, Gannon F, Krust 
A, Chambon P 1982 Cloning of cDNA sequences of 
hormone-regulated genes from the MCF-7 human breast 
cancer cell line. Nucleic Acids Res 10:7895-7903 
42. FoekensJA, Rio M·C, Seguin P, Van Pullen WW, Fauque 
J, Nap M. Klijn JGM, Chambon P 1990 Prediction of 
relapse and survival in breast cancer patients by pS2 
protein status. Cancer Res 50:3832-3837 
43. Foekens JA, Van Pullen WLJ, Portengen H, De Koning 
HYW CM, Thirion B, Alexieva-Figusch J, Klijn JGM 1993 
Prognostic value of PS2 and cathepsin D in 710 human 
primary breast tumors: multivariate analysis. J Clin Oncol 
11:899-908 
44. Read DR. Keith OK, Siamon OJ, Katzenellenbogen BS 
1990 Hormonal modulation of HER·2/neu protooncogene 
messenger ribonucleic acid and p185 protein expression 
In human breast cancer cell lines. Cancer Res 50:3947-
3951 
45. Waerri AM, Laine AM, MaJasuo KE, Alitalo KK, Haerko-
enen PL 1991 Estrogen suppression of erbB2 expression 
is associated with increased growth rate 01 ZR·75·1 hu· 
man breast cancer cells in vitro and in nude mice. Int J 
Cancer 49:616-623 
46. Russell KS, Hung MC 1992 Transcriptional repression of 
the neu protooncogene by estrogen stlmulaled estrogen 
receptor. Cancer Res 52:6624-6629 
47. Trask OK, Band V, Zajchowski DA, Yaswen P, Suh T. 
Sager R 1990 Keratins as markers that distinguish normal 
and lumor-derived mammary epithelial cells. Proc Nail 
Acad Sci USA 87:2319-2323 
48. Wolf OM, Jordan VC 1993 Drug resistance to tamoxifen 
during breast cancer therapy. Breast Cancer Res Treat 
27:27-40 
49. Bruenner N. Boulay V, Fojo A, Freter CEo Lippman ME. 
Clarke R 1993 Acquisition of hormone-independent 
growth in MCF-7 cells is accompanied by Increased 
expression of estrogen-regulated genes but without de· 
tectable DNA amplifications. Cancer Res 53:283-290 
50. Kasid A, Lippman ME, Papageorge AE, Lowy DR, Gelman 
EP 1985 Transfection of v-RasH DNA into MCF·7 human 
breast cancer cells bypasses dependence on estrogen for 
tumorgenlcity. Science 228:725-728 
51. McLeskey SW, Kurebayashl J, Honig SF. Zwiebel J, Upp-
man ME, Dickson AB, Kern FG 1993 Fibroblast growth 
factor 4 transfection of MCF· 7 cells produces cell lines 
that are tumorigeniC and metastatic in ovariectomized or 
tamoxifen·treated alhymic nude mice. Cancer Res 
53:2168-2177 
52. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, 
Coronado E, Shepard HM, Osborne CK 1992 Estrogen-
dependent, tamoxifen-resistant tumorigenic growth of 
MCF-7 cells transfected with HER2jneu. Breast Cancer 
Res Treat 24:85-95 
53. Toi M, Harris AL, Bicknell R 1993 cDNA transfection 
foHowed by the isolation of a MCF-7 breast cell line 
resistant to tamoxifen In vitro and (n vivo. Br J Cancer 
68:1088-1096 
54. Bates SE, Davidson NE, Valverius EM, FreterCE, Dickson 
AB, Tam JP, Kudlow JE, Lippman ME, Salomon OS 1988 
Expression of transforming growth factor alpha and its 
messenger ribonucleic acid in human breast cancer: Its 
regulation by estrogen and its possible functional signifi-
cance, Mo! Endocrinol 2:543-555 
55, AntonloW S, Maggiora P, Dali C, De Bortoli M 1992 
Tamoxifen up-regulates c-erb8·2 expression in oestro-
gen·responsive breast cancer cells (n vitro. Eur J Cancer 
28:318-321 
56, Klijn JGM, Berns PMJ J, Schmitz PIM, Foekens JA 1992 
The clinical significance of epidermal growth factor recep-
tor (EGF·A) In human breast cancer; A review on 5232 
patients. Endoc( Rev 13:3-17 
57. Nicholson S, Halcrow P, Sainsbury JAC, Angus 8, Cham-
bers P, Famdon JA, Harris AL 1988 Epidermal growth 
factor receptor {EGFrj status associated with failure of 
primary endocrine therapy in elderly postmenopausal pa-
tients with breast cancer. Br J Cancer 58:810-814 
58. Nicholson S, Halcrow P, Famdon JA, Sainsburyslamon 
JAC, Chambers P, Harris AL1989 Expression of epider· 
mal growth factor receptors associated with lack of re· 
sponse to endocrine therapy In recurrent breast cancer. 
Lancet 182-185 
59. Van Agthoven T, Timmermans M. Foekens JA, Dorssers 
LCJ, Henzen·Logmans SC 1994 Differential expression 
of estrogen, progesterone. and epidermal growth factor 
receptors in normal, benign, and malignant human breast 
tissues using dual staining Immunohistochemistry. Am J 
PathoI144:1238-1246 
60. Sharma AK, Horgan K, Douglas-Jones A, McClelland R, 
GeaJ, Nicholson A 1994 Dual immunocytochemical analy. 
sis of oestrogen and epidermal growth factor receptors In 
human breast cancer, Br J Cancer 69:1032-1037 
81. Sommers Cl, Walker.Jones D, Heckford SE, Worland P, 
Valverius E, Clark R, McCormick F, Stampfer M, Abular-
ach S, Gelmann EP 1989 Vimentin rather than keratin 
expression in some hormone·independent breast cancer 
cell lines and in oncogene·transformed mammary epithe-
lial celts. Cancer Res 49:4258-4263 
62. Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn 
M 1990 Vimentin is preferentially expressed in human 
breast carcinomas with low estrogen rereptor and high 
Ki-67 growth fraction. Am J PathoI136:219-227 
63. Cattorefli G, Andreela S, Clemente C, D'Amato l, Ailke 
F 1988 Viman!in and p53 expression on epidermal growth 
factor receptor·positive, oestrogen receptor-negative 
breast carcinomas. 8r J Cancer 57:353-357 
64. Mol! A, Franke WF, Schiller DL, tumors, cultured cells 
1982 The catalog of human cytokeratins: patterns of 
expression in normal epithelia. Cell 31:11-24 
65. Ramaekers F, Huysmans A, Schaart G, Moesker 0, Vooijs 
68 
P 1987 Tissue distribution of keratin 7 as monitored by a 
monoclonal antibody, Exp Cell Res 170:235-249 
66. EngellW, Young NA, Tralka TS, Lippman ME, O'Brien 
SJ, Joyce MJ 1978 Establishment and characterization of 
three continuous cell lines derived from human breast 
carcinomas. Cancer Aes 38:3352-3364 
67. Carmichael J, De Graff WG, Gadzar AF, Minna JD, Mitchell 
JB 1987 Evaluation of tetrazolium·based semi-automated 
colorimetric assay: assessment of chemosensitivity test-
ing. Cancer Aes 47;936-941 
68, Touw I, Van Gurp R, Schipper P, Van Agthoven T, Lbw-
enberg B 1992 Introduction of the human lnterleukin-6 
(IL·6) receptor In murine IL·3-dependent hematopoietic 
cells restores responsiveness to IL·6. Blood 79:2867-
2872 
69. MacDonald RJ. Swift GH, Przybyla AE. ChirgwinJM 1987 
Isolation of ANA using guanJdinium salts. In: 8erger SL, 
Kimmel AA (eds) Guide to Molecular Cloning Techniques. 
Methods In Enzymology. Academic Press, San Diego, 
CA, vol 152:219-227 
70. Sambrook J, Fritsch EF, Maniatis T 1989 Molecular Cion· 
ing: A laboratory Manual, ed2. Cold Spring HarborPress. 
Cold Spring Harbor, NY 
71, Green S, Walter P, Kumar V, Krust A, Bomert J·M, Argos 
P, Chambon P 1986 Human oestrogen receptor cDNA: 
sequence, expression and homology to v-fJrb·A. Nature 
320:134-139 
72. Ullrich A, Coussens L, Hayflick JS. Dull TJ. Gray A, Tam 
AW, Lea J, Yarden Y, Libermann TA, Schlessinger J, 
Downward J, Mayes ElV, Whittle N, Waterfield MO, 
Seaburg PH 1984 Human epidermal growth factor rerep-
lor cDNA sequence and aberrant expression of the am· 
plified gene in A431 epidermoid carcinoma cells. Nature 
309:418-425 
73. Derynck R, Aoberts AB, WInkler ME, Chen EY, Goeddel 
DV 1984 Human transforming growth factor alpha: pre-
cursor structure and expression in E. coli. Cell 38:287-
297 
74. Kastner P, Krust A, Turcotte B, Sltopp U, Tora L, Gro-
nemeyer H, Chambon P 1990 Two distinct estrogen· 
related promotors generate transcripts enCoding the two 
functionally different human progesterone receptor forms 
A and B. EMBQ J 9:1603-1614 . 
75. Coussens L, Yang·Feng TL, Liao Y, Chen E, Gray A, 
McGrath J, Seaburg PH, Libermann TA, SchleSSinger J, 
Francke U, Levinson A, Ullrich A 1985 Tyrosine kinase 
receptor with extensive homology to EGF receptor shares 
chromosomal location with neu oncogene. Sclence 
230:1132-1138 
76. Enoch T, Zinn K, Maniatis T 1986 Activation of the human 
.a-interferon gene requires an interferon inducible faclor. 
Mol Cell Bioi 6:801-810 
77. Benraad TJ, Foekens JA 1990 Hydroxylapatite assay to 
measure epidermal growth factor receptor in human pri-
mary breast tumours. Ann Clin 8iochem 27:272-273 
Aml'riam/Ollnwf 0/ Patbology. \'0/. N.J. Xo. 6./11111' 1994 
Cop)Tigbt 0 Anll'riC<l1l Soclely/or Im"t'Sligarln? Pmbology 
Differential Expression of Estrogen, 
Progesterone, and Epidermal Growth Factor 
Receptors in Normal, Benign, and Malignant 
Human Breast Tissues using Dual Staining 
Immunohistochemistry 
Ton van Agthoven,· Mieke Tlmmermans,ot 
John A. Foekens,:I: Lambert C. J. Dorssers,· 
and Sonja C. Henzen-Logmanst 
From Ihe Dtp(t,tmenl oj Molecular Biology! Departmellt oj 
Palhology. t alld Dill{s{on oj Endocrine Oncology, t 
(Deparill1ellf o/Medlcal Oncology), Dr. Dal/fel dell HOt'd 
Callcer Cellfer, Rotterdam, "file Nelherlal/tis 
Dlstrlbutloll ofestmgell (ER), progesterone (PR) 
receptOl's, and epldermalgrowthfaclol'(EGF) re-
ceptors was assayed by dllal stall1lng ImmwlO-
blstochemlst,y Oil 28 selected cytosollc ER-
positive breast carcinomas atld 22 IIo11l1lallglla"t 
breast tissues, ER-posltl11e tumor cells were de-
tected I" 26 (93%) mId EGF receptor positive ttl-
mOl-cells were detected /11 7 (25%) carcillomas, III 
fh'e tlllllors botb ER alld EGF I-eceptOl's wel'e de-
tected bllt localized It! dlslhlet tumor cells. OliO' I" 
olle case of dllclal care/lloma In situ co-
expressloll was observed III a subset of t"mol' 
cells. III cOlltrast, slmultaneolls e.\jJ1"essloll of 
ER/PR alld EGP receptors was obset"Ved I" lto1l-
"eoplastlc ductal ,-enma,,'s I" the majority oftbe 
carcillomas mId thejlbroadellomas. III addilioll, 
double-positive cells were occaslonalO' detected 
1"lmu/ual epithelial cells 0fllol'",,,1 breast tissue 
and mastopatlJies, This stud), shows that ER/PR 
and EGF '-eceptQI"s 111 b,·east IIImol' cells are 1,,-
vel'sel)' related at the slllgle cell level Howevel', 
demollstratloll of ER/PR am/ EGF receptm·s In 1,,-
dltlldllaillor",alillmillal cells sboll's tbat e:o:pl"es-
Sl011 Is IIot ",,,,,,all)' e.vcllls/lle, (Am J Patbot 
1994, 144,1238-1246) 
The estrogen receptor (ER) and the progesterone reo 
ceptor (PR) belong to the steroid hormone receptor 
family1,2 of ligand inducible transcription factors that 
5.3 69 
pray a role in the development and progression of 
breast cancer.3.4 Significant amounts of ER have 
been detected in over 50% of primary human breast 
cancers.5 Presence of ER in primary tumors identifies 
patients with a lower risk of relapse and better overall 
sUNivat.5.6 Furthermore. response to endocrine 
therapy largely depends on the presence of ER and 
PRo the latter indicating functional ER.7-9 As a con-
sequence, EA determination has become an estab-
lished procedure in the management of patients with 
breast cancer. 10 Approximately 50% of the patients 
with recurrent disease who had EA-positive primary 
tumors will respond to hormonal manipulation. How-
ever, duration of the response is limited because of 
progression to an estrogen-independent state of the 
tumor.:J·ll Although little is known about the mecha-
nisms underlying this progression, 12. 13 some prog-
nostic factors predicting failure of endocrine therapy 
have been identified. 14 The presence of EGF recep-
tors has been reported to be indicative of poor prog-
nosis and to correlate with lack of response to endo-
crine therapy in recurrent breast cancer. 15,16 
However, there is no agreement on the prognostic 
value of EGF receptor expression in breast cancer. 17 
It has been well established that expression of EGF 
receptor is inversely related with ER expression in pri-
mary breast tumors and in breast cancer cell lines, 
both on the protein and the mRNA levelY However, 
approximately 50% of ER-positive tumors contain 
EGF receptors. 1aln nonmalignant breast tissue, pres-
ence of both receptors was also demonstrated. 19 Un-
til now most determinations of ER and EGF receptors 
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have been performed in extracts of homogenates of 
tumor and nonmalignant breast tissue, which does 
not allow for the identification of the cellular origin of 
these receptors. Consequently, little is known on 
whether in breast tissues both receptors are ex-
pressed in different or in the same cells. 20 Further-
more, assays on tissue extracts do not allow for the 
assessment of the possible heterogeneity of ER and 
EGF receptors among cells or regions within a tumor 
specimen. In addition, the presence of normal cells in 
a tumor specimen may further complicate these 
analyses. Until now immunohistochemical analyses 
have been performed on tumor cells only for either 
receptor separately, thus solely excluding the pos-
sible contribution of normal cells. 20 
It would be of interest to determine the relationship 
of ER and EGF receptor expression at the single cell 
level using immunohistochemical techniques. We 
have studied whether in breast tumors with known ER 
status EGF receptors are inversely or co-expressed in 
individual cells. Furthermore, we have determined the 
expression patterns in normal tissues and of benign 
breast lesions. We have established a double immu-
nohistochemical staining method to determine ste-
roid hormone receptors and EGF receptor expression 
patterns in breast biopsies. Double immunohisto-
chemical analysis for PR and EGF receptors was per-
formed to determine whether the ER is functional in 
tumors expressing both ER and EGF receptors. The 
presence of PR indicates functional ER signal trans-
duction, because PR expression is regulated by ER.? 
The lack of breast cancer lines expressing both ER or 
PR and EGF receptors prompted us to use trans-
fected cell lines co-expressing these receptors to de-
velop a reliable assay. 
Materials and Methods 
Cell Lines 
lA/HERe cells were derived from lR-75-1 cells after 
introduction of the human EGF receptor cDNA,21 un-
der control of the herpes simplex thymidine kinase 
promotor, using a retroviral vector22 as previously de-
scribed. 23 MDNHEGO cells were derived from MDA-
MB-231 cells by co-transfection with 10 ~g of the hu-
man ER eDNA expression vector HEGO containing 
the early SV40 promoter24 and 1 I-Ig of the pLN ex-
pression vector for the neomycin resistance gene25 
by cationic liposomes (Upofectin Reagent, GIBCO-
BRL, Ufe Technologies Ltd., Paisley, UK). Colonies 
surviving 1 mg!ml of the neomycin analogue Gene-
ticin (GIBCO-BRL) were expanded to stable cell lines. 
70 
MDAlHEGO cell lines were selected for EA expres-
sion by Northern (RNA) analysis and cytosolic ER de-
termination. 
Culture Conditions 
lA-75-1 and the derived ZR/HERc cells were main-
tained in RPMI 1640 medium (GIBCO-BRL) supple-
mented with 10% heat-inactivated bovine calf serum 
(BCS) (HyClone Laboratories Inc., Logan, UT) and 1 
nmoliL 1713-estradiol (Merck, Darmstadt, Germany) 
as described.23 The RPM11640 culture medium of the 
MDA-MB-231 and the MDAlHEGO cells was supple-
mented with 10% BCS_ 
Quantitative Assessment of ER, PR, and 
EGF Receptors 
Cytosolic ER and PR was determined using a com-
mercially available enzyme immunoassay (EtA) kit 
(ER-EIA, PgR-EIA; Abbott Laboratories, Chicago, IL). 
EGF receptor expression was determined by Scat-
chard analyses of [1251]EGF binding and using hy-
droxylapatite to separate bound and free ligand as 
previously described.23.26 
Tissue Specimens and Cell Pellets 
Cell lines for immunohistochemical analyses were 
cultured in 225-cm2 flasks in the appropriate medium. 
At 90 to 100% confluence, cells were harvested by 
using 1 mmol/L EDTA in phosphate-buffered saline 
(PBS). The cells were pelletted by centrifugation for 
10 seconds in a microcentrifuge and were snap-
frozen in liquid nitrogen and stored at -80 C until use. 
Surgical biopsy specimens of normal breast tissue, 
benign breast lesions, and 28 mammary carcinomas 
(26 primary breast tumors and 2 with recurrent dis-
ease) were examined. The carcinomas were com-
prised of 21 invasive ductal carcinomas (6 of these 
contained a predominant intraductal component), 4 
invasive lobular carcinomas (1 of Ihese contained an 
in situ component), 2 mixed invasive (ductal/lobular) 
carcinomas (1 contained an in sifucomponent), and 
1 colloid carcinoma. 
Nonneoplastic breast tissues were analyzed in 22 
cases: 2 non involved tissue specimens adjacent to 
the tumor, 4 normal breast tissues from women who 
underwent mammoplastic surgery, and 8 mastopa-
thies. In addition, eight fibroadenomas were ana-
lyzed. All tissues were snap-frozen and stored in liq-
uid nitrogen. Histological diagnosis was assessed 
according to the World Health Organization (1981). 
For double immunohistochemical analysis tumors 
were selected containing cytosolic ER using the ER-
EIA assay, the lowest positive value was 9 fmolfmg 
protein. No EGF receptor data were available for se-
lecllon of the tumors. 
Immunohistochemical Procedures 
Immunohistochemical detection of EGF receptor was 
performed with monoclonat antibody (MAb) EGFRl 
(Amersham tnternational pic, Amersham, UK) and 
MAb clone 2E9 (Monosan, Uden, The Netherlands). 
The latter MAb was included for its strong reactivity 
with EGF receptor-positive cells. Both MAbs recog-
nize a protein determinant of the extracellular domain 
of the EGF receptor and do not cross-reacl with blood 
group A antigen.27,28 ER and PR detection was per-
formed with commercially avaHable immunocyto-
chemical (ICA) kils (ER-ICA, PgR-ICA: Abbotl Labo-
ratories). 
Cell pellets and tumor samples were mounted 
using Tissue Tee (OCT compound; Miles Diagnostics 
Division, Elkhart, IN). Frozen tissue samples and cell 
pellets were cut at 6 \J in a cryostat (at -20 C) and 
thaw-mounted on glass slides. Slides were air-dried 
for 30 minutes and fixed in 3.7% formaldehyde-PBS 
solution for 10 minutes followed by immersion in -20 
C ethanol for 5 minutes and in -20 C acetone for 3 
minutes. Each slide was immersed In 1% bovine se-
rum albumin (BSA) in PBS for 30 minutes before a 
60-minute room temperature incubation with the pri-
mary MAbs. Specific binding of either of the EGF re-
ceptor MAbs was visualized by incubation with rabbit 
anti-mouse IgG (Dakopatts, Glostrup, Denmark) for 
30 minutes, followed by incubation with mouse alka-
line phosphatase anti-alkaline phosphatase (APAAP; 
Sigma) for 30 minutes and subsequent color devel-
opment with Fast Blue SS saft (Sigma) creating a blue 
reaction product. Subsequently, the immunohisto-
chemical assay for ER or PR was performed as de-
scribed by the manufacturer (Abbott Laboratories) 
with the following modification. Primary ER or PR an-
tibody incubation was prolonged to overnight at am-
bient temperature in a moist chamber. Dfaminoben-
zidine (DAB) was used as chromogen, resulting in a 
brown nuclear localized reaction product. 
Control incubations were done by replacing the pri-
mary antibody with PBS or normal rat antibody. Slides 
were not counterstained to obtain maximum sensitiv-
ity. In all analyses serial sections cut from a single 
MONHEGO cell pellet were included in each slide to 
monitor the immunohistochemical staining proce-
71 
dure. For each experiment separate ER-JCA and 
EGFR·ICA were performed on the cel! pellets and the 
tumor biopsies as a control. In all cases, these ER-
ICAs and EGFR-tCAs showed identical results as the 
duallCAs, with respect to the number of ER- or EGF 
receptor-positive cells in cell line preparations and in 
tumors. Simultaneous detection of PR and EGF re-
ceptors was performed on the celt lines and a selec-
tion of biopsies using the same procedure as the 
double ER and EGF receptor ICA. In these analyses 
sections cut from a ZR/HERc pellet were included as 
control. The presence of myoepithelial cells was con-
firmed with an anti-muscle Actin IgG (ENZO Diag-
nostics, Inc., New York) on a serial section. 
Results 
Simultaneous Immunohistochemical 
Detection of Steroid Hormone and EGF 
Receptors 
Cell Lines 
The combination of an anti-ER rat IgG (H222) and 
anti-EGF receptor mouse IgG (EGFR-1 or 2E9) al-
lowed for double staining, as described in Materials 
and Methods. In a panel of cell lines, simultaneous 
immunohistochemical detection of ER and EGF re-
ceptor yielded clear labeling in contrasting colors of 
both receptors (Figure 1). In Table 1, the results ob-
tained with the double immunohistochemical assay 
on two established human breast cancer cell lines 
and their transfected derivatives are summarized. 
ZR-75-1 cells showed moderate expression of ER in 
approximately 40% of the nuclei and no EGF receptor 
was detected with either MAb EGFR1 or 2E9. ZR/ 
HERc cells (ZR-75-1 cells transfecled with the EGF 
receptor cDNA) expressed ER in 70% of the cells and 
EGF receptor was detected in all cells with both an-
tibodies. All MDA-MB·231 cells showed strong EGF 
receptor expression but no ER staining (Figure lA). In 
contrast, approximately two-thirds of the MDNHEGO 
cells (MDA-MB-231 cells transfected with the ER 
cDNA) also expressed ER (Figure 1 B). 
The same panel of cell lines was used to establish 
the feasibility of double immunohistochemical detec-
tion of PR and EGF receptors. The combination of an 
anti·PR rat 19G and an\1-EGF receptor mouse IgG 
(EGFR-l or 2E9) allowed for double staining, similarly 
as described for ER and EGF receptor. As shown in 
Table 1 and Figure 1, C and 0, PR was readily de-
tected in combination with EGF receptor. ZR-75-1 
cells expressed PR in 67% of the celfs and no EGF 
receptors were detected. The ZR/HERc cell line 
Figure 1. Dual sl(j{nlng Immunohl.s/DChemi((l1 mUl~)'sfs 0/ ER alld EGF ""ceplOr e.-qnes.sfoll (Iud PR and EGF receptor e.'tpres.sfon 011 breast CalKer 
(ell lilies, A: High magllificaliOIl 0/MDA-.UB-231 celis. r<'I\'a/l"8 EGFreceplor·!xJslIIlJ(' membrmle stall1ll1g and ER_l1cgalil'l? nt/clf>{, B: MDA/HEGO 
cdls sbou'i>l8 strollg EGF receptor membrane stalnl1l8 mId posltire rMel/o/! o//he tmdd lJ.ifb fhe aIll/-ER MAb, {lldicali,'g co-c.xfJressloll 0/ ER and 
EGF receptors. C: PR e,tpreSSIOtl 111 the nucld 0/ ZR-75-J ",lis, 110 react/OIl/or EGF receptor I.s obs~n'('d. 0: ZRlHERc celis. sboutng braun tnldeaf 
.<lal'I/l1g 0/ PR mId blue membralu' .<tailllllg 0/ EGF receptor u'i/b MAb 2E9, bldfwli1l8 ()-(!.>:prcSSIOIi 0/ PR and EGF receptor (X 1(10). Simllaf re-
slIll$ ue"" oblalned !lilh .IlAb EGFRl bill !rilb apProxima/ely/l1't! times rcdllced sla("llIg illtt'll5l1y(dala '10/ SbOU1!). 
Table 1, £'<Pressloll of ER and EGF Receptor De/emlilled 011 Breast Cancer Cel/Lilles 
Cell Une 
ZA·75--1 
ZA/HERc 
MDA-MB-231 
MONHEGO 
ER-EIA 
95 
100 
o 
202 
PR·EIA 
>500 
>500 
o 
o 
EGFR 
NO 
35 
879 
1012 
ER·ICA 
+ (40%) 
+ (70%) 
++ (70%) 
PR·ICA 
++ (67%) 
++ (68%) 
EGFA-1CA 
+ (100%) 
+++ (100%) 
+++ (100%) 
Receptor concentration determined with biochemical assays is expressed as fmoVmg prolein. NO, no EGFA deleclable. Dual immunohis-
tochem;cal assay was scored as follow$. Sla:ning inlensity: -, no slalning; +, weak positive staining; ++, moderately pOSitive sla1nlng; +++, 
strong positive staining. The percenlage of positive cells is shown, 
expressed PR in 68% of the cells and EGF receptors 
in all cells. PA was not detected in the ER-neg-
alive MDA-MB-231 cell line, nor in the ER-posilive 
MDNHEGOcelis with either the PR-ICA or the PA-EtA 
assay (Table 1). Introduction of the ER cDNA 
into hormone-independent MDA-MB-231 cells 
(MDA-HEGO) resulted in ER expression and 50% 
reduction of cell proliferation on estradiol addition 
to the culture medium. However, various EA-
regulated genes were not expressed in Ihese cells 
(unpublished observations in agreement with other 
studies).29.30 
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Tumor Biopsies 
tn Table 2, the results obtained with 28 human 
breast cancer biopsies are summarized. 
EA Expression, As expected from the selection cri-
teria (only EA-EIA positive tumors were included) the 
majority of the 28 (92.9%) carcinomas examined 
showed brown nuclear immunoreactivity in the tumor 
celis, indicating EA expression (Figure 2A). The per-
centageof immunoreactive tumor cells varied from 12 
to 95%. In addition, ER was also detected in luminal 
epithelial cells of nonneoplastic ductal remnants in 
Figure 2. DIIII/lmm/llwblstocbt!mICII/ slaliling ofER. PRo and EGF receptor 011 bT'IXISllisslles. A: Cast! 27 ilnwll'e drlCla/ am:lllonJalDCIS u'ilb ER-
posllll'e II/!¥Islte cells (arrow) (l1U/ DOS cdls (arrowhead) (lnd EGF r .. ceptorpMIIiI'e myocpltbellal c .. lls (open arrow). OrigilUl mlgnifknion x 16. 
B: High nmgllljl<"afioll of a Sub,-"I of DCIS cells from cas .. 27 showing co-..>.'1>,,,:»lo/l of ER mId £GF reaptor; ami cells e.xpfeS.5lng Oil&' Ol1e rt:<"eptor 
ty{Jf! (x631. C: Dllal Immwlobl$lo<:bemlcal sta/II/1lg oj II CIIrcilloma (eme 21) u'flb sI,-emg EGP nxeplor expr .. :»tol1 /II most of Ib .. IlIl>Ior celis 
(x 16'1. 0: ,\bmwl dllCI fflij(lce"l to the tlll71or{case 11) wllh t-o-e:presstoll ofER alld EGF receptors ill (!lmOwl epllb.:/lal cells (llid £GF nxepror 
e..\prt::»lolI /1/ tbe myoepltbellal cells (X 63). E: £-.:amplr of I>Imtopatby /I. lib PR r_'Pressloll III II/mllllli ct!lls (III</ EGF receptor-postlil,€, myocpltb('/Ial 
cdls (X 16). F: Flbroadelloma with EGF m.-Iptor-po,/til't' stromal cdls alld dUclldlb PR-pos/lh-e fumhmf cells lind EGF rec"'PlOr e_'Pn?SS/oll til/he 
myoepltbellal celis (X Hi). 
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Table 2, £"1!f':Js(OIl of ER, PR, alld EGF Rec('/Jt(JlS (II Bre(lst CardllOlllas [.'s(lIg D/lal Stail/illg 
Non-
CIS neoplastic 
EA/PR· Ductal 
Case Carcinoma Type EIA' Luminal Myoepithelial Invasive Stromat Remnants 
1 Invasive ductal 601 0 O/EGFR 
2 Invasive ductal 19/36 EGFR O{EGFA* 
3 Invasive ductal 204 0 0+ EGFA 
4 Invasive ductal 592 0 EGFA OjEGFR 
5 Invasive ductal 546 0 EGFR 
6 Invasive duclal 238 0 EGFR 0+ EGFR 
7 Invasive ductal 36/532 D,P + EGFRt O,P/EGFR 
8 Invasive ductal 61 0 EGFR 
9 fnvasive duclal 65 0 EGFA O/EGFA 
10 Invasive ductal 51 0 O/EGFR 
11 Invasive ductal 62 0 EGFR O{EGFR 
12 Invasive ductal 14/8 EGFR 
13 Invasive ductal 22 0 EGFR O/EGFR 
14 Invasive ductal 142 0 O/EGFR 
15 Invasive ductal/DCIS 305 0 EGFR 0 EGFR 
16 Invasive ductal/DCIS 193 0 EGFR 0 EGFR O{EGFR 
17 Invasive ductal/DCIS 98{559 Q,P + EGFR EGFR O,P EGFR O,P/EGFR 
18 Invasive ductal/DC IS 13 0 EGFR 0 O{EGFR 
19 Invasive ductal/DCIS 38/64 O,P + EGFR EGFR O,P EGFR O,P/EGFR 
20 Recurrent invasive 760 0 EGFR 
ductal 
21 Recurrent invasive 9/1 EGFR EGFR 0+ EGFR EGFR O,P/EGFR 
ductal/DCIS 
22 Invasive lobular 656 0 O/EGFR 
23 Invasive lobular 62 0 EGFR O/EGFR 
24 Invasive lobular 38 0 0 O/EGFR 
25 Invasive lobularl 52 0 EGFR 0 OjEGFR 
DCIS 
26 Invasive lobular/ 101 0 O/EGFR 
ductal 
27 Invasive lobularl 153/23 O{EGFA EGFA O,P EGFR O,P/EGFR 
ducUDCIS 
28 Colloid 271 0 EGFA O/EGFR 
The tumor biopSies were divided in carcinoma in sifu(CIS), with luminal celis and myoepithel'al cells. the invasive component. stroma, and 
nonneoplastic ductal remnants. The abbreviations used are: O. ER e~press:on: EGFR, EGFR e~pression: 0 + EGFR, EA and EGF receptor 
express;on on different subsets of cel~s: O/EGFR, expression 01 ER afld EGF lecep!ofs in the same cel:s and cel:s expressiflg only one recep~ 
tOI type: P. PR expression: DCIS, ductal carcinoma in situ . 
• PA·EIA data are oflly grven for the biopsies with EGFR·positive tumor cells (cases 2, 7. t2. 17, 19.21. afld 27) that were investigated in 
the doub:e PR/EGFA !CA. Receptor concentration determined w:th ER·EIA and PR·EIA is expressed as fmo'/mg protein. 
t Ce:rs reactive wi1h MAb 2E9 but not reactive with MAb EGFRI Viere detected, 
* No normat ducts presefll in section lor PR/EGF receptor analysis 
the tumor biopsy present in 25 of the 28 (89.3%) tu· 
mors (Figure 20). No ER expression was observed in 
the stroma or in myoepithelial cells. 
EGF Receptor Expression. Of the 28 carcinomas 7 
(25'%) showed immunoreactivity of tumor cells with 
MAbs EGFR1 and 2E9, indicating EGF receptor ex-
pression (Figure 2C, Table 2, cases 2,7,12,17,19, 
21, and 27). Of these seven EGF receptor· positive 
carcinomas, immunoreactivity was confined to the 
carcinoma in situ (CIS) component in three cases, 
Both membrane and cytoplasmic staining of the tu-
mor cells was observed with MAb 2E9 and EGFA1.ln 
addition, nonneoplastic ductal remnants in the tumor 
biopsy and normal breast ducts in adjacent breast 
tissue showed strong staining of the myoepithelial 
cells and moderate staining of some of the luminal 
cells (Figure 20). Furthermore, EGF receptor ex pres-
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sion of the surrounding myoepithelial cells of ductal 
carcinomas in situ (DCIS) was observed (Figure 2A, 
Table 2). In most cases MAb 2E9 exhibited a similar 
pattern but a more intense staining when compared 
with MAb EGFAI. Apart from reactivity with tumor 
cells and myoepithelial celis, MAb 2E9 but not MAb 
EGFAI showed weak to moderate staining with parts 
of the stroma containing actin-positive myofibrillic el-
ements (Table 2). 
Co-expression of EA, PR, and EGF receptors. Our 
study revealed that all biopsies contained EGF 
receptor-positive cells. However, only in 7 of the 28 
biopsies were EGF receptors expressed in the tumor 
cells. Five (17.9%) of the 28 tumors showed mosaic 
expression of EA and EGF receptor, ie, EA-positive 
tumor cells were distinct from EGF receptor-positive 
cells in the section. Only in a mixed invasive ductal 
Figure 2. Dllal Imlllll/lub«lochcmical.</{III/illg 0/ fR. PR, a/ld EGF m-cplor 011 hreaslll~'ues. A: Case 27/1!!m1!~ duc/al «lTc/lioma vas /11/0 ER-
posilir\> ifllm!/\' celr,(arrow) <I/ul DOS tells (aflOwhead) al/(I EGF rff('pl(ir-po.'iti!~ 1II.l'0cpllbrlia{ cdt> (open arrow). Orighu! mJgoifkation XJ6. 
B: IUgh IIWRl1ijJC(1fi(oI/ {if a subset 0/ DClS c<'ft, /rom C(I.'e 27 ,bOldnS CCH.'.\prc'ssioll oj ER a!ld EGF "'aPlo~ and cdl, c.xprcs'illg O!l(!' 0111' Tt'Ci.'P!IJr 
~Ipi.' (X63). c: D!l<IllmllllmubL'locfl('m!cal -,Iaiulllg 0/ a carc{/Willa (case 2}) rlllh siroug EGF rff<plor ('.11",'.<''</0/1 i., /lIust 0/ tho' IImror cdls 
(X 16). D: ,\'orma( dUi.1 ad/ac('1/1 to ,b,' III/JJor(ca<p 11) will> fO~\P"'S;!illr 0/ ER and EGF nx<plor; itllrrmil1al f"lIbelial cdl' (/lui EGF rex,plor 
'~11Jfi.';:'_'/OIl iI/ Ibe !I1.1v<pilhdia/ i.·dls (X 63)· E: Examp/p (if mastopalhy II ilb PR f'..'pres..'il>lI /11 llllllillar (("lis ami EGF ",(,ptoT-po.'II/", Ilt!'V(1rilbdfal 
('dis. (X 16). F: F!i>mi/,/(omIHI<I rUI/) EGF re(eplor-[>(!.<lIil,(, slromal cdt< aI/(/ dl/ftll lib PR·po:;/lil'(' l!lmiJla} cdls. (md EGF ,,'Up/or "'1'H'.<..,loli In In<' 
m}{>{.lJ{lnl..'.'Ial cdls(x 16). 
carcinoma, DCIS (case 27) co-expression of ER and 
EGF receptors (MAb 2E9) was observed in a subset 
of cells. In the DCIS 70% of the tumor cells expressed 
ER; 60% EGF receptors and approximately 30% con-
tained both receptors (Figure 2, A and 8). Co-
expression of ER and EGF receptor in individual tu-
mor cells was not observed with MAb EGFR1 
because of reduced staining intensity. 
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PR is regulated by the ER and often expressed at 
considerable higher levels than the latter. Double 
staining for PR and EGF receptor was performed on 
the EGF receptor-positive tumors to confirm the ab-
sence of hormone receptors in EGF receptor-
expressing tumor cells. Analogous to ER. PA-
expressing tumor cells were distinct from EGF 
receptor-expressing cells. The CIS component, con-
taining EA and EGF receptor double-positive cells, 
was not present in the remaining specimen of case 27 
for analysis of PR and EGF receptor co-expression. 
Expression of ER, PR, and EGF Receptor 
in Nonmalignant Breast Tissue 
Double-positive nonneoplastic ductal epithelial celis 
were observed in 21 of 28 tumor biopsies with EA 
MAb and the EGF receptor MAbs. In addition, in two 
samples of non involved breast tissue adjacent to the 
tumor, we noticed strong co-expression of ER and 
EGF receptor in up to 10% of the luminal epithelial 
cells (case 11 and 22, Figure 20). 
Analysis of another 22 nonmalignant tissue 
samples showed the following results. Four normal 
breast tissue specimens showed EGF receptor ex-
pression in the myoepithelial celis and the luminal epi-
thelial cells. Focal and heterogeneous expression of 
EA and PA was observed in the luminal epithelial 
celis. Co-expressional ER, PR, and EGF receptor was 
noticed in a small percentage of the luminal cells. In 
eight cases of mastopathy, weak to moderate expres-
sion of ER and PR in the majority of the luminal epi-
thelial celis was observed and moderate expression 
of EGF receptors in the surrounding myoepithelial 
cells (Figure 2E). Co-expression of ER, PR, and EGF 
receptors was observed in a small number of luminal 
epithelial ceHs. In eight cases of fibroadenoma the 
luminal cells expressed EA and the myoepithelial 
cells EGF receptors. Frequently, luminal celis showed 
strong co-expression of ER and EGF receptors. Simi-
lar observations were made for PR expression. In the 
stromal cells of alJ the fibroadenomas we noticed 
strong reactivity with MAb 2E9 (Figure 2F). EGF re-
ceplor was al$o visualized with MAb EGFR1 in the 
fibroadenomas, indicating high expression levels. 
Discussion 
In this study the expression patterns of EA, PR, and 
EGF receptor in individual cells of human breast car-
cinomas and nonmalignant breast tissues were de-
termined using dual staining immunohistochemical 
techniques. We have developed a method for the si-
multaneous detection of ER or PR and EGF receptor 
on frozen sections. Using a panel of transfected hu-
man breast cancer cell lines the procedure was op-
timized and verified for specificity and sensitivity. Our 
results show that low levels of hormone and EGF re-
ceptors can be detected simultaneously. ER levels 
determined in cytosolic preparations of cell lines 
(range 40 to 202 fmol/mg protein) were readily de-
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tectable in the tumor cells with the double immuno-
histochemical assay (range 25 to 70% positive cells). 
EA levels determined in cytosolic preparations of tu-
mor homage nates (range 9 to 760 Imol/mg protein) 
were readily detected with the immunohistochemical 
assay (range 12 to 95% positive tumor celis). Corre-
lation of ER-EIA and ER·ICA was 92.9%. Only in two 
ER-EIA-posllive cases (cases 2 and 12) ER-ICA failed 
to detect EA- or PR·positive tumor cells. However, one 
of these biopsies (case 2) contained EA-positive duc-
tal remnants, which may explain this difference. Dis-
crepancies may also arise due to sample differences 
for the EIA and ICA analysis. 
We detected 40 to 70% ER-positive celis in the cell 
lines in contrast to EGF receptor expression, which 
was observed in all celis of the EGF receptor-positive 
cell lines. Heterogeneity of EA expression by tumor 
celis is well established31 .32 and the failure to detect 
ER in all celis may be attributed to either low sensitivity 
of detection, mosaicism of tumor cells, or cell cycle 
regulation of ER protein levels. Using a MAb directed 
against PRo which is often expressed at considerably 
higher levels than ER, we found mostly similar num-
bers of positive celis. Immunohistochemistry with a 
different anti-ER mouse IgG (Oako) on the cell lines 
and a subset of the biopsies gave increased staining 
intensity, yet the degree of staining heterogeneilywas 
not significantly altered (data not shown). The ZA-
75·1 cell line and clonal derivative are fully estrogen 
dependenl and exhibit a homogeneous pheno-
type. 13.23 Expression of EA in the clonal MONHEGO 
cells is controlled by a heterologous promotor and is 
never delectable in all cells. These results show that 
neither the sensitivity nor the clonal state of these cell 
lines can explain the heterogeneous staining for EA. 
This suggests that EA and PR protein levels may be 
strongly regulated during cell cycle progression, in 
contrast to EGF receptors thai were detected in all 
cells of the EGF receplor-expressing cell lines. In the 
tumor biopsies EGF receptor expression levels were 
also less heterogeneous compared with ER expres-
sion.lnCIScomponentsofthe tumors we detected up 
to 95% ER-positive cells, possibly reflecting the dif-
ferent proliferation kinetics in the tumor in comparison 
to the cell lines. 
Screening of 28 breast carcinomas has shown that 
all possible expression patterns occur in individual 
tumor celis. Tumor cells expressing either ER or EGF 
receptors were readily detected. In addition, tumor 
areas without detectable ER or EGF receptors were 
observed, indicating absence or expression below 
our detection fevel. Thus, alternative signal pathways 
may be used for regulation of proliferation of ihese 
breast cancer celis. Alternatively, variant ER proteins 
missing exon 5 may have escaped detection by the 
ER antibody used,33.34 but analysis of PR did not re-
veal more double-positive cases. The fourth pheno-
type, ER and EGF receptors on the same tumor cell 
was only observed in one case of DCIS with MAb 2E9, 
indicating a low expression level of EGF receptors. In 
the majority of the tumors containing both ER and EGF 
receptors, these were inversely expressed in different 
subsets of tumor cells or in normal components 
present in the tumor biopsy. 
Our study shows that expression of ER and EGF 
receptors is heterogeneous with respect to tumor bi-
opsy compound (invasive/C1S/stroma/nonneoplastic 
ductal remnants) and thus this study further docu-
ments the heterogeneous nature of primary breast tu-
mors. Consequently, in addition to biochemical as-
says, immunohistochemical analysis of ER and EGF 
receptor expression may help to give better under-
standing concerning the biology, prognosis and the 
tumor response to hormonal therapy. ER and PR ex-
pression was exclusively restricted to actin-negative 
cells of the epithelial lineage but absent in actin-
positive myoepithelial breast cells. In contrast, EGF 
receptor expression was not only demonstrated in lu-
minal and myoepithelial cells but also in stromal cells 
surrounding the breast carcinoma cells and in all 
cases of fibroadenomas studied. 
In malignant breast tissues ER and EGF receptor 
are inversely related. Even in tumors expressing both 
receptors, ER and EGF receptor are rarely expressed 
simultaneously in the same cells. Apparently both re-
ceptor signal pathways become uncoupled during 
malignant progression. This may be explained by the 
negative interaction between ER and EGF receptor 
signal pathways observed in artificial celllines.23.29.3o 
It was demonstrated that in ER-posltive cells HER2/ 
neu becomes down-regulated on estrogen stim-
ulation. 3 5-37 Similar regulation mechanisms for ER 
and EGF receptor may exist in breast epithelial cens. 
However, our observations show that ER and EGF re-
ceptor are frequently co-expressed in nonmali\}nant 
breast tissue and thus the interplay of both receptor 
signal pathways must play an as yet unidentified role 
in the growth and differentiation of normal mammary 
ducts. 
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EXPRESSION OF ESTROGEN, PROGESTERONE AND EPIDERMAL 
GROWTH FACTOR RECEPTORS IN PRIMARY AND METASTATIC 
BREAST CANCER 
Ton VAN ACHHOVEN U , Mieke TI~IMER;\IANSL~, Lambert c.J. DORSSERS1 and Sonja C. HENZEt\-LoGMAc"Sl 
DepanmenlS of lMofCCllf(lr Biology (ll/d 1PatllOlogy, Dr. Dallicl def! Hoed Cancer Celller, Rollatiam, Tile Netherlands. 
The prognostic value of epidermal growth factor receptor 
(EGFR) expression and Its biological role In estrogen receptor-
positive (ER+) and ER-negative (ER-) primary breast cancer Is 
controversial, In thls study, distributions of ER, progesterone 
receptor and EGFR have been established usIng Immunohisto-
chemistry In both primary breast tumors and theIr matched 
axillary lymph node metastases of 26 patIents or their matched 
distant metuta.ses of 2 patients, In addition, S patients with 
bilateral breast cancer were studied, ER· tumor cells were 
detected in 22 (69%) and EGFR+ tumor cells were detected in 
II (34%) primary breait carclnom.u, ExpressIon of ER and 
EGFR was Inverse regarding the Individual tumor ceUs In both 
primary tumors and metastases. RelationShip of EGFR expres-
sion with poorly differentiated and large breast tumors was 
observed, Furthermore, primary tumon with a predominant 
lobular component were ER+ and. with one exception. EGFR-. 
Inv.ulve ductal carcinomas were more frequently EGFR+, No 
apparent differences In receptor exprenion were observed 
between primary tumors and lymph node metastases or chro-
nously or metachronously occurring bitateral breast cancen. 
Only one ER+ primary tumor showed a switch to EGFR expres-
sion In the Involved lymph node. Our study shows that a shUt in 
receptor phenotype between primary tumon and lymph node 
metastases Is a rare event and, thus, additional analyses of 
Involved lymph nodu will not likely serve as a better predictor 
for response to anti-estrogen therapy. We conclude that expres-
sion of EGFR Is not a prerequisite for development of metastases. 
e 1995 Wiley-LiJs, Inc. 
Multiple factors contribute to the development and progres-
sion of breast cancer. Among these factors estrogens playa 
crucial role. Estrogens bind to the estrogen receptor (ER), 
resulting in an activated complex that acts as a transcription 
faclor through binding to target genes (Evans, 1988; Beato, 
1989; Parker et af., 1993). Estrogens can stimulate tumor cells 
directly or indirectly by an autocrine growth mechanism 
(Clarke et al .. 1992). Estrogen·dependent growth can be 
blocked by anti-estrogens, which compete for binding to the 
ER (Pritchard and Sutherland, 1989; Jordan and Murphy, 
1990; Watts ef af., 199-1). Consequently, the presence of ER in 
primary tumors identifies breast cancer patients responsive to 
anti-estrogen therapy. However, the presence of ER is no 
warrant for response to endocrine therapy because half of the 
patients with ER· primary tumors do not respond (Jaiyesimi 
ef of., 1995). Furthermore, almost all patients will ultimately 
develop metastases refractory to treatment. The mechanisms 
underlying hormone resistance for the majority of eases 
remain unclear (Dorssers et IIf., 1991; Katzenelienbogen, 1991; 
King, 1992; Johnston et af .. 1992; Clarke ef IIf., 1992; Horn'itz, 
1993; Osborne and Fuqua, 199-1; Van Agthoven ef of., 199.\.b). 
Since the actions of estrogens and anti.estrogens are medi-
ated I'ia the ER, the development of ER- tumors would 
ultimately re ... utt in hormone resistance. E'pression of ER is 
inversely related to c~pression of the epiuermJI growth factor 
receptor (EGFR) in breast cancer (reviewed by Klijn el III .. 
1992). Patients with breast tumors containing high levels of 
EOFR fail to respond to endocrine therapy (Nicholson et af" 
1989). In a previous report, we described the e~prcssion 
patterns of ER, progesterone receptor (PR) and EGFR in a 
series of cytosolic ER + primal)' breast carcinomas (Van 
Agthoven et IIf., 199.\.a). Dual-staining immunohi,tochemistry 
allowed simultaneous detection of the steroid hormone recep-
tors and EOFR at the single-cell level. Expression of ER/PR 
and EGFR was deteeted in most biopsy specimens in either 
cancer celis or non-malignant cells present in the tumor. 
Co·expression of hormone receptors and EGFR in the same 
tumor cells was rarely observed (Van Agtho\'en el of., 199.\.a; 
Sharma ef of., 199-1). The purpose of the present work was to 
study further the biology of tumor progression by comparing 
the expression patterns of ER/PR and of EGFR in a series of 
primary breast tumors with their matched metastases. 
MATERIAL AND METHODS 
Seh'cliolZ of breaSI fIImors 
Frozen tumor specimens of both primary breast cancer and 
a.~i1Iary lymph node metastasis were available from 26 patients. 
Furthermore, 5 patients with either synchronously (n "" 3) or 
melachronously (n = 2) occurring bilateral breast cancer and 
2 patients with distant metastasis (one of the patients with 
synChronously occurring bilateral breast cancer) were ana-
lyzed. Patients were ehosen at random. Histological diagnosis 
was assessed according to the World Health Organization 
(Azzopardi et of., 1982). Tumors were graded according to the 
Bloom and Richardson system with minor modifications as 
described by Page and Anderson (1987). The age of the 
patients at the time of surgery, size of the primary tumor and 
number of involved lymph nodes were recorded as well. 
Slalistic allafysis 
Statistic analysis was performed using Fisher's exact tests. 
ImmllllOhistochemicaf procedllres 
Expressions of ER, PR and EGFR were individually as-
sessed in duplicate serial sections of snap-frozen tissues stored 
in liquid nitrogen as described (Van Agthovencl of., 199.fa). In 
addition, a part of the cases were ER/EGFR double-stained 
(Van Agthoven ef af., 1994</) to confirm the interpretations of 
the individually stained sections. Immunohistochemical detec-
tion of ER and PR was performcd with commercially ayailable 
immunocytochemical (ICA) kits, (ER-ICA, PgR-ICA; Abbott, 
Chicago, IL). Detection of EGFR was performed with a 
monoclonal antibody (MAb) clone 2E9 (Monosan, Uden, The 
Nelherlands) and MAb EGFRI (Amersham, Aylesbury, UK). 
In all analyses, serial sections of positive and negative control 
cell lines were included in each slide to monitor the immunohis· 
tochemical staining procedure. The prescnce of myoepithelial 
cells was confirmed with an anti-muscle actin IgO (Enzo, Nc\\ 
York, NY). Furthermore. a serial section was used to test the 
presence of keratin 8- or IS-positive epithelial cells using MAb 
CA:\1 5.2 (Becton Dickinson, Erebodegem, Belgium). All 
slides were analyzed by 3 im'estigators (T. V.A" M.T. and 
S.C.H.·L.). 
-'To ",hom correspondence and reprint reque~ts sh~luld be sen!, 31 
Department of M0lecular Biolag)'. Dr. DJniel den Hoed Can(er 
Center. Groene fldkdijk 301. 3075 EA RotterdJm. The Nethnlands. 
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TABLE 1- EXPRESSION Of lOR, PR AND EGfR ANO CHARACTERISTICS Of PRIMARY BREASTTUMORS A.'m '\IET ASTASES 
META 
AS' Sue '" Jnv",iH Strom. NSDR Numb~rof C,,-,( Tumorlyp( Gr.de (}eJr) (.m) Luminll M)'o inyoi>ed TumN Stroml 
nc'>Jes 
I 52 Invasive ductal II 2.4 OP E E I OP E 
2 45 In~asive ductal II 4 OP E EOP 4 0 E 
3 
" 
In~asive ductal II J OP E EOP 6 OP E 
4 58 Invasive du(ta\ II J E EOP 7 E 
5 61 Invasive du(tal III 5 OP II OP 
6 6J Invasive ductal III 3 0 EOP 2 0 
7 53 Invasive ductal III 5 E EOP 9 EIE 
8 43 Invasive ductal III 8 E E EP 7 E E 
9 55 Invasive ductal III 16 E E I E 
10 2J Invasive ductal III 5 E >8 E 
II 66 Invasive du(tal/DCIS II 4 0 E 0 EOP 3 OP 
12 62 Invasive du(tal/DClS II 1.5 OP E OP E EOP 4 OP E 
13 41 Invasive du(tal/DCIS II 1.3 E E E EOP 6 E E 
14 49 Invasive ductal/DCIS III 6 E E E E EP 7 E E 
15 
" 
Invasive ductal/DCIS III 2.2 OP E OP E EOP 4 OP E 
16 47 Im'asive lobular I 4 OP E EOP 4 OP E 
17 45 Invasive lobular I 4 OP E EOP 14 OP E 
18 45 Invasive lobular I 5 OP E EO 7 OP E 
19 45 Invasive lobular II 4.5 OP E EOP 8 OP E 
20 49 Invasive lobular II 7 OP E E 6 OP E 
21 50 Invasive lobular/ductal II 3 OP EOP 6 OP 
22 46 Invasive lobular/ductal II 3 OP E E 5 OP E 
2J 4J Invasive lobular/duclal II 2.7 OP E EOP I OP E 
24 43 Invasive lobular/ductal III 2.5 OP E E 2 OP E 
25 48 Invasive lobular/ductal DCIS II 3 OP E OP 8 E E 
26 45 Invasive lobular/ductal DCIS I 4.5 OP E OP E EOP 4 OP E 
27L 49 Invasi\'e ductal III 7 E E 28 E 
27R 49 Invash'e ductal III 7 E E 
28L 49 Invasive ductal III NO' E E NO 
28R 49 Invasive ductal III NO' E E 0 
28 50 Skin metastasis E 
29L 68 Colloid I 1.5 OP EOP 0 
29R 68 Colloid I 0.8 OP EOP 0 
30R 
" 
Invasive lobular/DCIS I 1.5 OPE E OP EOP I NO 
30L 59 Invasive lobular I 4 OPE E EOP 0 
JlL 46 Irwasive lobular/CIS I 3 OP OP EOP 10 NO 
JlR 49 Invasive lobular I NO OP E EOP 0 
J2 60 Invasive ductal III 4 E 0 
J2 6J Thorax meta III E 
Distribution of receptor e~pression was subdivided in case of primary tumors in carcinoma in situ (CIS) with luminal tumor cells and 
myoepithelial (myo~ cells, the invasiye tumor component, stromal and non.neoplastic ductal remnants (NNDR). Metastases were 
divided in tumor eel s and stroma, Further abbreviatIOns used are: 0, ER e:o;pression: P, PR expression; E, EGFR expression: L, tumor in 
left breast: R, tumor in right breast; DCIS, ductal carcinoma in situ; ND, not determined; ND', not determined, large tumor diffuse 
gcov.lh. 
RESULTS 15 and 160 in the lymph node metastases. Howcver, no gross 
The clini1:al, histological and immunohistochemical data of differences were obser.'ed between primary IUmors and metas· 
thc 32 patients arc listed in Table I and summarized in tases. 
Table n. Proges/erolle receptor 
Es/rogm receptor Expression patterns of PR were similar to those of ER. The 
Exprcssion of ER was restricted to malignant epithelial cells number of positive tumor cells varied between 2 and 139 in the primary tumors and between 2 and 150 in the lymph node 
and non-malignant luminal epithelial cells of non·neoplastic metastases. PR was detected in thc tumor cells of 20 of the 32 ductal remnants. Of the 32 primary breast carcinomas ana· (63%) primary tumors and in 16 of the 26 (62%) I)mph nodes. lyzed, ER was detected in the tumor cclls of22 (69%) patients. In onc casc (2), PR cxpression was not detcctcd in the involved ER was observed both in the invasive tumor cells and in the lymph nodc, which cannot be explained by hormone status of 
tumor cells of the carcinoma in 5illl (CIS) componcnt (7 cases). the patient because both biopsy specimens were removed at Of the 26 cases studied with lymph node metastascs, thc tumor the same time. In another primary tumor (11), .... c obser.-ed 
cells of 19 (73%) primary breast cancers and 18 (69'*) lymph PR- tumor cells and PR' non.neoplastic ductal remnants and 
node metastases were ER·. In one case (25) with an ER + clear PR' staining of the tumor cells in the lymph node. primary lumor, no ER + cclls in the lymph node metastasis 
wcrc detccted. Epidemw! groll'lh factor feet'plor 
In ailS ca~es with ER- primary breast tumors, l}mph node EGFR expression waS detected in tumor cells, n\)oepithelial 
metastases were ER- as well. Staining of ER was hctcrogc. cells of ductal carcinoma ill situ (DCIS) and m}'oepithelial cells 
neous with respcct to intensity and percentage of positivc cclls. and luminal cells of non·neoplastic ductal rCmnants with both 
The number of ER + tumor cells varied bctween 7 and MAbs EGFRI and 2E9 (Table I). Stromal components often 
152/40x high·power field in the primary tumors and between rcacted with the MAb 2E9 to EGFR both in primary tumors 
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TABLE 11- RF.LATtO,,"SIItP BEn\f.~~ £OFR EXPRESSIO..,. A .... O 
<:IIAIlACTERI5TtCS OF f'Rt\\ARYTU\1<mS 
\"~ri~~!c EGFR' EGFR- f-'··T~( 
Towl J2{IUO'() 11 (_W1) 21 (66<'J:) 
Tumort,pe 
18 (~6,() 8(.W7c~ Ducwl 10 (56'1) 
LODu];lr IJH1,() 1 (I:IQ) 12 (92':';' < 0.006 
Colloid I (YC) 0(0'"( ) I (lIKyq 
Tumor size 
TT (:o:;2cm) 4 (l.3c() I (25c() .3 (75Q) 
T:{>2-5 22 (6911) ~ (18<:() 18(82%) 
<m) 
TH (» 6(19Q) 5 (83<:() 1(17Q) <0.006 
<m) 
Gr:Jde 
I 7 (!2<J-) 1(I7'1~ 6 (86~i 
" 
1J(4m) 2 (15c( 11 (1-:5<;{-
III 12 (38<J-) 8 (67<;() 4 (.33<'J: <0.001 
Sodal status 
1-3 7 (24'1-) ] (14c(~ 61''"' l >3 22 (76~) 7 (32Q 15 68% N.s. 
Estrogen 
rece~tor 
ER· CA' 22 (69<'J: ~ I (5<:1) 21 (95%) 
ER·]CA- W(3m 10 (lOO<J-) 0(0%) <0.001 
Progesterone 
receptor 
20 (6J%~ 20 ~IOO<;{-) PR·]CA- o (O<'J:) 
PR-]CA- 12 (3SQ 10 (83<;() 2 17<)1) <0.001 
and metastases. TIle 2E9 }'1Abwas included in this study for its 
high sensitivity compared with the EOFRl MAb and spedfie 
detection of EOFR· cclts (Van Agthoven CI 01., 1994a). 
Staining of the tumor cells with the 2E9 MAb and EGFRI was 
in general more homogeneous in comparison with ER and PR. 
Similar to ER and PR, no appMcnt differences between 
primary tumors and metastases were observed, 
With respect to tumor cells, EGFR was detected in II 
(34(() primary tumors both in the invasive and the CIS 
component (13, 14) or only in the CIS component (30), Of the 
26 ca$CS studied with involved lvmph node met<tstases, 8 (3lo/t) 
primary tumors :Jnd 9 (35~) metastases were EGFR·, EGFR 
was also detected in 2 cases with distant metastases both in the 
primal)' tumor and the metasta.<.es (2 and 16), 
Rclalioll5hips of rcap/or oprcssioll wilh /I/IIIOT charac/cri.llics 
The relationship between EGFR e:\pression, tumor classifi· 
cation and steroid receptor e:\pression is shown in Table II, 
bpression of EGFR was inverse, with ER and PR 
(p < 0.001) both in the primary tumors and the metastases, 
One case (30) with ER/PR+ and EGFR+ tumor cells was 
ob~ef\'ed, However. e.'pression was on different tumor cells, 
which was confirmed with ER, PR and EGFR dnuhlc-staining, 
More than half of the cases with invasive ductal carcinoma 
were EGFR+ and ER~, A completely different distribution 
was obsef\'ed in the cases with a predominant inv:Jsive lobular 
component (p < 0,006). All cases (n = D) were ER+ and 
PR+ and. with one exception, EGFR-. This case of invasive 
lohular carcinoma with a DCIS component showed EGFR 
e:\pression in the DCIS part of the biopsy (30), 
With respect to tumor size, we obsef\'ed that large tumors 
were more often ER- and EGFR+ (83~) as compared with 
the smaller T1 (18<;() and T2 (251d) tumors (p < 0.006), 
Similar obsef\'ations w('re made with respect to degr('e of 
tumor differentiation, More than half of the high·grade tumors 
(67(() belonged to the ER-lEGFR+ group (p < 0.001), No 
ER-, EGFR + tumors were obsef\'ed in the grade I group and 
only 15~ in the grade II group (Table II), 
No clear relationship with the number of involved lymph 
nodes was obsef\'ed, though patients wilh more than 3 involved 
llndes tended to be more frequently EGFR', Interestingly. all 
patients with a tumor in the contralateral bre:Jst h,ld identical 
receptor status, for both tumors, Furthermore, both tumors 
were of identical hi~tnlogical type, i.t' .. invasive ductal carci· 
noma (27 and 28), im':Jsh'e lobular carcinoma (30 and .II) and 
colloid carcinoma (29; Tahle I). 
DISCUSSION 
Our study shows a rc1:Jtiomhip between degree of tumor 
differentiation and inverse expression of ER and EO FR. Most 
tumors expres~ing EGFR belonged 10 the high. grade, poorly 
differentiated malignande~, Furthermorc, large tumors more 
frequently showed e:\pression of EGFR. More than half of the 
invasive ductal carcinomas were ER- and EGFR +, In contrast. 
all primal)' breast tumors \\ith a predomin:Jnt lobular compo-
nent c:\pressed ER and, with one exception. were EOFR-, 
Interestingly, in normal breast tissues the highest frequency 
:Jnd e:\prc5sion levels of ER are found in the lobules compared 
to the ducts (Peterson, 1987), The publbhed data about the 
EGFR- phenot\"pe of lobular carcinoma arc controversial, as 
is the association of EGFR expression \\1th differentiation 
grade and tumor size (reviewed in Klijn e/ al., 1992). These 
discrepancies are at prescnt not dear; however, some may be 
explained by the different assay systems used. In tumor 
extracts, the presence of EGFR+ non·malignant cells in the 
biopsy may complicate the interpretation of results, 
In this study, we have confirmed our earlier obsef\'ation 
(Van Agtho\'en ellll., 1994a) thaI expression ofER and EGFR 
is completely inver~e in individual cancer cells, Most samples 
contained both ER+ and EGFR+ cells, but one receptor type 
was always expressed in a normal component of the tumor 
specimen, This result is in 3greement .",ith previous obsef\'a-
tions of inverse expression of EGFR and ER in breast tumor 
cell lines and primal)' breast tumors (for a review see KliJ'n 
el 01.. 1992), indicating that functional co·expression of these 
signal cascades is not favorable for breast tumor cells (Van 
Agthoven et jli., 1992, 199-lb), This inverse relation between 
ER and EOFR expression has now also been demonstrated for 
hreast tumor metastases in untreated p:Jtients, 
With only one exception, no switching of receptor type 
(ER/EGFR) was obscf\'ed between primal)' tumors an<:l 
involved J)1llph nodes or distant metastases or between synchro· 
nously and metachronously occurring bilateral breast cancers, 
It can be concluded that expression of EGFR is n?t a 
prerequi,ite for development of metastases, though patIents 
with high numbers of axilla I)' lymph node metastases were 
more often EGFR't, which may be explained by the aggressive 
phenotype of these tumors, Previously, we have shown, \\1th 
dual·staining immunohistochemistry, that primal)' tumors may 
consist of both EGFR· tumor cells and distinct ER + tumor 
cells (Van Agthoven et al., 19940), Although only one mi:\cd 
ER·, EGFR+ prim<ll)'tumor and no mL'Ied metastases were 
obserWd in this series, it cannot be exduded that a minor 
population of tumor cells with a different phenotype has been 
missed in our analyses, Such tumor cells could result from 
biological selection in metastasis with another receptor pheno· 
type. However, our ~tudy shows that a shift 1n receptor 
phenot}pc between primary tumors and lymph node metasta-
ses is a rare event and, thus, analyses of involved lymph node,S 
will not serve as a better predictor for response to <lntl' 
estrogen ther<lpy, 
Studies using breast cancer cell lines have indic:Jled thai 
switching from ER e:\pression to EGFR eXfrcssion may occur 
during anti-estrogen treatment (Long C/ a., 1992; Van Agth-
oven CIIIl., 1992,19940; DOrssers cl 01., 1993). Thus far little 
evidence for this mechanism is available for development of 
acquired anti-estrogen resistance in clinical breast cancer, 
Although :Jnti-estrogen therapy may select for <l switch in 
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receplor expre,sion in the tumor cells (ChrysogeJos ('/ til" 
199~), this docs no1 c:>orl;.!in the intrimic rcspome failure to 
[lnli-estrogen therapy in h"J( of the p:<licnts with mctas\3tic 
djsca~c and ER + primary tumors. Our study strongly ~uggcsls 
thai lymph node mct3sta~cs of ER· primal)' tumors are also 
ER+, Since the lymph node me!<lstascs analyzed were surgi-
cally r('mored al the same time as the primary lumor, the 
receptor expression rna)' reflect only a confined, possibly carly. 
~Iage in tumor progression. We have an;Jlyzcd the 2 cases with 
distant metastasis, which were removed, respectively. 1 and 3 
years after primary surgery. B01h the primary tumor and the 
metastasis were EGFR + and, thus, not informative for the 
existence of a possible 5witch in reccptor expression. 
In condusion, no evjdent differences in c:.pression of ER 
and EGFR were obserycd between primary tumors and 
mctast<Jse$ in our study. An interesting difference was ob· 
served between ductal and lobular carcinomas, the laller being 
almost exclusively EGFR- [lnd all expressing ER. Our study 
shows thut u ~hift in receptor e.\pression between primary 
tumors and lymph node metastasis is rare und, thus, receptor 
anal)"sis of involved lymph nodes will most likely not he a hetter 
predictor for response 10 anti·estrogen therapy, 
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Induction of Antiestrogen Resistance 
in Human Breast Cancer Cells by 
Random Insertional Mutagenesis 
Using Defective Retroviruses: 
Identification of bcar·1, a Common 
Integration Site 
Lambert C. J. Oorssers, Ton van Agthoven, Anita Dekker, 
Thecla L. A. van Agthoven, and Elisabeth M. Kok 
Or. Daniel den Hoed Cancer Center 
Department of Molecular Biology 
3008 AE Rollerdam. The Netherlands 
Duration of response to antleslrogen therapy In met-
astatic breast cancer Is limited due to the develop-
ment of antleslrogen'resistant tumors. The mecha· 
nlsms involved are not understood bul could orlgl· 
nate from (epi)genellc alterallons within the tumor 
cells. We have applied In vitro random insertional 
mutagenesis with replication detective relroviruses 
to Identify those genes playing a key role In devel· 
opment of antlestrogen resistance in human breast 
cancer cells. Eighty anlieslrogen-resislant cell 
clones were Isolated from 7 x lOa estrogen·depend· 
ent ZR.75-1"cells, mass-infected with defective re-
troviruses and subjecled to 4·0H-tamoxifen selec· 
lion. Integration site'speclfic DNA probes were 
made by inverse polymerase chain reaction tech· 
niques and used to search for common integration 
sites. Six cell clones were Identified with retroviral 
genome Integrations in the same orientation In a 
single locus, designated breast cancer anlieslrogen 
resistance locus-1 (bcar-1). These bcar-1 cell 
clones had lost estrogen receptor expression and 
had become estrogen independent. Our results 
strongly suggest that alteration of the bcar-1 locus 
is responsible for development of anti estrogen reo 
slstance In human breast cancer cells In vitro. In 
addition, we have shown that In vitro Insertional 
mutagenesis using defective retroviruses can be 
applied 'or gene tagging in human cells. (Molecular 
Endocrinology 7: 870-878, 1993) 
INTRODUCTION 
Normal breast epithelial cells depend on estrogen for 
their proliferation and differentiation. Endocrine therapy, 
Oaaa-iJ809m,087c.OO78S0300,0 
~ole<;u'ar E~c'oXrinologf 
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5.5 83 
involving estrogen ablation or administration of anties-
trogens, has been stlOwn to be beneficial in early and 
metastatic breast cancer (1-3). With respect to met-
astatic dlsease, objective responses occur In about 
50%. of the patients with estrogen receptor (ER)-posi-
live primary tumors. However, the response duration is 
rather limited due to the development of hormone· 
independent tumors in virtually all cases (1, 4, 5). The 
mechanism of action of anliestrogens is based on their 
ability to compete with estrogens for binding to the 
estrogen receptor and thus block cell proliferation (2, 
6). Although prognostic factors which predict a tack of 
response to endocrine therapy have been described (4, 
7), the mechanisms of progreSSion to hormone inde· 
pendence of an initially responsive tumor are still not 
understood. It is speculated that the tumor is hetero-
geneous and that hormone-Independent clones may be 
selected by the therapy applied. Alternatively, hormone-
dependent tumor cells may acquire (epi)genelic altera· 
tions, which result in resistance to the endocrine ther-
apy (8-15). Previous studies have shown that Introduc-
lion of either an activated ras or insulin-like growth 
factor·1I gene into breast tumor cell tines resulted in 
hormone-independent proliferation of the transfected 
cells (16, 17). In addition, we have presented evidence 
that ectopic expression of epidermal growth factor 
(EGF) receptor in human breast cancer cells can bypass 
the estrogen dependence (18). Furthermore, epigenetic 
alterations induced by demethylation with 5-azacytidine 
of ZR-7S-1 cells also resulted in hormone-independent 
proliferation (11; Van Agthoven, T., T, L A. Van Ag-
thoven, A. Dekker, J, A. Foekens, and l. C, J. Dorssers, 
manuscript in preparation). These results suggest that 
dominant genetic alterations playa role In hormone· 
independent progression of breast cancer cells. 
In order to identify specific genes involved in progres-
sion to hormone independence, we slarted a random 
insertion mutagenesis study on human breast cancer 
cells in vitro applying defective retroviruses, Retrovi· 
ruses randomly integrate in the host genome as part of 
their life cycle (19) and may thus disturb local genome 
structure and gene expression (20, 21). Furthermore, 
ttle integrated viral genome provides a tag to the gene 
locus of interest and can be used to isolate and cha-
racterize the gene involved. Insertional mutagenesis 
with replication-competent murine retroviruses has 
been used to identify rodent (onco)genes mye, Tpl-1, 
bml-1, pal-1, bla·1, and pim involved in lymphoma (22-
27), int In breast cancer (28-30), and Evl, Spi-1, FIi, and 
Vin-1 in leukemia (31-36) In vivo and in vitro. Replica' 
tion-defective retroviruses can be generated by use of 
amphotropic packaging cell lines and provide a safe 
and elegant procedure to mutate human cells without 
risk of secondary infections (19, 37). Our results docu-
ment that defective retroviral integration in the host 
genome transformed the estrogen dependency of ZR· 
75-1 human breast cancer cells and allowed for the 
identification of a locus, designated breast cancer an· 
tiestrogen resistance locus-1 (bear·l), involved in this 
process. 
RESULTS 
Generation of AntJeslrogen'Reslstant HUman 
Breast Cancer Cell lines 
In order to USe retroviral insertional mutagenesis for 
linkage of a specific gene to a biologlca! function in 
vitro, an extremely sensitive cell selection system is 
imperative. The widely used MCF-7 cells and the 
strongly hormone-dependent subtine MCF·7/McGrath 
(38) were not useful, since about 5-10% of the colonies, 
although smaller in size, were retained in the presence 
of 1 /lM of 4·0H·tamoxifen (OH·TAM), the active me-
tabolite of tamoxifen (2). Subcloning of these MCF-7 
cells or application of selection protocols to isolate a 
highly OH·TAM·sensilive subclone (39, 40) were not 
successful. ZR-75-1 cells (41) were completely de-
pendent on estrogen for cell proliferation (18) and faifed 
to produce surface colonies in the presence of 1 /lM 
OH-TAM (data not Shown). 
To infect these human breast cancer cells with retro-
viruses, we have generated amphotropic producers of 
N2· and LN-defective murine retroviruses (37) using the 
PA317 and CRIP packaging cel/lines (42, 43). These 
producers of defective viruses were selected for effi-
cient Infection of ZR-75-1 cells (more than 10~ G418-
resistant colony forming units/ml) and absence of rep-
lication competent virus and used in infection experi-
ments to generate antiestrogen-resistant ceU clones. In 
a typical experiment, 20-150 x 106 ZR·75-1 cells were 
treated for 2 days with conditioned medium (CM) of the 
amphotropic producers containing the defective virus 
and subsequently plated for selection with OH-TAM. 
About 30-50% of the cells showed resistance to the 
neomycin analog G416 in a surface colony assay, indio 
cating stable integration of the defective retrovirus. 
Proliferating colonies of cells were detected by visual 
inspection within 3-5 weeks in the infected cultures 
subjected to antiestrogen selection (Fig. 1), picked, and 
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expanded. In control experiments inVOlving more than 
2 x lOa ZR·75-1 cells, only one ant!estrogen-resistant 
cell clone was rescued. This result demonstrates the 
low spontaneous frequency ($10-5) of progression to 
OH·TAM resistance of ZR·75-1 cells under these se-
lective culture conditions. 
Expansion of antihormone-resistant clones appeared 
to be tedious, since many proliferating colonies (up to 
80~'o) were lost after picking and plating in mlcrotiter 
plates in the early series of experiments. A considerable 
growth advantage was noted during the infection cuI· 
ture in comparison to the untreated cells, suggesting 
the presence of growth-stimulatory SUbstances in the 
CM of the mouse fibroblast packaging cell line. The 
CAIP cell CM strongly enhanced attachment and 
growth of tamoxifen·resistant cell clones plated at low 
density (see also Fig. 4). Thus, in subsequent infection 
experiments picked clones were expanded in medium 
supplemented with 10% CRIP·CM and OH-TAM with a 
success rate of 87%. 
Southern analyses of Hindlll·, 8glll-, and BamHI-
digested DNA of all OH-TAM-resistant cell clones using 
an LN virus or NeoR probe were performed to establish 
the number of viral integrations. These restriction en-
zymes cut outside the viral DNA and the number of 
bands correlates directly with the number of integra-
tions (an example is shown In Fig. 3a). Most of the cell 
clones tested comprised 1-10 copies of the viral ge-
nome (median of two copies). Occasionally, restriction 
fragments hybridizing to a viral long termInal repeat 
(LTR) probe were observed which failed to hybridize to 
the NeaR probe. The size of these fragments was often 
too small to comprise a full-length viral genome, sug· 
gesting that part of the viral genome had been elimi-
nated before or after integration in the host genome 
(44). 
Overall we have now generated 80 OH·TAM-resisl· 
ant cell lines with integrated viral genomes (primarily LN 
virus) from a total of about 7 x 105 ZR-75-1 cells 
subjected to retroviral infection and antihormone selec-
tion. This cell panel has been used to identify common 
integration sites, which indicate the presence of genes 
involved in development of tamoxifen resistance. 
Generation ollnlegration Site· Specific Probes 
In order to identify common integration sites of retroviral 
genomes in independently arisen antiestrogen·resistant 
celt clones, probes flanking the provirus are required. 
We have used the inverse DNA amplification procedure 
(45), which employs outward directed primers located 
within the known viral LTR sequence (Fig. 2) after 
recircularization of digested genomiC DNA. We pres· 
entry use a large panel of enzymes with six base 
recognition sites on cell clones with only one or two 
viral integrations, since restriction enzymes with four 
base recognition sequences resulted mostly in very 
short stretches of genomic sequences. So far we have 
tried to obtain border probes from six different anties· 
trogen-resistant cell clones. In one case with a single 
integration, no fragments have been amplified with the 
panel of enzymes used so far. In two cases only very 
Fig. 1. Surface Colony of OH·TAM·Resislant, Infected ZR·75-1 Celfs 
Phase-contrast photomicrograph of infected ZA·75-1 celts subjected to 5 weeks of OH·TAM selection. A colony of proliferating, 
antiestrogen·resistant cells is shown In a background of nondividing cells. 
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Fig. 2. Genomic Map and Defective Retrovirus Integrations In the bcar·llocus 
Restriction sites are located with respect to the IN provirus (top) Integration in cell clone VUl21. Positions of primers used for 
Inverse peR are shown above the l TAs of the IN virus. Integration Site-specific probes 18/1 and 14B2(ApaU·Pstl) are hatched. 
The black box denotes the Alu sequence within the cloned PCR fragment 14B2. Integralion siles In the bcar·llocus of other cell 
clones (roman numerals) are Indicated. Restriction enzyme abbreviations are: A. ApaU; B, BCII; E, fcoRI; V, fcoRV; K, Kpnl; Nc, 
Ncol; N, Nhal; p. Psll; S, Sacl; and Sp, Sphl. 
smalt parts of genomic sequences consisting mainly of 
repetitive Alu sequences were obtained (not shown). 
From ceU clone VIII24 containing two integrations, two 
border clones have been prepared with'Ncol (2D. 300 
base pairs (bp)] and the mixture of BamHI, 8gm. and 
Bell (2E, 1000 bp). which both recognize the same viral 
integration locus (not shown). from cell clone VltI20 
carrying two integrated copies of the virus. a single 
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650·bp probe (3f) located downstream of the virus was 
recovered with the restriction enzyme Nhel. Cell clone 
VlU21 DNA (one viral genome and a 4·kifobase (kb) 
LTR fragment lacking NeoR sequences) digested with 
Psil or Sphl supplied three crones (1482, 18/1. and 
14B9). Clone 14B2 is located upstream of the virus and 
carries part of an Alu sequence, but an upstream ap-
proximately 500-bp ApaU·Pstl fragment detected the 
integration locus (Figs. 2 and 3f). Probe 18/1 was 
derived from the 3' ·LTR and comprises a 450·bp Spill 
fragment free of repetitive sequences (Fig. 3, b-e). 
Probe 1489 represents a Psil fragment also contained 
in clone 18/1 (Fig. 2). 
Identification of a Common Integration Site 
AU blots with Hindlll·, Bglll-, and BamHI·digested gen-
omic DNA were subjected to screening with the inte· 
gration site-specific probes derived from infection ex-
periment VIII. In addition, blots were made from DNA 
digested with EeoRV and Sacl, which cut within the 
viral L TA (Fig. 2). Probes 2D and 2E (clone V1II24) and 
3F (clone V1II20) only detected germ line restriction 
fragments in all ceU clones tested so far, indicating the 
absence of retroviral integrations in the neighborhood 
of these probes (data not shown). In contrast, probes 
18/1 and 14B2 derived from cell done Vlll21 did rec-
ognize restriction fragments, with altered mobility in five 
additional celtclones(XI13, X114, X116, XI21, and XII13). 
BglII (Fig. 3b) and BamHI restriction fragments with a 
reduced mobility, corresponding to the integration of a 
3·kb viral genome, were observed. The weak intensity 
of these a\lered fragments in comparison to the germ 
line band is explained by the presence of multiple copies 
of many chromosomes in the ZR-75-1 cells (18, 41). 
810ts carrying EeoRV digests of these DNA samples 
confirmed these results and further suggested that the 
integrations were In close proximity (Fig. 3, e and f). 
Detailed characterization of the integration locus by 
Southern hybridization suggested that clones XI14 and 
XI21 are derived from an infected ceU of which one 
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daughter cell acquired an additional viral copy during a 
subsequent infection cycle (Fig. 3a; BamHI and Hindlll 
blots not shown). The integration site in these clones 
falls within the probe 18/1, as both the left and right 
Bell and EcoRV fragments are recognized (Fig. 3, c and 
e, lane 2). Similarly, clones X[13 and XI16 originate from 
a single celf with two viral integrations, from which one 
daughter gathered two additional viral DNA copies. The 
Bg/ll doublet at approximately 6 kb in clone XI16 (Fig. 
3a, lane 5) is resolved in two bands by Hindlll and 
BamHI digestions (not shown). The integration site in 
clones XI13/16 is located upstream of the VUl21 inte-
gration and falls within the probe 1482. The 2.2-kbSacl 
germ line fragment is split into two bands (1 and 1.8 
kb), both hybridizing with the 1482 probe (not shown), 
the smaller one hybridizing with the 18/1 probe (Fig. 
3d, lane 4). The single viral DNA integration in cell clone 
XI113 is located approximately 3-4 kb upstream 01 the 
other Integrations within the Bell and EeoRV restriction 
fragments (Fig. 3, c and e, lane 6) without interrupting 
the Sacl germ line band (2.2 kb) recognized by the 
1482 (not shown) and 18/1 probes (Fig. 3d). The ori· 
entation of the provirus was determined with the NecR 
probe on Bell· and EeoAI-digested DNA and was found 
to be identical to VIII21 for X113/16, X114/21, and XH13. 
The large Bell fragments hybridizing to 18/1 probe (Fig. 
3c) also hybridized to the NeoA probe (data not shown). 
This common integration site identified by probes de· 
rived from celf clone VIII21 is designated bear·1, 
Loss of Estrogen Dopendence of Cell Clones with 
Integrations In the bCBr·l Locus 
Celf clones with integrations In the bear· 1 locus have 
been characterized with respect to thei:' response to 
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Fig. 3. Southern Analysis of ZR·75-1 and Derived Antiestrogen·Resistant Cell Clones 
Blots carrying genomic DNA digested wilh 8gm (a and b), Bell (c), Sael (d), and EcoRV (e and f) were hybridized with an NeoA 
(a), 18/t (b-e), or 14B2 (f) probe. Genomic DNA was prepared from ZA-75-1 cells (ZR) and antlestrogen·reslstant clones VIII21 
(1), XI21 (2). XI14 (3), XI13 (4), Xn6 (5), and XII13 (6). Fragment sizes (in kilobases) of X·DNA digested wilhHindll1 are denoted on 
ths/eft. 
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known stimulators and inhibitors of proliferation using 
the [3-(4 ,5-dimelhylthia zol-2 -yl)-2 ,5-diphenyltetrazo-
tiumbromide} (MIT) assay (46). In this assay, the re-
sponse is mostly proportional to the number of viable 
cells (18). Proliferation of the parental cell line ZR-75-1 
is completely dependent on estradiol supplementation 
to the culture (18) and is not influenced in the MIT 
assay by addition of either EGF or the pure antagonist 
IC1164,384 (Fig. 4). ZR-75-1 cells pretreated wilh RPM I 
medium supplemented with 10%. bovine calf serum (RI 
SCS medium) show a response to OH-TAM {Fig. 4}, 
which is probably due to the initial intrinsic agonistic 
effect of OH-TAM (47). This response is masked when 
pretreatment Is omitted (not shown) and does not sup-
port ZR-75-1 ceU proliferation to a significant extent 
(18). Contrary to the parental ceUs, the bcar-l cell 
clones were selected for proliferation In RISCS medium 
plus OH-TAM. Increase in MIT reduction thus repre-
sents stimulation above basal cell proliferation in AI 
BCS (representative examples VIII21 and XI21 shown 
In Fig. 4). No significant change in MIT reduction was 
observed at day 5 (Fig. 4) or day 10 for all bcar-1 cell 
clones after addition of either estradiol, ICI164,384, or 
OH-TAM. RNase protection studies (Fig. 5a) using 
labeled antlsense RNA copies of ER showed a strong 
reduction of EA mANA in these antiestrogen-resistant 
cell clones in comparison to the parental ZR-75-1 cells. 
Similarly, ER- and estradiol-induced progesterone re-
ceptor (PgR) protein, determined by enzyme-linked im-
mune assays ER-EIA and PgR-EIA, were very tow 
(between 0-8 fmolfmg protein) in all cell clones with 
integrations in the bcar-llocus, These assays in com-
plete medium show that the bcar -1 celt clones have 
lost their response to estrogen and display a hormone-
independent phenotype. 
In contrast to the parental celts, clones Vttl21 , X113, 
X114, and XII13 showed some increase in MIT reduc-
tion upon supplementation of EGF (Fig. 4). A more 
pronounced stimulatory effect of EGF addition (2.1 ± 
O.l-fold) was observed after plating of 2500 VUl21 celts 
and MIT assay at day 10. Low levels of EGF receptor 
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Fig, 4, Biological Characterization of bcar-l Cell Clones 
MTI reduction was determined at day 5 after plating of 
5000 antiestrogen·reslstanl cells or 2500 parental ZR-75-1 
cells, pretreated in RIBCS medium for 24 h, in A/BGS medium 
supplemenled with 1 jJM OH-TAM (0), 100 nM lG1164,384 (0), 
10 ng/ml EGF (l1li), 1 nM estradiol (O), or 10% GRIP,GM (19). 
Response Is given as the fraction of the R/BGS control culture. 
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mANA were detected in RNase protection experiments 
in alt bcar-l celt clones in contrast to the parental celt 
line (Fig. 5b). In addition, Scatchard analysis demon-
strated specific [125IJEGF binding to membrane prepa~ 
rations of celt clones XI13 and XI14 (40 and 15 fmol 
EGF receptorlmg protein, respectively), AU ZR-75-1-
derived celt lines were stimulated by the addition of 
10% CRIP-eM (Fig. 4), indicating the presence of un-
defined accessory components in the fibroblast me--
dium. 
DISCUSSION 
Linkage of a specific gene to a biological function by 
retroviral insertional mutagenesis has been achieved 
mainly in rodents in vivo and lead to the identification 
of genes involved in malignant processes (21), Mutage--
nesis in vitro was shown to be feasible (32, 33, 48) 
using replication-competent viruses in murine factor~ 
dependent celt tines, Defective retroviruses lack the 
capability to spread into the culture after integration 
and thus provide a safe and elegant way to perlorm 
mutagenesis (19, 37). The frequency of retroviral inte~ 
gration in a specific locus has been estimated in the 
order of 10-6_10-8 (20), thus requiring very low fre-
quencies of spontaneous progression to the selected 
phenotype. Initial control experiments indicated that, in 
contrast to the MCF-7 cell line tested, the spontaneous 
rate of ZR-75-1 cells to form an antiestrogen-resistant 
ce1l clone was below 10-8 • The virus-induced progres-
sion rate to tamoxifen resistance is calculated to be 
about 10-7 (range of 0.6-3 x 10-1 in six experiments), 
clearly above the spontaneous frequency. This figure 
represents a 2- to 3-fold underestimation of the actual 
value since efficiencies in infection have been disre-
garded. 
Using integration site-specific probes from three in· 
dependenlly arisen antlestrogen-resistant cell clones, 
we have identified a common integration site (bcar~1) 
In six ceU clones of our panel. Detailed analysis showed 
that these celt clones were derived from four Independ-
ent integration events within ±4 kb total distance, Fur~ 
ther screening of thIs chromosomal region may identify 
additional distanllntegrations in our panel of anliestro. 
gen-resistant clones. The occurrence of six integrations 
in the bear -1 locus in 80 cell clones carrying a tolal of 
approximately 190 retroviral integrations highly ex~ 
ceeds the reported frequencles (2-5 x 10-~) of base--
specific integrations In genomic hot spots (49). under 
the model that in surviving cell clones the location of 
the integrated virus is completely random, based on 
two integrations per cell the probability to find a retro-
viral genome in a given 10-kb genomiC DNA segment 
is 6.6 x 1O~6. As a consequence, the probability of 
identifying three additional Independent Integration 
events in this locus, among the remaining clones of the 
cell line panel, is extremely low (2 x 1O~1I, binomial 
distribution), This implies that the model of complete 
randomness has to be rejected, i.8. it strongly suggests 
that integration within the bcar-l locus is tightly linked 
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Fig,S. RNase Prole<:tion of ER and EGF Receptor mANA 
Auloradiograph of protected radiolabeled RNA probes (p) of ER (a) and EGF -receptor (b) after hybridization to 20 JlQ lolal een 
ANA as indicated, digestion with RNases, and fractionation on a denaturing 6% polyacrylamlde·urea gel. Exposure was for 12 
days or 16 h (') with IntenSifying screens at -80 C. Only the relevant parts of the autoradiographs are shown. No other protected 
fragments (>70 bases) were detected. ANA samples were from ZR-75-1 cells (ZR) and anlieSlrogen-resistant clones VI1I21 (1), 
XI21 (2), X114 (3), XI13 (4), XI16 (5), XIl13 (6), VIH24 (7), an EGF receptor-positive derivative of ZA-75-1 (+), and IRNA (I). 
to the selected biological phenotype of antiestrogen 
resistance. Dominant activation of a gene within the 
bcar-1 locus by either promotor/enhancer Insertion, 
removal of negative regulatory sequences, or mRNA 
destabilizing sequences allowed for celt proliferation 
independent of anl1estrogen frqm day 1 onward. Acti-
vation by enhancer insertion is mostly independent of 
orientation and position, whereas 3' -LTA promotion Is 
often accompanied by deletions in the viral genome 
(21). The identical orientation of Intact and functional 
viral Integrates (all bcar-l clones exhibit G418 resist-
ance) within the bcar-1locus suggests that either 5'-
LTR promotion or removal of mRNA destabilizing se-
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Quences is the most likely activation mechanism (21). 
Alternatively, gene inactivation cannot be exctuded but 
is rather unlikely in view of the presence of multiple 
caples of chromosomes in the ZA-75-1 cell line. Iden-
tification of the expressed sequences within the bear-
1 locus and their level of expression in antieslrogen-
resistant cell clones may answer these questions. 
The biological properties of the cell ctones with inle· 
grations within the bcar-1 locus are Quite similar. AU 
ctones show a virtually complete loss of response to 
estradiol, which is In agreement with the very low levels 
of wild type ER mANA (Fig. Sa) and ER- and estradiol· 
induced PgA protein. The strongly reduced EA expres· 
sion and function explains the lack of inhibition or 
stimulal!on of estrogen antagonists (OH-TAM and 
ICt164,384) on bcar-1 celt proliferation and excludes 
the possibility of acquired OH-TAM dependence (50), 
Production of constitutive transcriptionally active ER 
variants (tacking exon 5 sequences) is rather unlikely 
because of the absence of PgR expression in these 
cells (51), tn addition, no aberrant prolected transcript 
was seen in ZR-75-1 celts or in the tamoxifen-resislant 
ceU tines, Variants lacking exon 4 sequences would 
have been missed in this analysis, but deletion of the 
basic region flanking the second zinc finger has been 
shown to Impair DNA binding (52), Similarly, inactive 
fusion proteins Involving the N-terminal part of ER (53) 
would not have been detected in our mRNA and protein 
analysis, Variants lacking exon 7-encoded sequences 
and capable of interfering with normal ER function (54) 
would have been detected as wild type protein and 
protected ANA fragment. Our analysis thus strongly 
suggests that the cell clones with integrations in the 
bcar·1 locus do not produce significant levels of a 
functional ER (variant) and are truly estrogen independ-
ent. ER expression may have been down-modulated as 
a result of alteration of the bcar·1 locus and/or the 
stringent selection with antihormone (18), The latter 
seems plausible, because clone Vllt24 also showed a 
strong decrease In ER expression and an increase In 
EGF receptor expression (Fig, 5) without evidence of 
an integration within the bcar·1 locus, In contrast, one 
other OH-TAM-resistant cell clone obtained using this 
antiestrogen-selection protocol showed abundant ER 
and PgR expression (data not shown), Cell clones with 
Integrations in the bcar·1 locus showed increased lev· 
els of EGF receptor mRNA expression in comparison 
to ZR-75-1 ceUs (Fig, 5b), EGF receptor protein expres· 
sion in ceU clones XI13 and XI14 was clearly increased 
compared to the EGF receptor-negative ZR-75-1 pa· 
rental cells but lower than the expression level observed 
in the EGF-responsive ZA/HERc cells ectopically ex-
pressing the EGF receptor eDNA (18). The moderate 
response to EGF In complete medium of some celt 
clones (Fig, 4) suggests that this pathway Is fUnctional. 
The magnitude 01 this signal transduction pathway in 
prOliferation 01 bcar-l cell clones needs further analysis 
under serum-free conditions, 
Clinical progression of human breast cancer to hor· 
mone independence appears to occur frequently during 
antiestrogen therapy and is unlikely to depend on a 
single gene mechanism, Breast tumors are heteroge-
nous and may evade antihormone elimination via differ-
ent pathways, some anowing for second·line endocrine 
treatment (5. 7,55), We have provided strong evidence 
that development of antlestrogen resistance in vitro is 
directly linked to disruption of the bcar·1 locus by 
retroviral integration, It remains to be established 
whether bcar·l has a role in clinical breast cancer 
development or progression, Additional genes possibly 
tagged in our cell panel and contributing to alternative 
ways to escape hormonal regulation await Identifica· 
tlon, Our experiments also demonstrate that gene lag-
ging in human cells by In vitro insertional mutagenesis 
using defective retroviruses is feasible, 
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MATERIALS AND METHODS 
Cell Culturing and Virus Infection 
ZA-75-1 cells were obtained from Dr, A. J, B, King (Imperial 
Cancer Research Fund laboratories, london, United King-
dom) and maintained in APMI medium (Gibco BRl, Ufe Tech· 
nologies ltd., Paisly, United Kingdom) supplemented with 10% 
heat'inactivated bovine calf serum (R/BCS medium) and 1 nM 
estradiol for a maximum of 10 passages (18), Amphotropic 
producers of N2 (56) and lN (37) virus were established by 
Infection of CAIP (43) and PA317 (42) packaging cells with 
ecotroplc defective virus transiently produced by CRE cells 
(43) transfected with the respective plasmid construct. CM 
from subconnuent producer cells containing the amphotroplc 
virus was centrifuged (SOOO x g) and filtered through OAS-I'm 
fillers, adjusted to 8 Jig polybrene (Sigma, Sl. louis, MO)fml 
(20), and added undiluted to the ZR-75-1 cells. Approximately 
2 X 101 ZR-7S-1 celfs per 17S-cm2 nask were infected during 
a period of 2-3 days with addition of fresh virus-containing 
supernatant twice a day, After Infection, ZR-7S-1 cells were 
Irypsinized, counted, and seeded in 75-cm~ flasks at a density 
of 4 x 106 celts in RISCS with 1/'1.1 4·0H-TAM (ICI, Mec<:les-
field, United Kingdom), The wllure medium was changed twice 
a week, and surface colonies were scored and picked within 
5 weeks after seeding and expanded in the same medium. In 
following experiments, expansion of picked dones was per-
formed In medium additionally supplemented with 10% filtrated 
CM of nonproducer CRIP cells to Improve attachment and 
survival. Infection frequencies of ZR-75-1 cells were estimated 
by plating 2 x 10· cells after infection in 25-cm? flasks In the 
absence or presence 011 mgjml G418 (Gibco BAl) in complete 
medium. Surface colonies were scored 10-14 days later. The 
presence 01 replication-competenl virus was assayed by ap-
plyi'ng the undiluted culture medium of mass·lnfected ZR-75-
1 cells to Balb3T3 or ZR-75-1 cells and subsequent selection 
for G418 resistance, MIT assay In R/BCS medium, which 
measures the number of viable cells capable of reducing the 
tetrazolium compound 10 a blue formazan product (46), and 
measurements of hormone receptors (ER·EIA and PgA·EIA; 
Abbott laboratories, Chicago, IL) and EGF receptors were 
performed as described (18), 
AnalYsis of Nucleic AcIds 
DNA was prepared from the antiestrogen-reslstant cell clones 
using proteinase K and high salt (57), digested with Hindlll, 
BamHI, 8g/ll, Sacl, and EcoRV (Pharmacla pol Biochemicals 
Inc., Milwaukee, WI), fractionated on 0,6% agarose gels, and 
alkali blotted onto Hybond N+ (Amersham International pic, 
Amersham, United Kingdom) according 10 standard proce-
dures (58), DNA probes purified on low-melting point agarose 
were melted and radiolabeled with {oPPjdeoxy·ATP (Amer· 
sham) using the random primer procedure (59). Hybridization 
was carried out overnight at 65 e in 3x sse (1 x sse = 0,15 
1.1 NaC!, 0.015 1.1 Na citrate, pH 7,0), 0.1% sodium dodecyl 
sulfate, lOX Denhardl's, 9% dextran sulfate, and 50 pgjmt 
denatured herring sperm DNA. Filters were washed In 0.3x 
SSC/0,1 % sodium dodecyl sulfate at 65 C and autoradi-
ographed using intensifying screens, Total RNA was isolaled 
using the guanldinium isolhlcyanate/CsCI procedure and sub-
jected to RNase protection assays according to described 
procedures (58). Radiolabeled RNA probes from the Hindlll-
BglII fragment of ER [nucleotides (nl) 1248-1500)] (60) and 
the 8glll-$acl fragment of EGF receptor (nt 2951-3291) (61) 
were generated with T7-ANA polymerase as specified by the 
supplier (Promega, Madison, WI). 
Inverse polymerase Chain Reaction (peR) 
Sequences adjacent to the integrated viral genome were am-
plified as described (45) with minor modifications. Brieny, 
genomic DNA (1 "'9) was digested with a panel of restriction 
enzymes (Sac!, Pstl, EcoRI, Ncol, Sphl, Nhel, and 8amHI + 
Bgnl + Bell), heat treated (65-85 C) to inactivate the enzymes, 
diluted to approximately 10 jJ.g/ml, and religated with T 4·DNA 
ligase. A small aliquot (15-50 ng) was subjected to 30 cycles 
of DNA amplification with outward directed primers Int 204-
182 (5'gggatccgCATGCCTIGCAMATGGCGTIAC) and 
2833-2854 (5'ggaagcltGACCTGAMTGACCCTGTGCCT)J 
located on the l TR of the IN virus (37) using Taq polymerase 
(Promega) In the presence of radiolabeled dooxy·ATP. An· 
nealing was at 62-65 C for 2 min, and extensions were carried 
oul al 72 C for 2 min. Products were identified after gel 
electrophoresis by either ethidium bromide slaining Of autora· 
diography, Isolated, reamplified using one internal primer {nt 
688-709 (5'ggaagcIIGGTCTCCTCTGAGTGATIGACD), and 
doned in either T·tailed Hlncfl·digested pTl18R DNA (62) or 
pTZI8R DNA digested with BamHI and Hindllf. Transformed 
JM109 bacteria were characterized, and flanking sequences 
were acquired using the T7·DNA polymerase sequenCing kit 
(Pharmacia) on double-stranded templates. Probes were ob-
tained after appropriate digestion with restriction enzymes to 
remove plasmid and viral sequences and separated on low· 
melting point agarose gels. Before large-scale screening, all 
potential flanking probes were tested for the presence of 
repetitive sequences (using 32P·labeled low COT DNA; GIBCO 
BRL) and evaluated on Southem blots of the corresponding 
cell line DNA to verify the linkage to the Integrated viral DNA. 
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The antiestrogen tamoxlfen is important in the treat· 
ment of hormone·dependent breast cancer, although 
de\'elopment of resistance is inevitable. To unra\'el the 
molecular mechanisms of antiestrogen resistance, a 
search for imol\'ed genes was Initiated, Relro\'!rus· 
mediated Insertional mutagenesis was applied to 
human ZR·75-1 breast cancer cells. Infected cells were 
SUbjected to tamo.dfen selection and a panel of resistant 
cell clones was established. Screening for a common 
Integration site resulted in the Identification of a no\'el 
gene designated BCAR3. Transfer of this locus by cell 
fusion or transfeclion of the BCAR3 cDNA to ZR· 
75·1 and MCF·7 cells Induces antlestrogen resistance. 
BCAR3 represents a putath'e SH2 domain.contalning 
protein and Is partly homologous to the cell division 
cycle protein CDC48. 
Keywords: breast cancer/CDC48/estrogen receptorlSH2 
domainftamoxifen 
Introduction 
Growth and differentiation of the m3mmary gland is 
regulated by complex interactions between hormones and 
polypeptide growth factors with their specific receptors 
(Osbome, 1987; ~buvais-Jarvis et ai" 1988; Clarke el al., 
1992). Disruption of these strictly controlled sign3ling 
p3thways may result in the development of cancer. It is 
widely accepted that breast tumors initially are dependent 
upon estrogens for establishment and progression (Jensen, 
1981; Horwitz, 1993). Treatment of hormone-dependent 
breast cancer with antiestrogens like tamoxifen can delay 
recurrence or induce remissions of the disease (Early 
Breast Cancer Trial Collab Group, 1992). Antiestrogens 
compete with estrogen for the estrogen receptor (ER) 
(Jordan and Murphy. 1990; Jordan, 1994; Wolf and Fuqua, 
1996), resulting in blocking of hormone signaling and 
growth inhibition of the tumor cells (Jord3n and Murphy. 
1990; Musgrove el at., 1993). Unfortunately, nearly all 
patients who initially respond to antiestrogen therapy 
5.6 93 
experience a relapse due to the development of anti-
estrogen-resistant metastases. Understanding the mechan-
isms of drug resistance may lead to the development of 
new treatment strategies. A number of possibilities for 
tamoxifen resistance have been postulated (reviewed by 
King. 1990; Johnston et af., 1992; Horwitz, 1993; Wolf 
and Jordan, 1993; Clarke el af., 1994; Jordan, 1994; Klijn 
el af., 1994; Osborne and Fuqua, 1994; Clarke and BrOnner, 
1995). including loss of ER, alterations in structure andl 
or function of the ER.tamoxifen-stimuI3ted growth. altered 
drug metabolism and overexpression of different genes. 
However, the general mechanisms underlying the resist-
ance for the majority of breast cancers are stili not known, 
Progression of breast cancer to hormone insensitivity may 
be the result of a mutational event. followed by clonal 
selection (Dorssers et af., 1991; Clarke el al., 1993). 
Alternatively, the 31tered phenotype may be the result of 
epigenetic mechanisms involving stable changes in a large 
number of tumor cells (Van Agthoven et al., 1994). 
A random search for genes involved in antiestrogen 
resistance was initiated, Due to the inability to cultivate 
primary breast tumor cells in large quantities for prolonged 
times. the human breast cancer cell line ZR·75·1 (Engel 
et af., 1978) was selected as a model for hormone· 
dependent breast cancer. This cell line is strictly estrogen 
dependent for proliferation and can be inhibited fully by 
antiestrogens (Van Aglhoven et al., 1992; Domers et at., 
1993). Previously, we have shown th3t up·regulation of 
expression of a single gene is sufficient to induce estrogen 
independence. Transduction of estrogen-dependent ZR· 
75-1 cells with an expression vector carrying the epidem131 
growth factor (EOF) receptor resulted in proliferation 
independent of estradiol (Van Agthoven et al., 1992). 
Furthermore, in different experiments, we showed that 
random changes in the methylation pattern of the DNA, 
induced by 5-azacytidine. resulted in a high frequency of 
antiestrogen-resistant cell clones (Van Agthoven el 01,. 
1994). These results indicate that several escape mechan· 
isms of hormone dependence are possible. However. these 
strategies do not readily allow for the isolation of the 
involved genes. Hence, identification of (novel) genes 
connected with the development of antiestrogen resistance 
was approached by retrovirus-mediated insertional muta· 
genesis (Dorssers et of., 1993). Random integration of 
retroviruses may lead to alteration of expression or trunca-
tion of genes in the vicinity of the integration site. 
Consequently. insertional mutagenesis can mimic changes 
leading to tumor progression. The provirus, carrying long 
terminal repeats (LTRs) and a neomycin resistance (NeoR) 
gene. serves as a unique tag to identify genes in the 
proximity of the integration site. This approach has been 
successful in the identification of transforming genes in 
the mouse (Habets et of., 199-1.; Jonkers and Berns, 1996). 
and preliminary results show that this strategy may be 
useful for the identification for drug resist3nce genes 
involved in hum3n disease (Dorssers et 01., 1993; Dorssers 
and Vcldschoile, 1997). ZR-75-1 cells (8X lOs) were 
infected with defective retroviruses 3nd subsequently 
selected for growth in the presence of 4-h}'droxy-
tamoxifen, the active metabolite of t3nlOxifen. Eighty 
4-hydroxy-tamoxifen-resistant cell clones h3ve been isol· 
ated and established as stable cell lines. Many of the 
resistant clones carry more than one integrated provirus. 
The presence of a retroviral genome integrated in a 
particular locus of several cell clones which have arisen 
independently (common integration sile) slrong1}, suggests 
that a specific gene function is altered by the viral 
integration and contributes to the development of anties-
trogen resistance. Therefore, a search for common sites 
of integration in the established panel of resistant cell 
clones was perfomled to identify the loci of interest. This 
has resulted in the identification of three chromosomal 
loci, designated breast £ancer .;l.ntiestrogen resistance 
(BCAR) locus I (Dorssers et 01., 1993), 2 (Domers and 
Veldscholte, 1997) and 3. This report describes the cloning 
and characteriz3tion of the BCAR3 gene, involved in 
antiestrogen resistance, identified by retrovirus-mediated 
insertional mutagenesis. 
Results 
Common sito 01 intogration BCAR3 
To identify genes involved in antiestrogen resistance, cell 
clone X-3-6 was selected from our panel of 80 cell 
clones resistant to 4-hydroxy-tamoxifen. Cell clone X-3-6 
contains only one integrated provirus which is expected 
to induce the resistant phenotype. Furthermore, cell clone 
X-3-6 does not belong to the clones which contain a viral 
integration in the BCARI or BeARl loci. To ~creen for 
additional clones with an insertion in this region, an 
integration site-specific probe was created by inverse PCR 
(Figure lA). Chromosomal DNA of clone X-3-6, digested 
with a panel of restriction enzymes, was analyzed by 
Southern blotting techniques. Hybridization with a NeoR 
probe, specific for the retroviral integration, showed th3t 
a combination of BamHI and BgnI digestion resulted in 
a restriction fr3gment of .... 6.5 kb, convenient for isolation 
of a large fragment adjacent to the viral integration (Figure 
IA). DNA of cell clone X-3-6 cleaved with BamHI and 
B8m restriction enzymes W3S circularized by ligation and 
amplified using outward-directed primers located within 
the NeoR and viral gag sequences. Subsequently, this 
inverse PCR product was 3mplified with two sets of 
nested primers located within the LTRs (Figure tAl. This 
approach resulted in a 3.2 kb PCR fr3gment of genomic 
sequences adjacent to the viral integration site. Alu-
repetitive sequences were removed from this fragment by 
subcloning, which resulted in a 1.6 kb probe (Figure tAl. 
Southern analysis of X-J-6 3nd parental ZR-75-1 DNA 
digested with a panel of restriction enz)'llles and hybridized 
with the integration probe 3nd a NeoR probe confirnled 
the specificity of this probe for the X-3-6 integration site. 
Subsequently, the cell line p3nel was screened for the 
occurrence of a common site of integration. Southern 
blots of the 80 antiestrogen-resistant cell lines containing 
DNA, digested with either BamHI, Bgm or Hil/dIll, were 
hybridized with the integration-specific probe of clone 
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FIg. I. (A) Genomic aoal).\is of the BCAR3 inlegr.l.!Jon locus. The 
primers u>ed for inl'er,e PCR to obtain an integralion site-~pedfie 
probe are indicated below the LN \-irus (open mOils). The position 
and orientation of the different retro\'iraJ integrations ru-e indicated 
with an mow. Mapping of the d;ffer~nl integrations was perfonned by 
Southern blOl\ing te.:hniques and PCR anal)'.\!s with primm located 
on the 3' LTR and on the integr.ltion probe (open arrows). The 
positions of the integrations are mapped with respe.::t to the retrovind 
integratioo in cell clone X-3-6. The integrJtion site-specific probe is 
mark~d. The non detected neru- the lntegrJtions is denoted as a black 
box, Restriction sites Bcn and 8gm. BmnHI (B) and l/illdlll (H) and 
the gag region are indicated (B) CommoD integralion site. A Southern 
blot with genomic DNA of cd! lines digested with the resuktion 
enz)'me IlindIIJ \\as hybridiled with the BCAR3 integration probe. 
Roman numerals indicate the different BCAR3 cell clones. In the six 
independentl)' derived BCAR3 cell lines of a total panel of 80 celt 
lines, an additional tru-ser restriction fragment i> detected as a result of 
the integration of the provirus. The intensily of the additional band in 
cell clone XlV·2·-'\c is less in comparison with the other cell lines. 
This may be e~plained by contamination with a different clone during 
isolation. Clone XlV-2-4C was omilled from further (RNA) anal)'sis. 
X·3-6. Figure IB shows that this probe identified a 15 kb 
HindIIJ restriction fragment in the parental ZR-75-1 cells 
and in the derived integration cell clones. In the X-3-6 
cell clone, an additional fragment (-18 kb) was observed, 
resulting from integration of the LN retrovirus (-3 kb) in 
the other allele (Figure I B). TIlis analysis revealed five 
additional cell clones with a provirus integrated in this 
region. In total, a region of -25 kb surrounding the 
X-3-6 integmtion site was analyzed. Additional integra-
tions further up- or downstream of this region cannot be 
excluded. Detailed mapping analysis of the six integration 
sites demonstrated that the}' were distinct and thus con-
finned the independent origin of the clones (Figure tAl. 
In addition, Southern analysis and PCR m3pping showed 
that all clones have a similar 5' to 3' direction of 
transcription of the integrated retrovirus. Five viral integra-
tions have occurred in a I kb region and one, in clone 
X-I·2B, is integrated 5 kb upstream. TIle occurrence of 
six relroviral insertions in six ceUlines which have arisen 
independently in a panel of 80 cell lines in a region of 
5 kb is unlikely to be the result of a r3ndom process 
(2.9X 10-19, binomial distribution) (Dorssers el 01., \993). 
TIlis common site of integr3tion is thus tightly linked with 
anti estrogen resistance ill vi/yo and is tcmled the Qreast 
£ancer f!.nticstrogen resistance 3 (BCARJ) locus. 
• 
Fig. 1. Transfer of the BCAR) locus. Somatic cell h)'brlds v,ith (A) or without (8) the BCAR310cus "'ere cultured in the presence of 4-bydrmy 
tamo.ufen. Representive examples were stained with hemato:\ylin-eosin 3t day 10. Hybrid cells with the DCAR) locus (A) prolifer.lte in medium 
containing 4.hydro\y,tamoxifen. while hybrid cells ""ilh the non·relevant integration locus (B) are full)' inhibited by 4.hydroxy,umoxifen. 
Transfer of the BCAR3 locus by somatic cell fusion 
Subsequently, we wished to detemtine whether the altera-
tion in the BCAR3 locus, caused by retrovirai mutagenesis, 
is a dominant or recessive event. Southern blotting analysis 
showed that one of the integration clones, XI-I-6A, carries 
Iwo integrated proviruses, one in the BeAR3 locus and 
an additional integration which is expected to be non-
relevant for antiestrogen resistance, 111is cell line was 
chosen for generation of somatic cell hybrids between a 
hygromycin B-resistant sUbclone of the parental ZR-75-1 
cells (ZH3D7) and XI-J-6A cells. The presence of the 
additional proviral integration in this cell line serves as 
an internal control. An approach was chosen in which the 
donor cells were lethally irradiated. Somatic cell hybrids 
were selected with hygromycin Band 0418, resulting 
solely in hybrids consisting of parental ZR-75-1 cells 
which have acquired at least one of the NeoR-containing 
integration loci. In total, 11 hybrids were obtained which 
were characterized with an infom13tive HllldIII restriction 
digestion to distinguish between the two viral integrations. 
This analysis showed that five hybrids contained the locus 
with the viral integration in the BCAR3 locus and six 
hybrids carried the other viral integration site. Sub-
sequently, we tested whether the hybrids were antiestrogen 
resistant. The growth performance of triplicate cultures of 
the cell hybrids was compared with the parental ZR-75-1, 
ZH3D7 and XI-I-6A cells in culture medium containing 
I JlM of 4-hydroxy-tamoxifen, Antiestrogen sensitivity of 
cell hybrids was scored on days 7 and to, Cultures of 
hybrid cells showing poor, rounded cell morphology, loose 
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attachment to the culture flask, low numbers of mitoses 
and little or no increase in cell numbers (measured as the 
percentage of coyered surface, -20-30%) comparable 
with ZR-75-I and ZH3D7 cells were scored 4-hydroxy-
lamoxifen sensitive (Figure 28), Hybrids which looked 
healthy, with a tlattened morphology, firmly attached to 
the culture flask with readily visible numbers of mitoses, 
and cell numbers occupying up to 90% of surface of the 
culture flask, comparable with XI-1-6A cells, were scored 
tamoxifen resistant (Figure 2A). This analysis showed that 
only the five hybrid cell lines carrying the BCAR) locus 
were resistant to 4-hydroxy-tamoxifen. These results indi-
cate that transfer of the BCAR) integration locus instantly 
confers dominant resistance 10 the parental ZR-7S-l cells, 
Idenrfflcarion of coding sequellces in the BCAR3 
locus 
In five out of six resistant cell lines, the integration of the 
retrovirus occurred in a very narrow region (Figure I), 
This indicates a positive selection for this region and a 
common mechanism of alteration of gene expression. 
Northern blots with RNA of the integration clones were 
screened with the genomic inverse PCR probe to identify 
possible transcribed sequences, Large transcripts were 
observed in the BCAR3 ciones, which vary in size in the 
various cell clones and were not detected in the parental 
ZR-75-1 cells (Figure 3). Northern blot hYbridization 
demonstrated that these are chimeric transcripts composed 
of LTR, NeoR and BCAR3 sequences (data not shown). 
The observed differences in mRNA sizes in individual 
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Fig. 3. mR..";'A e~pre~$ion of BCAR). Nonhem bloLl containing total 
Ro.'1A from ZR-75-1 cells, antiestrogen-resistant cell clones and 
MDA-MB-231 brC<ll'1 cancer cells were h)-bridized \\ im a BCAR) 
probe. ZR-75-1 cells were cultured in the presence (E2) or ablen(,; 
(BeS) of I n!l.1 17p-e5lradio! or in medium containing I )1M 
4-b),droxy-tamoxifen (TAM). Antiemogen.resistant cell done; were 
cultured in the presence of 4-h)'drox)·-tamoxifen. The positions of ISS 
and 28S rRNA5 are indicated. 
cell clones can be explained by the position of the 
integrated retroviruses relative to the BeAR3 sequences 
and readthrough transcripts from the virai LTR (Figures J 
and 3). More importantly, screening of Northern blots 
with Rl\'A of a panel of cell lines revealed a transcript 
of -3.4 kb in the estrogen-independent MDA-MB-231 
(Cailleau el al., 1974) breast cancer cell line (Figure 3). 
This indicates that this genomic integration probe contains 
exon sequences. This BeAR3 transcript appears also to 
be present in the integration dones and is barely detectable 
in the ZR-75-1 cells. Estrogens can modulate gene expres-
sion of target genes. However, BCAR3 is not regulated 
detectably in ZR-75-1 cells. Cultivation of ZR-75-1 cells 
in the presence and absence of estradiol and in the presence 
of 4-hydroxy-tamoxifen did not result in up-regulation of 
BCAR3 expression (Figure 3). Therefore, it is most likely 
that the observed up-regulation of the BCAR3 RNA is 
induced by the integrated virus. 
BCAR3 eDNA clonIng and predicted amino acid 
sequence 
To isolate the gene corresponding to the observed tran-
script, a human testis eDNA library was screened with 
the integration site-~pecific probe. [n the first screening 
round, a 1.9 kbcDNA done was isolated (#16, Figure 4A). 
Sequence comparison of the genomic integration probe 
with the eDNA showed that the genomic probe contains 
a 133 bp exon, identical to sequences of the cDNA done 
#16 (represented by nudeotides 456--589 in Figure 4B) 
with consensus splice donor and acceptor sites. Northern 
blot analysis confirmed that this eDNA done recognizes 
the BCAR3 transcripts. In successive screening efforts to 
obtain the full-length cDNA, overlapping dones were 
isolated (Figure 4A). The assembled eDNA clones consist 
of 3004 bp, while the mRNA is -3.4 kb as estimated on 
Northern blots. The first ATG is not preceded by an in-
frame stop codon. Therefore, a 5' RACE (rapid amplifica-
tion of eDNA ends) strategy was perfonned to obtain the 
additional sequences at the 5' end of the BeAR3 mRNA. 
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Total RNA of MDA-MB-231 celis, which show abundant 
expression of BCAR), was used to obtain the full coding 
region of BCAR3. Several 5' RACE clones were isolated 
and sequenced. It was shown that an in-frame stop codon 
(TGA) is present 72 bp upstream of the first ATG. The 
cDNA obtained is 3042 bp in total and contains the 
complete coding region. Three ATGs are present in the 
first 174 bp of Ihe eDNA. Analysis of the surrounding 
sequences of the three putative start sites indicates that 
the first ATG codon at position 99 fits the Kozak consensus 
sequence (Kozak, 1991). The open reading frame (ORF) 
is Ranked by an in-frame TGA translation termination 
codon at position 2574, followed by a 448 nucleotide 
3' ·untranslated region and a poly(A) tail of 19 nucleotides. 
BCAR3 has a single ORF that encodes a protein of 825 
amino acids with a predicted molecular mass of 92 kDa, 
assuming thai translation starts at the first ATG (Figure 4B). 
Comparison of the sequence of BCAR3 with the available 
protein and nucleotide databases revealed that BeAR3 is 
a newly identified gene whose product has a single stretch 
of amino acids (codons 154---253 in Figure 4) with strong 
homology with Src homology 2 (SH2) domains of other 
proteins (Figure 4C). A profile scan utilizing the Prosite 
profile database detected no further putative protein 
domains. However, sequences homologous to part of the 
yeast cell division cycle protein CDC48 were obsen'ed 
by using the BLASTP algorithm (codons 699-812, 
Figure 40). 
mRNA expression of BCAR3 
We next e\'aluated the expression of BCAR3 mRNA in 
various nornlal tissues. For this purpose, commercially 
available Northern blots were hybridized with the 1.9 kb 
eDNA probe clone #16. BCAR3 mRNA is widely 
expressed, and abundant transcripts were obsen'ed in 
heart, placenta, skeletal muscle, spleen, prostate, testis, 
ovary, small intestine, colon and fetal kidney. In skeletal 
muscle and heart, an additional 6 kb mRNA is present 
(Figure 5). The nature of this larger transcript is at present 
unclear but may be explained by alternative splicing. [n 
addition, Northern analysis was perfornled on RNA isol-
ated from non-malignant breast tissues. No expression of 
BCAR3 was detected in these samples (11 '" 6). However, 
the amount of luminal epithelial cells in normal breast is 
small compared with stromal cells, T11erefore, it cannot 
be excluded that BCAR3 is expressed by the glandular 
epithelial cells. A panel of cell lines originating from 
breast, ovarian and endometrial cancer was screened by 
Northern analysis for expression of BCAR3. These results 
were compared with ER and EGF receptor protein expres-
sion (Table I). In the cell lines, only the 3.4 kb BCAR3 
mRNA was detected. In the breast cancer cell lines tested 
(ZR-75-I, BT·474, MCF-7, T47D, ER-positive; EVSA·T, 
SK-BR-3, MOA-MB-134, ER-negative), no expression of 
BCAR3 was detected. In the ER-negative breast cancer 
cells BT-20, HS·578 and MDA-MB-231, abundant expres-
sion of BCAR3 was obsen'ed. In two ER-negative immor-
talized mammary epithelial cell lines, RC-6 and HBL-
100, only the latter showed expression. In ovarian cell 
lines (SKOV3, SKOV6, OVCAR3, 2174, 2780, HOC7 
and KB3.1, all ER-negative), expression of BCAR3 was 
obsen'ed except for in 2780. In the endometrial cell lines 
tested (SCRe, AN-3-CA, HEClA, HECIB, RL 95-2 and 
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Fig .... Structure of BCAR). (A) Schematic repre>crlutirln of the BCAR) gene. The thick lines represent the overlapping cDNAs. TIle ;lITOW indk;lles 
the position of the \'irJI integrJlion ~ites in the genome compared I\ith the cDNA sequence. The e~on detected ne;u the integrations is indicated 
(blac).; bo~, see also Figure IA). The hatched box indicates the 5' region obtained by RACE. The location of the p\ltatil'e SHl domain and the 
region homologous to CDC48 is showII. (8) BCARJ deduced amino add ~cqucnce. The amino add sequence is giren in the one· leiter code. The 
predicted N-terminal methionine and the ATG codon (M) of the shortene.1 product obser .. e.1 in the BCARJ cel! clones and the first slOp codon (t) are 
indicated. The region of similarity to other SHl domain"conlaining proteins is underlined and lhe region homologous to CDC48 is double 
underlined. (e) Sequence alignment of the SH2 d,'main of the human BCAR3 and other human SI-I1·comaining proteins, The comerwd re,idues of 
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fig. S. The e~pre~sion of BCAR3 mRNA in various normal human 
tissues. Northern blots (e]oolub) containing 2 Ilg of pol}'(A)+ RNA 
from the indkated tissues II'ne h)'bridiud with BCAR3 eDNA probe, 
done #16, The mobi!it)' of RNA molecular size mndard, j, indicaled 
on the left in kilob.1J:es. 
Table I. E'pression of BCAR3 mRNA \las compared \.lith e~pression 
of ER and EGF receptor protein 
Cell line 
Breast 
ZR·75·\ 
)o..1CF·7 
T-47D 
BT--tH 
BT-10 
EVSA-T 
HS·578-T 
MDA-!'.fB-IJ~ 
MDA·!'.fB·231 
SK·BR-3 
HBL·lOO 
RC·6 
OI'aI)' 
2780 
2774 
UOC-7 
Kllli 
OVCAR-J 
SK·OV-3 
SK·OV·6 
Endometrium 
ECC·\ 
AN·J·CA 
HEC·J·A 
HEC·I-B 
KLE 
SCRC 
RL 95·2 
BCAR3 
++ 
+++ 
+ 
++ 
+ 
+ 
+ 
+ 
+ 
+ 
++ 
+ 
++ 
++ 
ER EGFR 
+ (100) -(0) 
+ (JOO) - (20) 
+ (100) + (600) 
+ (23) od 
- «10) od 
- «10) + (67) 
- (<!OJ od 
-«10) od 
-«\0) + (>1600) 
- «10) + (560) 
- «10) 0' 
-«IO) od 
-«10) + (220) 
-«IO) + (.) 
-«~in) + (O) 
-«10) od 
- «10) + (l200) 
-«10) + (>1600) 
-«10) + (>I600) 
+ (82) + (8~) 
-«10) + (1550) 
- «10) + (>1600) 
-«10) + (>1600) 
- «10) + (530) 
-«10) + (>1600) 
- «!O) + (>1600) 
Receptor concentratjon~ determined ..,.jlb biochemicaJ assays are 
e,pre,sed as fmollmg protein, Expre"ion of ER >10 fmollmg and 
EGF receptor >50 fmollmgof protein lias 5cored positil'e (+). ND 
nol done. (fj E'prcssion determined b)' Northern anal)"!" E'prc.ssion 
lewis of BCAR3 mRNA varied Ixtween -, no e\pres~ion detected 
after 7 days expowre MId + + +, high c'pression dcte(ted after 
overnight e~posure on ti1m. 
KLE, ER·negalive and ECCI, ER-positive}, high mRNA 
levels were observed except for in ECCI and KLE. The 
integrity of the mRNA on Northern blots was examined 
by hybridization to a GAPDH Or actin probe, Correlation 
of ER and EGF receptor expression with expression of 
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Fig. 6, Itl 1';"0 transcription translation. III \it,o tran.shted full-lengt1J 
BCAR3 {B3j was compared \\it1J the shortened form {BJs) of BCAR3. 
as deduced from analyses of t1Je virus clone.s (nucleoti.xs J83-195J). 
Control re3(:!ions with 3 luciferase construCI (6J kOa product, 10% 
loaded) and rea(tion without plasmid DNA (-) are sholln, Dctc,tion 
was by chemilumlncscence. The mobility of molecular ~ize ~{andards 
is indicated on the left in lilod~1tons. 
BCAR3 showed an inverse relationship between expression 
of BCAR3 and ER (McNemar test, P = 0.025), 
In vitro transcription translation of BCAR3 
Figures I and 4 show that all proviral integrations had 
occtlITed in an intron in lhe 5' region of the BCAR3 gene. 
most likely resulting in a shorter mRNA. Northern blot 
analysis with a specific probe for the 5' part of the gene 
(represented by nucleotides 38-420) demonstrated that 
these sequences were not present in the shortened BCAR3 
mRNA of the integration clones, but were present in 
the MDA·MB-231 BCAR3 transcripts (not shown). The 
shortened BCAR) gene in the antiestrogen·resistant clones 
may encode a protein of 699 amino acids with a predicted 
mass of 78 kDa. assuming that the ATG codon al position 
477 is the initiator methionine. Both BCAR3 and a 
shortened construct (represented by nucleotides 421-2989) 
resembling the presumed situation in the BCAR3 clones 
were subcloned in a vector which allows the expressed 
protein to start with the authentic ATG codon. 11/ !Ii/ro 
transcription translated BCAR3 migrated as a single band 
by SDS-PAGE at -90 kDa (Figure 6), 1/1 vitro transcription 
translation analysis of the shortened construct showed a 
single band of -74 kDa (Figure 6). 
Ectopic expression of BCAR31nduces estrogen 
independence III ZR·75·, alld MCF·7 cells 
Stable transfectants with the BCAR3 gene were established 
to provide conclusive evidence that BCAR3 is the gene 
responsible for antiestrogen resistance in this locus. For 
this purpose, two expression constructs were made in 
which the BCAR3 cDNA 1132, cont3ining the complete 
coding region, was positioned under control ofa cytomega· 
lovirus (CMV) and a LTR promoter, These expression 
vectors were transfected into ZR·75·1 cells and stable 
G418-resistant clones were generated and isolated. These 
transfectan(s, designated ZRlBCAR3 cells, were expanded 
in the presence of 17~-estradiol to certify estrogen depend-
ence. We next detemllned the proliferation capacity of the 
BCAR3 transfectants in the presence of the anticstrogen 
4-hydroxy-tamoxifen. In Figure 7, the increase in cell 
numbers over an II day culture period of p3rental ZR-
75-1 cells. vector controls and eight independently derived 
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Fig. 1. BCAR) induces antiwJOgen resiHance. (t\) ZR-15-1: all lines 
containing the upression vector \\ilhoul the BCAR) eDNA, BCAR3 
transfe.::tanll and parenlal ZR-75-1 eeUs (O.7X 106) were plated in 
(tlllure medium ""lth 10% nes and I 11M 4·h),droxy.tamoxifen in 
triplicate. Cell numbers were determined on day II. Cell lines 
indicated are: parental ZR-75·J cells (ZR), LNCX (;werage of four 
different cell clones) and LXSN vector controls and the BCAR3 
tran,reClanLS (C4, C5, C9 and CIO under control of a CMV pmmoter 
and L6. L24, LJI and L33 under control of the LTR promoter). 
(H) !IIeF-?: pools of MCFlIBCAR3 transfectants, ~lCF7!l.NCX 
"ector cooaol tr;l.mfectants and parental MeF·7 cells were pbled in 
medium with 10% FCS with 100 IL\I of the pure antiewogen ICI 
182,780 in triplicate. Cells .... ere counted al the indicated days and 
replated at the initial density of 0.25 X]06 cells per 2.5 cm2 flask. 
Cumulative ceU numbers are pre,enled o\er a 50 day culture perioo. 
transfectants is presented. Parental ZR· 75·1 cells, which 
are fully dependent on estradiol for proliferation, give rise 
to maximally one generation in the prcsence of 4·hydroxy· 
tamoxifen (Figure 7A). As expected, similar results were 
obtained with the LNCX ilnd LXSN vcctor controls. In 
contrast, the ZR/BCAR3 cells have acquired the ability 
to proliferale in the presence of 4·hydroxy·tamoxifen. In 
addition, the proliferation capacity of the Iransfectants is 
99 
similar in the presence or absence of antieslrogens and 
thus not dependent on antiestrogens. Suocultivalion after 
the 11 day culture period of ZR· 75·1 cells and transfectants 
with Ihe vector alone, ill the presence of 4·hydroxy· 
tamoxifell, resulted in rapid decline of these cultures. 
Transfectants C5, C9, CIO with BCAR3 under control of 
the CMV promoter were subcultured successfully and 
became expanding cultures. Cell clone L24 of Ihe BCAR3 
lransfectants with the LTR promoter only developed as a 
stable estrogen·independent cell line. The reason for these 
variations are at present not clear, but may be attributed 
to differences in BCAR3 protein levels. In total, 40 
transfectants were tested and 25 (62.5%) showed objective 
growth in the presence of 4-hydroxy-tamoxifen. Similar 
results were obtained with the antiestrogen ICI 182,780 a 
pure antagonist of esu-ogen-stimulated proliferation. None 
of the vector control cell lines or the parental ZR· 75·1 
cells, which were tested repeatedly, were able to grow in 
the presence of 4·hydroxy-tamoxifen or ICI 182,780. 
Additional experiments were performed to establish 
whether BCAR3 can induce antiestrogen resistance in the 
ER-positive },'1CF-7 breast cancer cell line. MeF·7 cells 
were transfected with BCAR3 under conlrol of the CMV 
promotor (MCF7/BCAR3) or with the LNCX vector 
without the insert (1\fCF7ILNCX). Both pools of stably 
transfected cells and individually established clones were 
obtained in medium containing 10% fetal calf serum 
(FCS) and 0418. In total, 20 MCF7IDCAR3 clones and 
eight MCF7ILNCX vector clones were isolated and tested 
for proliferation ability in the presence of the pure anties-
trogen ICI 182,780. Fourteen out of 20 MCF7/BCAR3 
clones (70%) showed objective growth compared with the 
MCF7ILNCX clones. Similar results were obtained with 
cultures in the presence of 4-hydroxy-tamoxifen. Growth 
curvcs of the pools of tramfcctants and the parental 
MCF·7 cells in the presence of antiesu-ogen are presented 
in Figure 7B, and demonstratc the requirement for BCAR3 
for antiesu-ogen·resistant proliferation. 
Discussion 
Treatment failure of progressive breast cancer is inevitably 
due to the unremitting progression of the tumor cells to a 
morc malignant honnone·independent phenotype. Insight 
into the different signaling pathways of nomlal and breast 
cancer cells leading to proliferation is a prerequisite for 
future development of new treutmenl strategies. BCAR3, 
a novel gene involved in progression of breast cancer cells 
to estrogen independence, was identified using retroviral 
insertional mutagenesis in I'itro. A panel of 80 anti· 
estrogen-resistant cell clones was screened for new com-
mon integration sites. In six cell clones, a proviral 
integration was detected in a restricted region. All viruses 
were integrated in an inu-on located in the 5' region of 
the BCAR3 gene. Somatic cell hybrids between estrogen-
dependent ZR-75·J cells and one of the estrogen·independ-
ent BCAR3 integration clones were established. Transfer 
of the BCAR3 chromosomal locus resulted in immediate 
induction of antiestrogen resistance of the cell hybrids. 
Most likely as a consequence of the proviral integrations, 
a truncated protein Jacking the N-terminal part of the 
protein is expressed in these cells. It was detern1ined by 
Northern amlysis that the large transcripts in the BCAR3 
integration clones consisted of BCAR3, LTR and NeoR 
sequences. In addition, shorter BCAR3 mRNAs, lacking 
the first exon(s), were observed in these cells. The shorter 
BCAR3 product may origin<lte from read through transcripts 
initiated by the viml 5' LTR (Kung el al., 1991; Jonkers 
and Berns, 1996). These chimeric transcripts could be 
spliced from the splice donor site preceding the gag 
sequences (Miller and Rosman, 1989) in the retrovirus to 
the BCAR3 exon sequenees adjacent to the integmtion 
site. Translation of the resulting mRNAs may initiate at 
the ATG codon at position477 and would result in a 
smaller protein. However, Ihis truncation of BCAR3 is 
not a prerequisite for the induction of the hormone· 
independent phenotype. Transfection of the BCAR3 eDNA 
10 estrogen·dependent ZR·75-1 and MCF-7 cells resulted 
in bypassing of hormone dependence and immediate 
antiestrogen resistance. These results suggest that up-
regulation of BCAR3 stimulates an alternative growth path 
independently of hoonone, both in the presence and 
absence of amiestrogens. In the est<lblished cell lines 
studied, derived from the breast, ovary and endometrium, 
an inverse relationship between expression of BCAR3 
mRNA and ER protein was observed (McNemar test, 
P = 0.025). BCAR3 expression was not detected in ER-
positive cell lines. The strongest predictor for response to 
tamoxifen is expression of a functional ER in primary 
breast tumors (Foekens el al., 1994; Spyratos el (II., 1994; 
Johnston el (II., 1995), while EGF receptor expression has 
been associated with lack of response to endocrine therapy 
(Nicholson el (II., 1988, 1989). In the panel of breast-
derived cell lines studied so far, EGF receptor expression 
is not tightly linked to BCAR3 expression. 
Sequence similarity analysis showed that BCAR3 con-
truns a copy of a putative SH2 protein domain. SH2 
protein domains are found within a wide varielY of 
C)10plasmie signaling molecules that can bind protein 
sequences phosphorylated at tyrosine residues (Cohen 
et (1/., 1995; Pawson, 1995). The homolog)' of BCAR3 
wilh other SH2 domain-containing proteins is limited to 
this domain. TIle amino acid residues implicated in protein 
structure and in interaction with the phosphotyrosine are 
well conserved. Major sequence differences are observed 
in the amino acid sequences spacing the ~-sheets and 
a-helices as well as residues implicated in the interaction 
with substrate amino acid residues adjacent to the phos-
phorylated tyrosine (Cohen er al., 1995). The BCAR3 SH2 
domain shows the strongest homology to SH2 domains of 
She, Grb2, Fer and Fes. In analogy to these related 
proteins, BCAR) may act as an adaptor protein and eouple 
activated growth factor receptors to a signaling pathway 
that regul<ltes the proliferation in these breast cancer cells. 
Its substrate specificity may resemble that of the Grb2 
protein (Songyang ct al., 1994), based on the conservation 
of the critical residues (Figure 4C, marked with #) in the 
~D region, and indicates a link to the Ras signaling 
cascade (Rozakis-Adcock el al., 1992). 
BCAR) protein displays striking partial homology with 
a cell division cycle gene product (CDC48) from yea~t. 
Mut,1tion or elimination of CDC48 in yeast results in 
arrest of cell division in the large budded Slate with an 
undivided nucleus and unseparated spindle pole body 
(Frohlich el (1/., 1991). TlJe characteristic feuture of this 
protein is an intemally duplicated domain for nucleotide 
100 
binding, which is conserved in its mammalian homolog 
the valosin·containing protein (VCP). ATPase activity has 
been demonstrated for these proteins (Schulte el al., 1994; 
Frohlich el al., 1995). CDC48 proteins ~hows significant 
homology to a group of NSF·like proteins which also 
comprise the duplicated ATPase domain and are involved 
in homeotypic fusion of intracellular membranes (Frohlich 
el 01., 1991; Aeharya el al., 1995; Latlerich el 0/.,1995; 
Mellman, 1995; Rabouille et al., 1995). None of the 
domains shared between CDC48 and the NSF-like proteins 
are conserved in the BCAR3 protein. BCAR3 has acquired 
the C-tenninal part of CDC48 proteins, which has not yet 
been implieated in a specifie function and includes -30 
amino acid residues contained within the duplicated 
domain. The mammalian CDC48 is strongly phosphoryl-
ated on tyrosine and serine residues in Band T cells and 
in v-Src transfonned fibroblasts (Egerton et al., 1992; 
Schulte et al., 1994). Primarily from ill \'ilro experiments 
with T cells it was concluded that the C-termina\ T)'r805 
in murine CDC48 is the predominant target for phosphoryl-
ation, but pho~phorylation of this residue is non-essential 
for ATPase funetion (Egerton and Samelson, 1994). This 
particular tyrosine residue is not conserved in BCAR3 nor 
in the archaebaeterial homolog of CDC48 (Figure 4D, 
Sa). An adjacent tyrosine residue is conserved in CDC48 
proteins of all species tested and in the BCAR) protein, 
and represents an attractive target for C-terminal phos-
phorylation and funetional modulation of these proteins. 
The BCAR3 protein has characteristics of a molecule 
involved in signal transduction. The putative SH2 domain 
is mosllikely involved in binding of tyrosine·phosphoryl-
ated proteins and Illay represent an essential component 
of cascades transporting signals from the cell membrane 
to the nucleus. TIle C-tcrminal domain of BCAR3 is 
homologous to the CDC48 protein which is responsible 
for cell division control in yeast and subject to tyrosine 
phosphorylation in mammalian cells. The combination of 
these features may explain its dominant role in anties-
trogen-arrested breast cancer cell proliferation upon over-
expression by retroviral insertion or ectopic expression. 
Future experiments will attempt to delineate the contribu-
tion of these components and define the signaling pathway 
involved. Further work will be required to establish 
whether BCAR3 is involved in elinical breast cancer and 
possibly in other endocrine-related tumors. 
Materials and methods 
Cel/lines and culture conditions 
Cell line; \\ere obtained from the American Type Culture Collection 
(Ro<:k\'ille. /liD). e,\Cepl for ZR-7S·1 and MCF·7 \\hich \\ne kind 
gifls of RJ.B,King (!CRF, London) JIld R.B,Dichon (Net, Belhesda) 
re,pecti\,ely. Cell culture \\a.s performed e"entialty os Je~cri\:>cd (VJIl 
Agthoyen .'1 <II., 1992. 199~: Domers tl a/ .. 1993: Sieu\\"erts a a/., 
1997), ZR·7S·I, ZHJD7, hybrid ood ZRJBCARJ cells were cultured in 
RP~H 16-l0 m~dium supplementeJ \Ii!h 10:<- heal·inactivated bovine 
calf mum (fiCS) and I nM 17p.es!radio!. BCAR) inlegration cell done; 
\1~le m~inlained in RP:-.t1 16~0 medium supplemented \\ith IS'} BCS. 
10:<- wnditioneJ medium of CRIP cdls (a m(1u~e fibwb!J.lt cell line) 
and l).lM 4.hydw.\r·lamoxifen. MCF·7 JIld MCf7mCAR3 cells \\ere 
cultured in RPMI 16~0 \\ilh 107, hc~t·inaCli\aled FCS. 
Cell fusion 
Cdt fUlion e~rerimc(1\s I\ere performed as descrikd (Domen and 
VcJdlchohe. 1997). Briefly. ZR·75-t ails Ilere U;lJ1lfMCd with the 
expres\ion conslruct PGK·Hyg B' Ilhich confers hygrom)"cio B resist· 
3nee, and Ilere uled as a,.:eptor cells (design~ted ZH3D7). Clone XI-
1·6A, CMT)'ing \\\0 l'irJ.i inteFJtions, \\as ,elected as dOnor cel! line, 
As a cDfl,equence of the re[[OIiral insertions, the,e cells are both 
antiestrog.cn· and G~ 18·re,i5tanl. Furthermore, the ~-hydro~y-tamo~ifen­
resimnt cells Ilae lethally irrJdiated!O prel'ent Olltgrollth of the donor 
cells. ZH"'D7 and XI-I·6A cells were fused with polyethylene gl)"col 
(pEG, Boehringa :"llnnheim, Gennany) u'>ing a procedure for adherent 
celis (Eijdems (I al.. 1992) and according to the manuf3Cturer's rewm· 
mended conditions. Arter fu\ion, tbe {<"Us \Iere allo\\ed to recowr for 
2 day> and subsequently selected Ilith I mgfml G-t 18 (Gen;:ticin, Gitxo-
BRL. Life Technologies ltd. PJi,ley, UK) in the prC\enCe of I n:"l 
17p-wradiol. After 10 dJ)'s. the $elwion \.las continued \lith 
500 ).Iglnll G418 Jnd 25 ).Igfrnl hHH.>m)'cin B (Boehringer Mannheim) 
until clones del'eloped. Clones wac picked, expanded, cbar~cterized by 
Southern anal)'si, and challenged for antkstwgen rcsislan'e, 
r,ansfect(on of expressIon constructs 
A ncar full· length BCAR3 cDNA (1r32, nucleotides 39-2989) \.las cloned 
into the pLXSN and pL'>:CX expression wctors (Miller and Rosman, 
19&9) in \lhkb tranSCription is driwn in the former by the LTR promoter 
and in the laller by J CMV promoter. E\preSlion constructs Jnd control 
I'ectors \.Iithout inserts Ilere transfected using lipofectin reagent (Life 
Technologies). ZR-75_1 cells (2XI~) were seeded in 25 cm2 flasks 
(Costar, CJmbridge, MA) in medium containing l'Jp·estradiol. After 
2 dJ)·s, the cclis were wa.\hed tllice Ilith serum·free Optimem medium 
(Life Technologie.), To th~ cells. 3 ml of Optimem medium with 30).11 
of lipofectin \.las added, After 1 h incubation at 37'C, 2-5 ).Ig of 
linearized plasmid DNA was added. Following 5 h incubation, the DNA-
containing medium lIas repl~ced by RPMI medium, containing 10% 
DCS Jnd I nM np·estradioL Sublequentl)', Jfter 2 dnys, selection Ililh 
G418 lIas stJfted.lndil'idu.1l transfectants \.Iere i,ol~ted and propJgated 
in medium with estrJdiol nnd G~18. lv1CF·7 cells Ilere transfected 
similarly Ilith pLNCX with and without insertion in RP:..n medium 
containing 10% FCS. 
DNA and RNA analysIs 
Genomic DNA was isOlated using NaCI e\traClion prOCedure, described 
by Miller (I aI, (1988). Total RNA v.a~ i<.obted using guanidinekesium 
chloride extrJction ~nd used for NNthern anal)se, a.> prel'ioult)' desnibcd 
(Van Agthol'en il aI" 199~). Probes lIere r;mdom.primed labeled using 
[a_·;2PjdATP (ICN Pharm3ceuticals Inc. CAl. Blots were exposed to 
X-OMAT AR film (Easunan Kodsk Company, NY). 
Isolation and sequencIng of BCAR3 eDNA clones 
A testis eO}"'A library (C!ontech Ljbor.ltories, Inc., CAl was screened 
I'oith the BCAR3 integration-.lpedfk pwbe. Plaque, were purified and 
the cD}lA ins-erts were recloned in pGBI4Z (Promega, Madison, WI). 
The nucleotide sequence \las detennined on bolh strands by dideox), 
sequencing reactio[ls using n DNA pol)mcw:e (Phmmcia Biotecb, 
Sweden) and [a)lPjdATP (lCN Pharmaceulicals Inc.). 5' RACE experi-
ments Ilere performed JC(ording to the manufacturer's recommendations 
(Boehringer Mannheim), 
In vitro tffmsfatlon 
The neM fuH-lenSth BCAR) eDNA done 1r32 \\,3, recloned in the 
£wRI ,ite of pGEM4Z. A shortened COllstrucl (nucleotide, 421-29&9) 
re,embl ing the Jlieration in the BCAR 3 clone, was obtained by subi:loning 
the cDNA clone 11..,2. The plasmid Ila, tr.lmcribed from the T7 promoter 
and translated in rabbit reticul<X')'te I)·sate by uling the TNT Coupled 
Reticulocyte Lysate System (Promega). After SOS-PAGE, recombinant 
proteins were clectrOiransferred to nitr<X'ellulose membr.1nes Jnd proteins 
were dete{1cd I\ith th<" Non-R~diNctil"e Translation Dete(lion Sy~tenl 
(Promega) and chemiluminicelLle (Amer>ham International. Bu(ks, UK) 
by exposinS to X-O~fAT AR film. 
Growth assays 
ZR-75-1 cells Jnd tran>fectants cultil"Jted in the presence of 1 nM 
I7p-eltrJdiol were hMl'csted b)· treatment \.lith \J)'p~in·EOTA. Sinsle 
(ells (O.7x lif, were plated in 25 cml plastic culture flasb in triplicate. 
The exp~rimental medium containing 1O'k B(S and 1 ).1M 4-h)·dro'Y-
tamoxifcn lIas (banged t\\ice a Ileek. After II days. the culture, wert 
hM\'cmd by tl)'p,inil.l.tion and counted. Subsequently. 1,5xlif cells 
Ilere repbted to detennine the se,ond:iIY gro\\th rate, MeF-7 cells and 
tr~nsfectants routinely v.ere cuhuled in medium containing 1O'l FCS. 
Cells (0.25X 106) \lefe phted in e'perimental medium with 10';( FCS 
and 100 nM ICI 182,780, har\,e,ted at days 8 and 11, and r<plated at 
the initial densily!O determine the secondary gWllth rJte, 
Receptor determfnations 
ER and proge<lefont rcaptor were determined as described {VJn 
Agthol'en (I 01., 1992), using COlnmerdall)· available enl)mC immuno-
amy kits (ER·EIA. PR-EIA; Abbott Laboratories, Chicago, ILl, EGF 
rcaptors \.I;:re detcnnined using a wmmercially available enl)me-
linhd imrnu/lowrlxnt a.'B), kit (Oncogene Science, CMIlbridge, MA). 
Nucleotide acces5/on number 
The sequence data reported here hal'e been ~ut>milled 10 the DDBl/ 
E:..mUGenBank database under accession number U92715. 
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Summary 
Breast cancer is the most common malignancy of women in the Western world, 
and is one of the leading causes of cancer mortality. Breast tumor growth appears to 
be estrogen-dependent in early stages of the disease. The effects of estrogens are 
exerted tlu'ough the estrogen receptor (ER) which can be inhibited with antagonists of 
estrogens. Adjuvant treatment of patients with primary breast cancer with 
antiestrogens like tamoxifen increases both the disease-free period and overall 
survival. Unfortunately, virtually all patients with advanced breast cancer and 
responsive tumors eventually experience a disease progression due to the 
development of hormone-independent metastases. Many mechanisms for 
antiestrogen resistance have been proposed including tumor heterogeneity and clonal 
selection of ER-negative tumor cells, functional alterations in the ER, changes in the 
metabolism of tamoxifen, and overexpression of various genes. Substantial evidence 
for any of these mechanisms in antiestrogen resistance in clinical breast cancer is still 
lacking. 
The hypothesis, that antiestrogen resistance may be the result of (epi-) genetic 
alterations, resulting in changes in gene expression in the tumor cells, is the research 
subject of this thesis. The human ZR-75-1 breast cancer cell line was selected as a 
model system to study the progression to hormone independence. This cell line is 
fully dependent on estrogens for proliferation and growth can be inhibited with 
different antiestrogens. We have applied insertional mutagenesis with retroviruses in 
ZR-75-1 cells, to identify genes involved in development of tamoxifen resistance. 
Retroviruses integrate into the DNA of the host cell as a part of their life cycle and 
can disturb the expression of neighboring genes. When this alteration in gene 
expression results in antiestrogen resistance, the integrated retrovirus can be used as 
a tag to isolate the involved gene. Subsequently, the candidate gene can be 
transfected to the parental cell line, to study its role in antiestrogen resistance ill vitro. 
Next, the gene (product) should be studied in clinical breast cancer samples to 
establish the role in clinical hormone resistance. In this thesis, the application of 
retroviral insertional mutagenesis to isolate (unknown) genes involved in 
antiestrogen resistance is described. Several experiments were performed to evaluate 
the feasibility of this approach in the study of breast cancer. 
Expression of ER is inversely related to expression of epidermal growth factor 
(EGF) receptor in breast cancer. Furthermore, the EGF receptor is implicated in poor 
prognosis and antiestrogen unresponsiveness of breast cancer. The EGF receptor 
cDNA was introduced into ZR-75-1 cells, to establish a possible role for expression of 
this receptor in development of antiestrogen resistance. These cells, designated 
ZR/HERc, showed expression of functional EGF receptor and a proliferative 
response to EGF even in the presence of antiestrogens. ZR/HERc cells rapidly 
progressed to an ER-negative phenotype in the presence of antiestrogens, suggesting 
a role for EGF receptor expression in progression of breast tumors to hormone 
independence. Interference between the ER and EGF receptor signaling cascades in 
these ZR/HERc cells was observed which may explain the inverse relationship of 
these receptors observed in breast tumors (Chapter 5.1). Furthermore, these 
experiments showed that alteration of the expression level of a single gene in these 
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cells is sufficient to bypass estl'Ogen dependence and to allow for pl'Oliferation in th, 
presence of antiestl'Ogens (chapter 5.1). This notion is important, because it is , 
prerequisite for successful retroviral insertional mutagenesis. A change of phenotyp' 
requiring simultaneous modification of more than one gene in a single cell b) 
retroviral insertional mutagenesis is technically not feasible. 
In different experiments, it was shown that antiestl'Ogen resistance could IJj 
induced by epigenetic changes in gene expression. ZR-7S-1 cells were treated with 5 
azacytidine, a DNA demethylating agent, which may result in up-regulation of genE 
expression. Cells were selected in the absence of estradiol or in the presence 0: 
different antiestl'Ogens. Pools of these cells were shown to express EGF receptor ane 
to secrete EGF-like peptides. Pl'Oliferation could be inhibited with EGF receptor· 
blocking monoclonal antibodies, indicating the activation of an autocrine growtr 
mechanism (Chapter 5.2). These results show that alterations in gene expression an 
sufficient to induce resistance in this cell line, but this appl'Oach does not easily permil 
the identification of the involved genes. 
As a consequence of the former studies, a double-immunohistochemical staininf 
method was developed to study the expression of ER and EGF receptor at the SinglE 
cell level. Fl'Om data of clinical studies and cell line studies, it was apparent thai 
expression of ER and EGF is inversely related. However, appl'Oximately 50% 01 
primary breast tumors show co-expression of these receptors. It was not knowr 
whether ER and EGF receptor are expressed in the same individual cell or that this i~ 
mutually exclusive in a single breast (tumor) cell, because most analyses have been 
performed on homogenates of tumor cells. Analysis of primary breast tumor biopsie~ 
showed that expression of both receptors in the same tumor cell is a rarE 
phenomenon. However, in non-malignant luminal epithelial cells of the breast, it wa, 
shown that simultaneous expression of ER and EGF receptor in individual cells doe, 
occur (Chapter 5.3). In Chapter 5.4 it is described that there is little difference in 
expression of ER and EGF receptor between primary breast tumor cells and 
corresponding lymph node metastases. 
The results of the EGF receptor transfections and the 5-azacytidine experiments, in 
Chapters 5.1 and 5.2, supported the feasibility of the retl'Oviral insertional 
mutagenesis appl'Oach. Large numbers of hormone-dependent breast cancer cells 
were infected with retl'Oviruses and selected for proliferation in the presence 01 
tamoxifen to establish a panel of resistant cell lines. In total, a panel of 80 antiestrogen 
resistant cell lines was generated. Southern blots, containing DNA of these cell clones, 
were screened with integration site-specific probes to identify independent cell clones 
with a viral integration in an identical locus. In Chapter 5.5, the first common 
integration site linked with anti estrogen resistance is described. In four independent 
cell clones, a viral integration in a locus termed breast cancer antiestrogen resistance 1 
(BCAR1) was detected. 
In Chapter 5.6, we describe the identification and partial characterization of the 
BCAR3 gene. BCAR3 is the third locus, involved in antiestrogen resistance, identified 
with retroviral insertional mutagenesis so far. Six independent cell clones of the panel 
of resistant cell clones contained an integration in the BCAR3 locus in a narrow 
region. Linkage of this locus with antiestrogen resistance was further documented by 
somatic cell hybrid experiments. Cell fusion experiments were performed with the 
parental ZR-75-1 cells and one of the BCAR3 clones. Somatic cell hybrids containing 
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the BCAR3 locus were antiestrogen resistant, in contrast to cell hybrids lacking this 
locus. Hybridization of Northern blots with an integration site-specific probe detected 
a transcript that is up-regulated in the BCAR3 clones in comparison with the parental 
cell line, which shows very low expression. BCAR3 eDNA was isolated from a testis 
cDNA library. Transfection experiments with a BCAR3 expression construct in the 
parental ZR-7S-1 and MCF-7 cells (another estrogen-dependent breast cancer cell 
line) confirmed that expression of BCAR3 induces antiestrogen resistance. 
Characterization of the gene by sequence analysis showed little sequence homology 
with other known genes. Only similarity of a part of the BCAR3 protein with the 5H2 
domain of the adapter proteins 5HC and FER was observed. In addition, some 
protein sequence homology was detected of a part of the protein with the yeast 
CDC48 gene product, which has a role in cell division and apoptosis. The presence of 
an 5H2 domain in BCAR3 suggests a role in signal transduction. 
Future experiments will be aimed at establishing the role of the different BCAR 
genes and the involved signaling cascades in clinical breast cancer. Most likely many, 
different genes are responsible for development of hormone resistance. Therefore, it 
is important to address the question which signaling cascades are utilized by the 
tumor cells progressing to a more malignant phenotype. The growing understanding 
of breast cancer biology will hopefully result in the development of more satisfactory 
treatment strategies based on biological principles. 
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Samenvatting 
Borstkanker is de meest voorkomende maligniteit bij vrouwen in de westerse 
wereld en een van de belangrijkste doodsoorzaken op dit moment. In een vroeg 
stadium van de ziekte is de groei van borstkankerceIlen, naar aangenomen wordt, 
afhankelijk van oestrogenen. De effecten van oestrogenen worden doorgegeven via 
de oestrogeenreceptor, die geblokkeerd kan worden met specifieke antagonisten 
(anti-oestrogenen). Behandeling van pati~nten met primaire borstkanker na operatie 
met anti-oestrogenen, zoais tamoxifen, verlengt zowel de ziektevrije periode ais de 
totale overleving van de patienten. Helaas blijkt bij bijna aIle responderende 
patienten met borstkanker in een gevorderd stadium na verloop van tijd de 
ziekteverschijnselen terug te keren door het ontstaan van hormoononafhankelijke 
metastasen. Vele mogelijke mechanismen Vaal' resistentie tegen anti-oestrogenen zijn 
gepostuleerd, zoaIs: heterogeniteit in de tumoren en k10nale uitgroei van 
oestrogeenreceptor-negatieve cellen; veranderingen in het functioneren van de 
oestrogeenreceptor; veranderingen in het metabolisme van tamoxifen en 
overexpressie van een verscheidenheid aan genen. Echter overtuigende bewijzen 
Vaal' de verschillende gepostuleerde mechanismen van resistentie zijn nag niet 
geleverd. 
De hypothese dat resistentie tegen tamoxifen veroorzaakt kan worden door (epi-) 
genetische veranderingen in de tumorceIlen, resulterend in een veranderd 
genexpressie patroon, bepaalt het onderzoekprogramma van ons laboratorium. ZR-
75-1 is een humane borstkankercellijn die is gekozen ais modelsysteem Vaal' het 
bestuderen van de progressie naar hormoononafhankelijkheid. Deze cellijn is voor 
groei volledig afhankelijk van oestrogeen. Celproliferatie kan worden geblokkeerd 
met verschillende soorten anti-oestrogenen. We hebben insertiemutagenese met 
retrovirussen toegepast op deze ZR-75-1 ceIlen, am genen te identificeren, die 
betrokken zijn bij anti-oestrogeen resistentie. 
Retrovirussen integreren in het DNA van hun gastheercel ais onderdeel van hun 
levenscyclus. Deze inserties kunnen leiden tot verandering in expressie van 
nabijgelegen genen, en zo (epi-) genetische effecten nabootsen. Ais de integra tie 
resulteert in resistentie tegen anti-oestrogenen, dan kan het retrovirus gebruikt 
worden ais een label Vaal' de isolatie van het betrokken gen. Vervolgens kan het 
kandidaatgen getransfecteerd worden naar de oorspronkelijke ceIlijn, am diens rol in 
de resistentie tegen anti-oestrogeen ill vitro te bevestigen. Vervolgens moet de 
expressie van het gen(product) in borstkanker biopten worden geanalyseerd am de 
rol bij hormoonresistentie in de k1iniek te kunnen bevestigen. In dit proefschrift 
wordt de toepassing van retrovirale insertiemutagenese beschreven, met ais doel 
(nieuwe) genen te isoleren die betrokken zijn bij resistentie tegen anti-oestrogenen. 
Verschillende experimenten zijn gedaan am de haalbaarheid van deze nieuwe 
aanpak te onderzoeken. 
De expressie van de oestrogeenreceptor is omgekeerd evenredig met de expressie 
van de epidermal growth factor (EGF) receptor in borstkanker. Expressie van de 
EGF-receptot' lijkt gekoppeld te zijn aan een sIeehte prognose en het niet l'eageren op 
anti-oestrogenen bij de behandeling van borstkanker. Het EGF-receptor eDNA werd 
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in ZR-75-1 cellen ingebracht met als doel een mogelijke rol voor deze receptor vast te 
stellen bij de ontwikkeling van resistentie tegen anti-oestragenen. Deze 
getransfecteerde cellen (ZR/HERc) brengen functianele EGF-receptor tot expressie en 
vertanen een groeirespans op de groeifactar EGF, oak in de aanwezigheid van anti-
oestrogenen. ZR/HERc cellen veranderden snel in een oestrogeenreceptar-negatief 
fenatype in de aanwezigheid van tamaxifen, wat een ral suggereert voor EGF-
receptor expressie bij de pragressie van barstkanker naar harmaananafhankelijkheid. 
Er werd interierentie tussen de signaaltransductiepaden van de oestrogeenreceptar 
en de EGF-receptor waargenamen, die magelijk de inverse relatie tussen deze 
receptoren in barstkankercellen kan verklaren (Hoofdstuk 5.1). Verder lieten deze 
resultaten zien dat verandering in het expressieniveau van slechts een gen voldoende 
is om oestrogeenafhankelijkheid te amzeilen en proliferatie in de aanwezigheid van 
anti-oestrogenen magelijk te maken (Hoofdstuk 5.1). Oil gegeven is belangrijk want 
het is een vereiste voar het slagen van retrovirale insertiemutagenese. Een 
fenotypische verandering die de gelijktijdige aanpassing vereist in meer dan een gen 
in dezelfde cel, is technisch niet haalbaar met retrovirale insertie mutagenese. 
Verder hebben we laten zien dat het magelijk is anti-oestrogeen resistentie te 
induceren door epigenetische veranderingen in genexpressie teweeg te brengen. ZR-
75-1 cellen werden behandeld met 5-azacytidine, een staf die demethylering van 
DNA tot stand brengt, wat kan leiden tot veranderingen, vooral tot verhaging van 
genexpressie. Cellen werden geselecteerd in de afwezigheid van oestradiol of in de 
aanwezigheid van verschillende anti-oestrogenen. Verzamelingen van celklanen 
vertoonden EGF-receptar expressie en scheidden EGF-achtige peptiden uit in het 
medium. Proliferatie van deze cellen kon worden geremd met EGF-receptor-
blakkerende antilichamen, suggererend dat een autoCl'ien groeimechanisme was 
geactiveerd (Hoofdstuk 5.2). Deze resultaten laten zien dat veranderingen in 
genexpressie voldoende zijn om resistentie in deze cellijn te induceren, maar met 
deze aanpak is het niet eenvoudig de betrokken genen te identificeren en te isaleren. 
Op grand van de vOOl'gaande studies hebben we een immunahistochemische 
dubbelkleuring onlwikkeld vaar de gelijktijdige aankleuring van de 
oestrageenreceptor en EGF-receptar, amdat immunahislochemie het magelijk maakt 
de expressie van individuele cellen te bestuderen. Vii gegevens van klinische studies 
en studies met cellijnen was het duidelijk dat de expressie van oestrogeenreceptor en 
EGF-receptor omgekeerd evenredig is, maar toch leek ongeveer de helft van de 
primaire tumaren deze receptoren gelijktijdig tot expressie Ie brengen. Het was niet 
bekend of deze gelijktijdige expressie plaatsvond in dezelfde eel of in verschillende 
cellen, omdat de meesle analyses ap tumarhamogenaten waren gedaan. Analyse van 
biopten van primaire tumaren liet zien dat gelijktijdige expressie van deze twee 
receptoren in een tumarcel slechts zelden voorkomt (Haofdstuk 5.3). Echter in niet-
maligne cellen van het klierepilheel in de barst komt gelijktijdige expressie wei voor. 
In Haofdstuk 5.4 wordt beschreven dat er weinig verschil is in de expressie niveaus 
van oestrogeenreceptar en EGF-receptor in primaire tumoren en hun 
Iymfkliermetastasen. 
De resultaten van de EGF-receptor transfecties en de 5-azacytidine experimenten, 
beschreven in Hoofdstukken 5.1 en 5.2, steunden de haalbaarheid van de 
experimenten met behulp van retrovirale insertiemutagenese. Grote aantallen 
harmaonafhankelijke borstkankercellen werden geYnfecteerd met retrovirussen en 
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geselecteerd op groei in aanwezigheid van tamoxifen, met als doel een panel van 
resistente klonen te maken. In totaal is een panel van 80 resistente klonen 
gegenereerd, die elk zijn opgegroeid tot cellijnen. Southem blots met daarop DNA 
van deze klonen zijn gescreend met integratieplaats specilieke probes om 
onafhankelijke klonen te identificeren met een integra tie in dezelfde locus. In 
Hoofdstuk 5.5 is de eerste gemeenschappelijke integra tie plaats beschreven, die 
gekoppeld is aan resistentie tegen anti-oestrogenen. In vier onafhankelijke klonen 
werd een integra tie in dezelfde locus gevonden. Dit locus is breast cancel' 
antiestrogen resistance 1 (BCAR1) genoemd. 
In Hoofdstuk 5.6 beschl'ijven we de identificatie en gedeeltelijke karakterisering 
van het BCAR3 gen. BCAR3 is het derde locus, dat geYdentificeerd werd door middel 
van retrovirale insertiemutagenese, dat betrokken is bij resistentie tegen anti-
oestrogenen. Zes onafhankelijke klonen uit het panel resistente klonen bleken een 
integratie in een klein gebied van dit locus te bevatten. Het verband tussen dit locus 
en resistentie tegen anti-oestrogenen werd verder aangetoond door middel van 
somatische celhybriden. Celfusie experimenten werden uitgevoerd met de 
oudercellijn ZR-75-1 en een van de BCAR3 klonen. Hybriden die het BCAR3 
integratielocus bevatten waren anti-oestrogeen resistent in tegenstelling tot de 
hybriden die het locus niet bevatten. Hybridisatie van Northem blots met een 
integl'atiespecifieke probe detecteerde een transcript dat verhoogd tot expressie komt 
in de BCAR3 klonen in vergelijking tot de oudercellijn, die slechts zeer lage expressie 
vertoonde. Het BCAR3 cDNA werd geYsoleerd uit een testis cDNA bank. Transfectie 
experimenten met een BCAR3 expressie consh'uct in de ZR-75-1 en MCF-7, een 
tweede oestrogeenafhankelijke borstkanker cellijn, bevestigde dat BCAR3 resistentie 
tegen anti-oestrogenen induceert. Karaktel'isering van het gen door mi~del van 
sequentieanalyse liet weinig homologie zien met andere bekende genen. Er werd 
aileen een sterke overeenkornst gevonden met een gedeelte van het eiwit en het SH2 
domein van de adaptergenen SHC en FER. Tevens werd er enige homologie 
gevonden tussen een gedeelte van het cDNA en het gistgen CDC48, dat een rol speelt 
bij celdeling en apoptose. De aanwezigheid van een SH2 domein duidt erop dat 
BCAR3 mogelijk een rol heef! in signaaltransductie. 
Toekornstige experimenten zullen erop gericht zijn de rol van de verschillende 
BCAR genen en de betrokken signaalcascaden te bepalen bij de progt'essie van 
borstkanker. Het is zeer waarschijnlijk dat er een groot aantal genen verantwoordelijk 
kunnen zijn voor hormoon resistentie. Daarom is het belangt'ijk te onderzoeken welke 
signaaltransductiepaden de tumorcellen kunnen gebruiken tijdens hun progressie 
naar een meer kwaadaardig fenotype. De groeiende hoeveelheid kennis van de 
biologie van borstkanker zal dan hopelijk leiden tot de ontwikkeling van betere 
behandelingsmethoden, die gebaseerd zijn op biologische principes. 
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CURRICULUM VITAE 
Ton van Agthoven werd op 16 februari 1956 geboren te Rotterdam. Na vier jaar 
atheneum koos de auteur van dit proefsehrift voor een meer gerichte opleiding. Hij 
behaalde het diploma analist in de biologisehe riehting aan het Antoni van 
Leeuwenhoek Instituut te Delft in 1976. Na een onderbreking om het vaderland te 
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